Use
these
links
rapidly
review
the
document
TABLE
CONTENTS
ITEM
FINANCIAL
STATEMENTS
AND
SUPPLEMENTARY
DATA
Table
Contents
UNITED
STATES
SECURITIES
AND
EXCHANGE
COMMISSION
Washington
Form
ANNUAL
REPORT
PURSUANT
SECTION
THE
SECURITIES
EXCHANGE
ACT
For
the
fiscal
year
ended
December
TRANSITION
REPORT
PURSUANT
SECTION
THE
SECURITIES
EXCHANGE
ACT
Commission
File
Number
BRUKER
CORPORATION
Exact
name
registrant
specified
its
charter
Delaware
State
other
jurisdiction
Incorporation
organization
Employer
Identification
Manning
Road
Billerica
Address
principal
executive
offices
Zip
Code
Registrant
telephone
number
including
area
code
Securities
registered
pursuant
Section
the
Act
Title
Each
Class
Common
Stock
par
value
per
share
Name
Each
Exchange
Which
Registered
The
Nasdaq
Global
Select
Market
Securities
registered
pursuant
Section
the
Act
None
Indicate
check
mark
the
registrant
well known
seasoned
issuer
defined
Rule
the
Securities
Act
Yes
Indicate
check
mark
the
registrant
not
required
file
reports
pursuant
Section
Section
the
Act
Yes
Indicate
check
mark
whether
the
registrant
has
filed
all
reports
required
filed
Section
the
Securities
Exchange
Act
during
the
preceding
months
for
such
shorter
period
that
the
registrant
was
required
file
such
reports
and
has
been
subject
such
filing
requirements
for
the
past
days
Yes
Indicate
check
mark
whether
the
registrant
has
submitted
electronically
and
posted
its
corporate
Web
site
any
every
Interactive
Data
File
required
submitted
and
posted
pursuant
Rule
Regulation
during
the
preceding
months
for
such
shorter
period
that
the
registrant
was
required
submit
and
post
such
files
Yes
Indicate
check
mark
disclosure
delinquent
filers
pursuant
Item
Regulation
not
contained
herein
and
will
not
contained
the
best
the
registrant
knowledge
definitive
proxy
information
statements
incorporated
reference
Part
III
this
Form
any
amendment
this
Form
Indicate
check
mark
whether
the
registrant
large
accelerated
filer
accelerated
filer
non accelerated
filer
smaller
reporting
company
emerging
growth
company
See
the
definitions
large
accelerated
filer
accelerated
filer
smaller
reporting
company
and
emerging
growth
company
Rule
the
Exchange
Act
Large
accelerated
filer
Accelerated
filer
Non accelerated
filer
not
check
smaller
reporting
company
Smaller
reporting
company
Emerging
growth
company
emerging
growth
company
indicate
check
mark
the
registrant
has
elected
not
use
the
extended
transition
period
for
complying
with
any
new
revised
financial
accounting
standards
provided
pursuant
Section
the
Exchange
Act
Indicate
check
mark
whether
the
registrant
shell
company
defined
Rule
the
Exchange
Act
Yes
The
aggregate
market
value
the
voting
and
non voting
stock
held
non affiliates
the
registrant
June
the
last
business
day
the
registrant
most
recently
completed
second
fiscal
quarter
was
based
the
reported
last
sale
price
the
Nasdaq
Global
Select
Market
This
amount
excludes
aggregate
shares
common
stock
held
officers
and
directors
and
each
person
known
the
registrant
own
more
the
outstanding
common
stock
the
registrant
June
Exclusion
shares
held
any
person
should
not
construed
indicate
that
such
person
possesses
the
power
direct
indirect
direct
cause
the
direction
management
policies
the
registrant
that
such
person
controlled
under
common
control
with
the
registrant
The
number
shares
the
registrant
common
stock
outstanding
March
was
DOCUMENTS
INCORPORATED
REFERENCE
Portions
the
information
required
Part
III
this
report
Items
and
are
incorporated
reference
from
the
registrant
definitive
Proxy
Statement
for
its
Annual
Meeting
Stockholders
filed
within
days
the
close
the
registrant
fiscal
year
Table
Contents
BRUKER
CORPORATION
ANNUAL
REPORT
FORM
TABLE
CONTENTS
Page
Part
Item
Item
Item
Item
Item
Item
Business
Risk
Factors
Unresolved
Staff
Comments
Properties
Legal
Proceedings
Mine
Safety
Disclosure
Part
Item
Item
Item
Item
Item
Item
Item
Item
Market
for
Registrant
Common
Equity
Related
Stockholder
Matters
and
Issuer
Purchases
Equity
Securities
Selected
Financial
Data
Management
Discussion
and
Analysis
Financial
Condition
and
Results
Operations
Quantitative
and
Qualitative
Disclosures
About
Market
Risk
Financial
Statements
and
Supplementary
Data
Changes
and
Disagreements
with
Accountants
Auditing
and
Financial
Disclosure
Controls
and
Procedures
Other
Information
Part
III
Item
Item
Item
Item
Item
Directors
Executive
Officers
and
Corporate
Governance
Executive
Compensation
Security
Ownership
Certain
Beneficial
Owners
and
Management
and
Related
Stockholder
Matters
Certain
Relationships
and
Related
Transactions
and
Director
Independence
Principal
Accounting
Fees
and
Services
Part
Item
Exhibits
Financial
Statements
and
Schedules
Item
Form
Summary
Signatures
Any
statements
contained
this
Annual
Report
Form
that
are
not
statements
historical
fact
may
deemed
forward looking
statements
within
the
meaning
Section
the
Securities
Exchange
Act
Without
limiting
the
foregoing
the
words
believes
anticipates
plans
expects
seeks
estimates
should
and
similar
expressions
are
intended
identify
forward looking
statements
Any
forward looking
statements
contained
herein
are
based
current
expectations
but
are
subject
number
risks
and
uncertainties
The
factors
that
could
cause
actual
future
results
differ
materially
from
current
expectations
include
but
are
not
limited
risks
and
uncertainties
related
adverse
changes
the
economic
and
political
conditions
the
countries
which
operate
the
integration
businesses
have
acquired
may
acquire
the
future
our
restructuring
and
cost control
initiatives
changing
technologies
product
development
and
market
acceptance
our
products
the
cost
and
pricing
our
products
manufacturing
and
outsourcing
competition
dependence
collaborative
partners
key
suppliers
and
third
party
distributors
capital
spending
and
government
funding
policies
changes
governmental
regulations
intellectual
property
Table
Contents
rights
litigation
exposure
foreign
currency
fluctuations
our
ability
service
our
debt
obligations
and
fund
our
anticipated
cash
needs
and
other
factors
Many
these
factors
are
described
more
detail
this
Annual
Report
Form
under
Item
Risk
Factors
and
from
time
time
other
filings
may
make
with
the
Securities
and
Exchange
Commission
While
the
Company
may
elect
update
forward looking
statements
the
future
specifically
disclaims
any
obligation
even
the
Company
estimates
change
and
readers
should
not
rely
those
forward looking
statements
representing
the
Company
views
any
date
subsequent
the
date
the
filing
this
report
References
our
management
the
Company
refer
Bruker
Corporation
and
some
cases
its
subsidiaries
well
all
predecessor
entities
Our
principal
executive
offices
are
located
Manning
Road
Billerica
and
our
telephone
number
Information
about
Bruker
Corporation
available
bruker
The
information
our
website
not
incorporated
reference
into
and
does
not
form
part
this
report
All
trademarks
trade
names
copyrights
referred
this
report
are
the
property
their
respective
owners
Table
Contents
PART
ITEM
BUSINESS
Our
Business
are
developer
manufacturer
and
distributor
high performance
scientific
instruments
and
analytical
and
diagnostic
solutions
that
enable
our
customers
explore
life
and
materials
microscopic
molecular
and
cellular
levels
Many
our
products
are
used
detect
measure
and
visualize
structural
characteristics
chemical
biological
and
industrial
material
samples
Our
products
address
the
rapidly
evolving
needs
diverse
array
customers
life
science
research
pharmaceuticals
biotechnology
applied
markets
cell
biology
clinical
research
microbiology
vitro
diagnostics
nanotechnology
and
materials
science
research
Our
technology
platforms
include
magnetic
resonance
technologies
mass
spectrometry
technologies
gas
and
liquid
chromatography
triple
quadrupole
mass
spectrometry
technologies
ray
technologies
spark optical
emission
spectroscopy
atomic
force
microscopy
stylus
and
optical
metrology
technology
fluorescence
optical
microscopy
and
infrared
and
Raman
molecular
spectroscopy
technologies
also
develop
manufacture
and
distribute
broad
range
field
analytical
systems
for
chemical
biological
radiological
nuclear
and
explosives
CBRNE
detection
also
develop
manufacture
and
market
high
and
low
temperature
superconducting
materials
and
devices
based
primarily
metallic
low
temperature
superconductors
Our
corporate
headquarters
are
located
Billerica
Massachusetts
maintain
major
technical
and
manufacturing
centers
Europe
and
North
America
and
have
sales
offices
located
throughout
the
world
Business
Segments
have
two
reportable
segments
Bruker Scientific Instruments BSI
which
represented
approximately
our
revenues
during
the
year
ended
December
and
Bruker Energy Supercon Technologies BEST
which
represented
the
remainder
our
revenues
Within
BSI
are
organized
into
three
operating
segments
the
Bruker
BioSpin
Group
the
Bruker
CALID
Group
and
the
Bruker
Nano
Group
For
financial
reporting
purposes
the
Bruker
BioSpin
Bruker
CALID
and
Bruker
Nano
operating
segments
are
aggregated
into
the
BSI
reportable
segment
because
each
has
similar
economic
characteristics
production
processes
service
offerings
types
and
classes
customers
methods
distribution
and
regulatory
environments
BSI
Segment
Bruker BioSpin Group
The
Bruker
BioSpin
Group
comprises
the
Bruker
Magnetic
Resonance
Applied
Industrial
and
Clinical
Preclinical
Imaging
and
Service
and
Lifecycle
Support
Divisions
and
designs
manufactures
and
distributes
enabling
life
science
tools
based
magnetic
resonance
technology
Magnetic
resonance
natural
phenomenon
occurring
when
molecule
placed
magnetic
field
gives
off
signature
radio
frequency
The
signature
radio
frequency
characteristic
the
particular
molecule
and
provides
multitude
precise
chemical
and
structural
information
Depending
the
intended
application
market
and
sell
our
customers
NMR
system
EPR
system
each
defined
below
Bruker
BioSpin
also
manufactures
and
sells
single
and
multiple
modality
systems
using
MRI
PET
SPECT
and
MPI
each
defined
below
Bruker
BioSpin
products
which
have
particular
application
structural
proteomics
drug
discovery
pharmaceutical
and
biotechnology
research
and
production
and
food
and
materials
science
fields
provide
customers
with
the
ability
determine
the
structure
dynamics
and
function
specific
molecules
such
proteins
and
characterize
and
determine
the
composition
mixtures
Table
Contents
The
majority
Bruker
BioSpin
revenues
are
generated
academic
and
government
research
customers
Other
customers
include
pharmaceutical
and
biotechnology
companies
chemical
food
and
beverage
clinical
and
polymer
companies
and
nonprofit
laboratories
During
launched
number
new
products
and
technologies
including
the
next
generation
NMR
electronics
consoles
new
software
and
hardware
for
enhanced
workflow
solutions
for
NMR
spectroscopy
research
and
analysis
and
new
solution
for
the
quantification
metabolites
urine
using
NMR
Bruker
BioSpin
Group
instruments
are
based
the
following
technology
platforms
NMR
Nuclear
magnetic
resonance
EPR
Electron
paramagnetic
resonance
MRI
Magnetic
resonance
imaging
MPI
Magnetic
Particle
Imaging
PET
Positron
Emission
Tomography
SPECT
Single
Photon
Emission
Tomography
and
Computed
Tomography
NMR
qualitative
and
quantitative
analytical
technique
that
used
determine
the
molecular
structure
and
purity
sample
Molecules
are
placed
magnetic
field
and
give
off
radio
frequency
signature
that
recorded
sensitive
detector
Analysis
software
helps
determine
the
molecular
structure
the
sample
The
NMR
technique
used
academia
pharmaceutical
biotechnology
food
and
beverage
and
clinical
companies
and
other
industrial
users
life
science
and
material
science
research
EPR
process
absorption
microwave
radiation
paramagnetic
ions
molecules
with
least
one
unpaired
electron
that
spins
the
presence
static
magnetic
field
EPR
detects
unpaired
electrons
unambiguously
whereas
other
techniques
can
only
provide
indirect
evidence
their
presence
addition
EPR
can
identify
the
paramagnetic
species
that
are
detected
which
present
information
the
molecular
structure
near
the
unpaired
electron
and
give
insight
into
dynamic
processes
such
molecular
motions
fluidity
Our
EPR
instruments
are
used
for
wide
range
applications
including
advanced
materials
research
materials
analysis
and
quality
control
MRI
process
creating
image
from
the
manipulation
hydrogen
atoms
magnetic
field
the
presence
external
magnetic
field
atoms
will
align
with
against
the
external
magnetic
field
Application
radio
frequency
causes
the
atoms
jump
between
high
and
low
energy
states
MRI
and
magnetic
resonance
spectroscopy
MRS
include
many
methods
including
diffusion weighted
perfusion weighted
molecular
imaging
and
contrast enhance
MRI
offers
high
resolution
morphologic
information
well
functional
metabolic
molecular
information
Customers
use
our
MRI
systems
pharmaceutical
research
including
metabolomics
study
number
diseases
including
diabetes
neurology
oncology
and
cardiovascular
disorders
MPI
process
creating
image
from
magnetic
particles
administered
the
body
animal
The
magnetic
particles
are
manipulated
combination
oscillating
magnetic
fields
exhibiting
field
free
zone
The
response
the
particles
allows
real
time
data
set
acquisition
the
whole
body
animal
showing
the
contrast
agent
distributing
and
flowing
through
the
body
This
imaging
modality
used
detect
cardiovascular
disorders
PET
process
creating
image
from
positrons
after
administration
positron
emitting
radionuclide
the
body
animal
Annihilation
the
positron
produces
two
photons
which
show
angle
between
them
distinguishing
these
photons
from
photons
originating
from
other
Table
Contents
sources
The
PET
tracer
enriches
certain
regions
interest
within
the
body
and
gains
molecular
information
from
the
animal
vivo
This
has
widespread
applications
most
importantly
for
oncology
inflammation
neurology
and
cardiovascular
disorders
well
metabolic
disease
drug
discovery
and
bone
disease
SPECT
uses
contrast
agent
containing
radionuclides
which
directly
emit
single
photons
The
contrast
agent
enriches
certain
parts
the
body
animal
and
generates
images
the
radionuclide
distribution
the
body
SPECT
has
widespread
application
animal
investigations
vivo
most
importantly
oncology
neurology
and
cardiovascular
disorders
technology
based
rays
which
are
used
generate
complete
data
set
The
most
important
applications
are
tissue
sample
analysis
noninvasive
vivo animal
imaging
offers
the
highest
spatial
resolution
all
preclinical
imaging
modalities
and
especially
useful
generate
morphological
information
about
the
object
animal
under
investigation
being
used
wide
range
preclinical
investigations
such
bone orthopedics
cardiovascular
pulmonary
oncology
metabolism
and
others
Bruker CALID Group
The
Bruker
CALID
Group
comprises
the
Bruker
Daltonics
Bruker
Detection
and
Bruker
Optics
Divisions
The
Bruker
Daltonics
Division
primarily
designs
manufactures
and
distributes
life
science
mass
spectrometry
instruments
that
can
integrated
and
used
along
with
other
sample
preparation
chromatography
instruments
These
products
are
used
research
pharmaceutical
and
biotechnology
development
and
clinical
diagnostic
settings
Mass
spectrometers
are
sophisticated
devices
that
measure
the
mass
weight
molecule
and
can
provide
accurate
information
the
identity
quantity
and
primary
structure
molecules
Mass
spectrometry
based
solutions
often
combine
advanced
mass
spectrometry
instrumentation
automated
sampling
and
sample
preparation
robots
reagent
kits
and
other
disposable
products
used
conducting
tests
assays
and
bioinformatics
software
offer
mass
spectrometry
systems
and
integrated
solutions
for
applications
multiple
existing
and
emerging
life
science
markets
and
chemical
and
applied
markets
including
expression
proteomics
clinical
proteomics
metabolic
and
peptide
biomarker
profiling
drug
discovery
and
development
molecular
diagnostics
research
and
molecular
and
systems
biology
well
basic
molecular
medicine
research
and
clinical
microbiology
for
vitro
diagnostic
IVD
use
only
certain
countries
and
certain
configurations
The
Bruker
Detection
Division
supplies
various
systems
based
mass
spectrometry
ion
mobility
spectrometry
infrared
spectroscopy
and
radiological nuclear
detectors
for
Chemical
Biological
Radiological
Nuclear
and
Explosive
CBRNE
detection
emergency
response
homeland
security
and
defense
applications
The
Bruker
Optics
Division
manufactures
and
distributes
research
analytical
and
process
analysis
instruments
and
solutions
based
infrared
and
Raman
molecular
spectroscopy
technologies
These
products
are
utilized
industry
government
and
academia
for
wide
range
applications
and
solutions
for
life
science
pharmaceutical
food
and
agricultural
analysis
quality
control
and
process
analysis
applications
Infrared
and
Raman
spectroscopy
are
widely
used
both
research
and
industry
simple
rapid
nondestructive
and
reliable
techniques
for
applications
ranging
from
basic
sample
identification
and
quality
control
advanced
research
The
Bruker
Optics
Division
also
utilizes
Fourier
transform
and
dispersive
Raman
measurement
techniques
extensive
range
laboratory
and
process
spectrometers
The
Bruker
Optics
Division
products
are
complemented
wide
range
sampling
accessories
and
techniques
which
include
among
others
microanalysis
and
high throughput
screening
help
users
find
suitable
solutions
analyze
their
samples
effectively
Customers
our
Bruker
CALID
Group
include
pharmaceutical
biotechnology
and
diagnostics
companies
contract
research
organizations
academic
institutions
medical
schools
nonprofit
Table
Contents
for profit
forensics
agriculture
food
and
beverage
safety
environmental
and
clinical
microbiology
laboratories
hospitals
and
government
departments
and
agencies
During
launched
number
new
mass
spectrometry
based
product
solutions
including
the
timsTOFPro
for
PASEF
mass
spectrometry
which
uses
proprietary
trapped
ion
mobility
spectrometry
introduced
major
innovations
for
strain
typing
hospital
hygiene
and
infection
control
with
the
Biotyper
also
expanded
the
assay
and
consumable
kits
offer
further
enhance
the
MALDI
Biotyper
platform
Software
releases
accompanied
our
instrument
solutions
launches
The
Bruker
CALID
Group
instruments
are
based
the
following
technology
platforms
MALDI TOF
Matrix assisted
laser
desorption
ionization
time flight
mass
spectrometry
including
tandem
time flight
systems
MALDITOF TOF
ESI TOF
Electrospray
ionization
time flight
spectrometry
including
tandem
mass
spectrometry
systems
based
ESI quadrupole TOF
mass
spectrometry
ESI TOF
FTMS
Fourier
transform
mass
spectrometry
including
hybrid
systems
with
quadrupole
front
end
FTMS
ITMS
Ion
trap
mass
spectrometry
Gas
chromatography mass
spectrometry
systems
utilizing
triple quadrupole
time flight
mass
spectrometry
Liquid
chromatography mass
spectrometry
systems
utilizing
triple quadrupole
time
flight
mass
spectrometry
Fourier
transform infrared
spectroscopy
NIR
Near infrared
spectroscopy
and
Raman
Raman
spectroscopy
MALDI TOF
mass
spectrometers
utilize
ionization
process
analyze
solid
samples
using
laser
that
combines
high
sample
throughput
with
high
mass
range
and
sensitivity
Our
MALDI TOF
mass
spectrometers
are
particularly
useful
for
applications
clinical
diagnostics
environmental
and
taxonomical
research
and
food
processing
and
quality
control
Specific
applications
include
oligonucleotide
and
synthetic
polymer
analysis
protein
identification
and
quantification
peptide
novo
sequencing
determination
post translational
modifications
proteins
interaction
proteomics
and
protein
function
analysis
drug
discovery
and
development
and
fast
body
fluid
and
tissue
peptide
protein
biomarker
detection
MALDI
mass
spectrometry
allows
users
classify
and
identify
microorganisms
quickly
and
reliably
with
minimal
sample
preparation
efforts
and
life
cycle
costs
Our
MALDI
Biotyper
solution
which
serves
the
clinical
microbiology
market
enables
identification
taxonomical
classification
dereplication
microorganisms
like
bacteria
yeasts
and
fungi
ESI TOF
mass
spectrometers
utilize
electrospray
ionization
process
analyze
liquid
samples
This
ionization
process
which
does
not
dissociate
the
molecules
allows
for
rapid
data
acquisition
and
analysis
large
biological
molecules
ESI TOF
mass
spectrometers
are
particularly
useful
for
identification
protein
analysis
and
functional
complex
analysis
proteomics
and
protein
function
molecular
identification
metabolomics
natural
product
and
drug
metabolite
analysis
combinatorial
chemistry
high
throughput
screening
and
fast
liquid
chromatography
mass
spectrometry
liquid
chromatography
mass
spectrometry
LCMS
drug
discovery
and
development
FTMS
systems
utilize
high field
superconducting
magnets
offer
the
highest
resolution
selectivity
and
mass
accuracy
currently
achievable
mass
spectrometry
Our
systems
based
this
technology
often
eliminate
the
need
for
time consuming
separation
techniques
complex
mixture
analyses
Table
Contents
addition
our
systems
can
fragment
molecular
ions
perform
exact
mass
analysis
all
fragments
determine
molecular
structure
FTMS
systems
are
particularly
useful
for
the
study
structure
and
function
biomolecules
including
proteins
DNA
and
natural
products
complex
mixture
analysis
including
body
fluids
combinatorial
libraries
high throughput
proteomics
and
metabolomics
and
top down
proteomics
intact
proteins
without
the
need
for
enzymatic
digestion
the
proteins
prior
analysis
offer
next generation
hybrid
FTMS
systems
that
combine
traditional
external
quadrupole
mass
selector
and
hexapole
collision
cell
with
high performance
FTMS
for
further
ion
dissociation
top down
proteomics
tools
and
ultra high
resolution
detection
ITMS
systems
collect
all
ions
simultaneously
which
improves
sensitivity
relative
previous
quadrupole
mass
spectrometers
Ion
trap
mass
spectrometers
are
particularly
useful
for
sequencing
and
identification
based
peptide
structural
analysis
quantitative
liquid
chromatography
mass
spectrometry
identification
combinatorial
libraries
and
generally
enhancing
the
speed
and
efficiency
the
drug
discovery
and
development
process
systems
combine
the
features
gas
chromatography
and
mass
spectrometry
identify
different
substances
within
test
sample
The
two
components
used
together
allow
for
finer
degree
substance
identification
than
either
system
when
used
separately
The
result
quantitative
analysis
the
components
and
the
mass
spectrum
each
component
Our
systems
are
available
triple
quadrupole
configurations
and
can
configured
with
variety
options
suit
range
applications
Our
systems
have
applications
food
and
product
safety
forensics
clinical
and
toxicology
testing
and
environmental
pharmaceutical
and
chemical
analysis
systems
combine
the
separation
features
liquid
chromatography
with
the
molecular
identification
features
mass
spectrometry
separate
identify
and
quantify
different
substances
within
test
sample
complementary
technique
which
analyzes
volatile
compounds
can
used
analyze
wide
range
non volatile
compounds
complex
samples
Our
systems
are
available
wide
range
configurations
suit
user
specific
needs
Although
primarily
used
for
life
science
applications
our
systems
also
have
applications
food
and
product
safety
forensics
and
clinical
and
toxicology
testing
well
environmental
pharmaceutical
and
chemical
analysis
spectrometers
utilize
the
mid
and
far infrared
regions
the
electromagnetic
spectrum
Our
systems
are
commonly
used
for
various
quality
control
and
materials
research
applications
NIR
spectrometers
utilize
the
near infrared
region
the
electromagnetic
spectrum
Our
NIR
instruments
are
primarily
used
for
quality
and
process
control
applications
the
pharmaceutical
food
and
agriculture
and
chemical
industries
The
pharmaceutical
industry
the
leading
user
NIR
instruments
and
applications
include
quality
control
research
and
development
and
process
analytical
technology
The
food
and
agricultural
industry
the
second
largest
user
NIR
instrumentation
with
increasing
demand
for
food
forage
and
beverage
quality
control
Raman
spectroscopy
provides
information
molecular
structure
The
mechanism
Raman
scattering
different
from
that
infrared
absorption
that
Raman
and
spectra
provide
complementary
information
Raman
useful
for
the
identification
both
organic
and
inorganic
compounds
and
functional
groups
nondestructive
technique
and
can
used
for
the
analysis
both
liquids
and
solids
Raman
well
suited
for
use
the
polymer
and
pharmaceutical
industries
and
has
applications
the
metals
electronics
and
semiconductors
industries
The
technique
also
has
applications
life
sciences
forensics
and
artwork
authentication
Additionally
the
Bruker
Detection
Division
offers
wide
range
portable
analytical
and
bioanalytical
detection
systems
and
related
products
for
CBRNE
detection
Our
customers
use
these
devices
for
nuclear
biological
agent
and
chemical
agent
defense
applications
anti terrorism
law
enforcement
and
process
and
facilities
monitoring
Our
CBRNE
detection
products
use
many
the
Table
Contents
same
technology
platforms
our
life
science
products
well
additional
technologies
including
infrared
stand off
detection
and
ion
mobility
spectrometry
for
handheld
chemical
detectors
also
provide
integrated
comprehensive
detection
suites
that
include
our
multiple
detection
systems
consumables
training
and
simulators
Bruker Nano Group
The
Bruker
Nano
Group
comprises
the
Bruker
AXS
Bruker
Nano
Surfaces
Bruker
Nano
Analytics
and
Bruker
Semiconductor
Divisions
The
Bruker
AXS
Division
designs
manufactures
and
distributes
advanced
ray
instruments
that
use
electromagnetic
radiation
with
extremely
short
wavelengths
determine
the
characteristics
matter
and
the
three dimensional
structure
molecules
This
includes
product
portfolio
instruments
based
ray
fluorescence
spectroscopy
XRF
ray
diffraction
XRD
and
ray
micro
computed
tomography
well
spark
optical
emission
spectroscopy
systems
OES
used
analyze
the
concentration
elements
metallic
samples
Bruker
Nano
Surfaces
Division
products
include
atomic
force
microscopy
instrumentation
AFM
Such
instruments
provide
atomic
near
atomic
resolution
surface
topography
and
mechanical
electrical
and
chemical
information
using
nano
scale
probes
addition
the
Bruker
Nano
Surfaces
Division
provides
advanced
fluorescence
optical
microscopy
instruments
for
multi photon
multipoint
scanning
confocal
and
high speed
super resolution
studies
life
science
applications
The
Bruker
Nano
Surfaces
Division
also
provides
non contact
nanometer
resolution
topography
through
white
light
interferometry
and
stylus
profilometry
The
Bruker
Nano
Analytics
Division
manufactures
and
markets
analytical
tools
for
electron
microscopes
including
energy dispersive
ray
spectrometers
EDS
electron
backscatter
diffraction
systems
EBSD
and
accessories
well
mobile
and
bench top
micro
ray
fluorescence
total
reflection
ray
fluorescence
spectrometers
TXRF
and
handheld
portable
and
mobile
ray
fluorescence
HMP XRF
spectrometry
instruments
The
Bruker
Semiconductor
Division
manufactures
and
markets
ray
metrology
and
automated
AFM
defect detection
equipment
for
semiconductor
process
control
Customers
our
Bruker
Nano
Group
include
biotechnology
and
pharmaceutical
companies
academic
institutions
governmental
customers
nanotechnology
companies
semiconductor
companies
raw
material
manufacturers
industrial
companies
and
other
businesses
involved
materials
analysis
During
launched
several
new
products
including
the
next
generation
wavelength
dispersive
XRF
spectrometer
and
new
high
performance
technology
for
laboratory
macromolecular
crystallography
also
released
next
generation
models
several
other
products
including
the
EBSD
detectors
and
software
The
Bruker
Nano
Group
systems
are
based
the
following
technology
platforms
XRD
Polycrystalline
ray
diffraction
often
referred
ray
diffraction
XRF
ray
fluorescence
also
called
ray
spectrometry
including
handheld
XRF
systems
XRD
Single
crystal
ray
diffraction
often
referred
ray
crystallography
ray
micro
computed
tomography
EDS
Energy
dispersive
ray
spectroscopy
electron
microscopes
EBSD
Electron
backscatter
diffraction
electron
microscopes
OES
Spark
optical
emission
spectroscopy
Table
Contents
ONH
Combustion
analysis
for
carbon
sulfur
oxygen
nitrogen
and
hydrogen
solids
AFM
Atomic
force
microscopy
Fluorescence
optical
microscopy
SOM
Stylus
and
optical
metrology
and
TMT
Tribology
and
mechanical
test
systems
for
analysis
friction
and
wear
XRD
systems
investigate
polycrystalline
samples
thin
films
with
single
wavelength
rays
The
atoms
the
polycrystalline
sample
scatter
the
rays
create
unique
diffraction
pattern
recorded
detector
Computer
software
processes
the
pattern
and
produces
variety
information
including
stress
texture
qualitative
and
quantitative
phase
composition
crystallite
size
percent
crystallinity
and
layer
thickness
composition
defects
and
density
thin
films
and
semiconductor
material
Our
XRD
systems
contribute
reduction
the
development
cycles
for
new
products
the
catalyst
polymer
electronic
optical
material
and
semiconductor
industries
Customers
also
use
our
XRD
systems
academic
and
government
research
facilities
well
variety
other
fields
including
forensics
art
and
archaeology
XRF
systems
determine
the
elemental
composition
material
and
provide
full
qualitative
and
quantitative
analysis
Our
XRF
systems
direct
rays
sample
and
the
atoms
the
sample
absorb
the
ray
energy
The
elements
the
sample
then
emit
rays
that
are
characteristic
for
each
element
The
system
collects
the
rays
and
the
software
analyzes
the
resulting
data
determine
the
elements
that
are
present
Our
XRF
products
provide
automated
solutions
turn key
basis
for
industrial
users
that
require
automated
controlled
production
processes
that
reduce
product
and
process
cost
increase
output
and
improve
product
quality
Our
XRF
products
cover
substantially
all
the
periodic
table
and
can
analyze
solid
powder
liquid
samples
XRD
systems
determine
the
three dimensional
structures
molecules
chemical
mineral
biological
substance
being
analyzed
XRD
systems
have
the
capability
determine
structure
both
small
chemical
molecules
and
larger
biomolecules
XRD
systems
direct
ray
beam
solid
single
crystal
sample
The
atoms
the
crystal
sample
scatter
the
rays
create
precise
diffraction
pattern
recorded
electronic
detector
Software
then
reconstructs
model
the
structure
and
provides
the
unique
arrangement
the
atoms
the
sample
This
information
the
exact
arrangement
atoms
the
sample
critical
part
molecular
analysis
and
can
provide
insight
into
variety
areas
including
how
protein
functions
interacts
with
second
molecule
Our
XRD
systems
are
designed
for
use
the
life
sciences
industry
academic
research
and
variety
other
applications
ray
imaging
the
same
method
used
hospital
scans
but
small
scale
with
massively
increased
resolution
microscopy
allows
users
image
the
internal
structure
objects
non destructively
very
fine
scale
Bruker
available
range
easy use
desktop
instruments
which
generate
images
the
sample
morphology
and
internal
microstructure
with
resolution
down
the
sub micron
level
Our
systems
are
used
for
numerous
applications
materials
research
and
the
life
sciences
industry
EDS
systems
analyze
the
chemical
composition
materials
under
investigation
electron
microscopes
utilizing
the
fact
that
atoms
different
chemical
elements
when
exposed
the
high
energy
electron
beam
generated
the
microscope
irradiate
rays
different
characteristic
energy
The
evaluation
the
energy
spectrum
collected
our
spectrometer
allows
the
determination
the
qualitative
and
quantitative
chemical
sample
composition
the
current
beam
position
EDS
systems
allow
for
simultaneous
analysis
all
elements
the
periodic
table
beginning
with
atomic
number
beryllium
Our
EDS
systems
are
used
for
range
applications
including
nanotechnology
and
Table
Contents
advanced
materials
research
well
materials
analysis
and
quality
control
Customers
for
EDS
systems
include
industrial
customers
academia
and
government
research
facilities
EBSD
systems
are
used
perform
quantitative
microstructure
analysis
crystalline
samples
electron
microscopes
The
microscope
electron
beam
strikes
the
tilted
sample
and
diffracted
electrons
form
pattern
fluorescent
screen
This
pattern
characteristic
the
crystal
structure
and
orientation
the
sample
region
from
which
was
generated
provides
the
absolute
crystal
orientation
with
sub micron
resolution
EBSD
can
used
characterize
materials
with
regard
crystal
orientation
texture
stress
strain
and
grain
size
EBSD
also
allows
the
identification
crystalline
phases
and
their
distribution
and
applied
many
industries
such
metals
processing
aerospace
automotive
microelectronics
and
earth
sciences
OES
instruments
are
used
for
analyzing
metals
OES
covers
broad
range
applications
for
metals
analysis
from
pure
metals
trace
analysis
high
alloyed
grades
and
allow
for
analysis
complete
range
relevant
elements
simultaneously
OES
instruments
pass
electric
spark
onto
sample
which
burns
the
surface
the
sample
and
causes
atoms
jump
higher
orbit
Our
detectors
quantify
the
light
emitted
these
atoms
and
help
our
customers
determine
the
elemental
composition
the
material
This
technique
widely
used
production
control
laboratories
foundries
and
steel
mills
ONH
carrier
gas
systems
incorporate
furnace
and
infrared
thermal
conductivity
detection
analyze
inorganic
materials
for
the
determination
carbon
sulfur
nitrogen
oxygen
and
hydrogen
Combustion
and
inert
gas
fusion
analyzers
are
used
for
applications
metal
production
and
processing
chemicals
ceramics
and
cement
coal
processing
oil
refining
and
semiconductors
AFM
systems
provide
atomic
near atomic
resolution
material
surface
topography
using
nano scale
probe
that
brought
into
light
contact
with
the
sample
being
investigated
addition
presenting
surface
image
AFM
can
also
provide
quantitative
nano scale
measurements
feature
sizes
material
properties
electrical
information
chemical
properties
and
other
sample
characteristics
Our
AFM
systems
are
used
for
applications
academic
and
governmental
materials
and
biological
research
and
semiconductor
data
storage
hard
drive
LED
battery
solar
cells
polymers
and
pharmaceutical
product
development
and
manufacturing
products
use
fluorescence
microscopy
determine
the
structure
and
composition
life
science
samples
Our
products
include
two photon
microscopes
multipoint
scanning
confocal
microscopes
laser
illumination
sources
photoactivation
photostimulation
and
photoablation
accessories
and
synchronization
and
analysis
software
Two photon
microscopes
allow
imaging
deep
into
tissues
and
cells
and
are
used
widely
neuroscience
Multipoint
scanning
confocal
systems
allow
live
cell
imaging
with
rapid
acquisition
images
for
structural
and
composition
analysis
also
offer
super resolution
and
single molecule
localization
microscopy
products
which
can
break
the
optical
diffraction
limit
order
magnitude
SOM
systems
provide
atomic
near atomic
two
dimensional
and
three
dimensional
surface
resolution
using
white
light
interferometry
confocal
optical
and
stylus
profilometry
methods
SOM
profilers
range
from
low cost
manual
tools
for
single
measurements
advanced
highly
automated
systems
for
production
line
quality
assurance
and
quality
control
applications
where
the
combination
throughput
repeatability
and
reproducibility
essential
SOM
profilers
support
range
applications
research
product
development
tribology
quality
control
and
failure
analysis
related
materials
and
machining
the
automotive
orthopedic
ophthalmic
high
brightness
LED
semiconductor
data
storage
optics
and
other
markets
TMT
systems
provide
platform
for
all
types
common
mechanical
friction
durability
scratch
and
indentation
tests
for
wide
spectrum
materials
Tribology
systems
are
utilized
for
both
academic
research
the
fundamental
material
properties
and
industrial
applications
the
semiconductor
aerospace
petroleum
automotive
and
other
industries
Table
Contents
BEST
Segment
BEST
designs
manufactures
and
distributes
superconducting
materials
primarily
metallic
low
temperature
superconductors
for
use
magnetic
resonance
imaging
nuclear
magnetic
resonance
fusion
energy
research
and
other
applications
BEST
also
develops
manufactures
and
markets
ceramic
second
generation
high
temperature
superconductors
for
energy
technology
and
magnet
research
applications
Additionally
BEST
develops
manufactures
and
markets
sophisticated
devices
and
complex
tools
based
primarily
metallic
low
temperature
superconductors
that
have
applications
big
science
research
including
radio
frequency
accelerator
cavities
and
modules
power
couplers
and
linear
accelerators
BEST
also
manufactures
and
sells
non superconducting
high
technology
tools
such
synchrotron
and
beamline
instrumentation
principally
customers
engaged
materials
research
and
big
science
research
projects
Sales
and
Marketing
maintain
direct
sales
forces
throughout
North
America
Europe
Russia
China
Japan
and
elsewhere
the
Asia
Pacific
region
also
utilize
indirect
sales
channels
reach
customers
have
various
international
distributors
independent
sales
representatives
and
various
other
representatives
parts
Asia
Latin
America
Africa
the
Middle
East
and
Eastern
Europe
These
entities
augment
our
direct
sales
force
and
provide
coverage
areas
where
not
have
direct
sales
personnel
addition
have
adopted
distribution
business
model
which
engage
strategic
distribution
alliances
with
other
companies
address
certain
market
segments
The
sales
cycle
for
our
products
dependent
the
size
and
complexity
the
system
and
budgeting
cycles
our
customers
Our
sales
cycle
typically
three
twenty four
months
for
academic
and
high end
research
products
and
two
weeks
six
months
for
industrial
products
The
sales
cycle
our
low
temperature
superconducting
materials
typically
four
twelve
months
with
cycles
certain
high end
materials
exceeding
one
year
Sales
our
high end
NMR
and
superconducting
devices
typically
take
more
than
one
year
and
certain
large
complex
contracts
can
take
more
than
two
years
complete
have
well equipped
applications
and
demonstration
facilities
and
qualified
application
personnel
who
assist
customers
and
provide
product
demonstrations
specific
application
areas
maintain
our
primary
demonstration
facilities
our
production
facilities
well
other
key
market
locations
Seasonal
Nature
Business
Historically
have
higher
levels
revenue
the
fourth
quarter
and
lower
levels
revenues
the
first
quarter
the
year
which
believe
influenced
our
customers
budgeting
cycles
Major
Customers
The
Company
has
broad
and
diversified
customer
base
and
not
depend
any
single
customer
single
customer
accounted
for
more
than
revenue
any
the
last
three
fiscal
years
more
than
accounts
receivable
December
Competition
Our
existing
products
and
solutions
and
any
products
and
solutions
that
develop
the
future
may
compete
multiple
highly
competitive
markets
addition
there
has
been
trend
towards
consolidation
our
industries
and
many
our
competitors
have
substantially
greater
financial
technical
and
marketing
resources
than
Our
competitors
may
succeed
developing
and
offering
products
that
could
render
our
products
those
our
strategic
partners
obsolete
noncompetitive
Our
competitors
may
also
have
cost
and
price
advantages
based
upon
the
value
their
currencies
compared
with
the
Dollar
Euro
addition
many
these
competitors
have
significantly
more
Table
Contents
experience
the
life
sciences
chemical
and
materials
markets
Our
ability
compete
successfully
will
depend
our
ability
develop
proprietary
products
that
reach
our
target
markets
timely
manner
and
are
technologically
superior
and
less
expensive
more
cost
effective
than
products
marketed
our
competitors
Current
competitors
other
companies
may
possess
develop
technologies
and
products
that
are
more
effective
than
ours
Our
technologies
and
products
may
rendered
obsolete
uneconomical
technological
advances
entirely
different
approaches
developed
one
more
our
competitors
also
compete
with
companies
that
provide
analytical
automation
tools
based
technologies
other
than
those
offer
These
technologies
may
prove
more
successful
meeting
demands
the
markets
that
our
products
and
solutions
are
intended
serve
addition
other
companies
may
choose
enter
our
fields
the
future
believe
that
the
principal
competitive
factors
our
markets
are
technology based
applications
expertise
product
specifications
functionality
reliability
marketing
expertise
distribution
capability
proprietary
patent
portfolios
and
cost
effectiveness
BSI
Segment
Bruker
BioSpin
competes
with
companies
that
offer
magnetic
resonance
spectrometers
mainly
JEOL
and
Oxford
Instruments
the
field
preclinical
imaging
Bruker
BioSpin
competes
with
Perkin
Elmer
Mediso
Trifoil
Solutions
and
others
Bruker
CALID
competes
with
variety
companies
that
offer
mass
spectrometry
based
systems
Bruker
CALID
competitors
the
life
science
markets
and
chemical
and
applied
markets
include
Danaher
Agilent
GEHealthcare
Waters
Thermo
Fisher
Scientific
Shimadzu
Hitachi
and
JEOL
the
microbiology
market
compete
with
Biomerieux
Bruker
CALID
CBRNE
detection
customers
are
highly
fragmented
and
compete
with
number
companies
this
area
which
the
most
significant
competitor
Smiths
Detection
Bruker
CALID
also
competes
with
variety
companies
that
offer
molecular
spectrometry
based
systems
including
Thermo
Fisher
Scientific
PerkinElmer
Agilent
Foss
ABB
Bomem
Buchi
Shimadzu
and
Jasco
addition
there
are
several
smaller
companies
specializing
various
markets
with
which
the
Bruker
CALID
Group
frequently
competes
Bruker
Nano
competes
with
companies
that
offer
analytical
ray
solutions
OES
systems
AFM
and
SOM
systems
and
optical
fluorescence
systems
primarily
Rigaku
Oxford
Instruments
Agilent
Thermo
Fisher
Scientific
Ametek
Spectro
and
Edax
divisions
PANalytical
Olympus
Nikon
Zeiss
and
Danaher
Leica
business
BEST
Segment
BEST
competes
with
Luvata
and
Jastec
Ltd
low
temperature
superconducting
materials
addition
BEST
competes
with
Fujikura
SuperPower
Furukawa
company
Superconductor
Technologies
Inc
and
SuNam
Ltd
the
market
for
second
generation
high
temperature
superconducting
materials
BEST
further
competes
with
Zanon
Mitsubishi
Electric
and
AES
the
development
and
supply
accelerator
cavities
with
Thales
Toshiba
and
CPI
International
the
development
and
supply
radio
frequency
couplers
with
Mitsubishi
Heavy
Industries
the
development
and
supply
superconducting
accelerator
modules
and
with
AES
and
Thales
for
electron
linear
accelerators
Manufacturing
and
Supplies
Several
our
manufacturing
facilities
are
certified
under
ISO
and
ISO
international
quality
standard
manufacture
and
test
our
magnetic
resonance
products
our
facilities
Faellanden
Switzerland
Wissembourg
France
and
Karlsruhe
Germany
manufacture
and
test
our
preclinical
imaging
products
our
facilities
Ettlingen
Germany
Wissembourg
France
Kontich
Belgium
and
Faellanden
Switzerland
manufacture
and
test
our
mass
spectrometry
products
including
CBRNE
detection
products
our
facilities
Bremen
Germany
and
Leipzig
Germany
principally
manufacture
and
test
our
molecular
spectroscopy
products
our
facilities
Table
Contents
Ettlingen
Germany
manufacture
and
test
our
ray
OES
and
AFM
products
our
facilities
Karlsruhe
Germany
Berlin
Germany
Madison
Wisconsin
Santa
Barbara
California
Kennewick
Washington
and
Migdal
Emek
Israel
manufacture
and
test
the
majority
our
energy
and
superconducting
products
our
facilities
Hanau
Germany
Bergisch
Gladbach
Germany
Perth
Scotland
and
Carteret
New
Jersey
Manufacturing
processes
our
facilities
Europe
Israel
and
California
include
all
phases
manufacturing
such
machining
fabrication
subassembly
system
assembly
and
final
testing
Our
other
facilities
primarily
perform
high level
assembly
system
integration
and
final
testing
typically
manufacture
critical
components
house
ensure
key
competence
and
outsource
third
party
manufacturers
non
critical
components
purchase
materials
and
components
from
various
suppliers
that
are
either
standard
products
built
our
specifications
obtain
some
the
components
included
our
products
from
limited
group
suppliers
from
single source
supplier
for
items
such
charge
coupled
device
area
detectors
Xray
tubes
robotics
infrared
optics
and
others
Bruker
AXS
has
ongoing
collaboration
and
joint
development
project
with
the
Siemens
Medical
Solutions
Vacuum
Technology
Division
Germany
for
the
development
ray
tubes
Some
Bruker
entities
specifically
Bruker
Nano
GmbH
and
Bruker
AXS
Handheld
Inc
presently
procure
key
ray
detector
chips
and
certain
OES
optical
detectors
and
miniaturized
ray
sources
from
single source
suppliers
addition
BEST
sources
niobium
titanium
and
other
niobium
products
from
single
supplier
Research
and
Development
commit
substantial
capital
and
resources
internal
and
collaborative
research
and
development
projects
order
provide
innovative
products
and
solutions
our
customers
conduct
research
primarily
enhance
system
performance
and
improve
the
reliability
existing
products
and
develop
revolutionary
new
products
and
solutions
expensed
million
revenue
million
revenue
and
million
revenue
and
respectively
for
research
and
development
purposes
Our
research
and
development
efforts
are
conducted
for
the
relevant
products
within
each
the
operating
segments
well
collaboration
with
others
areas
such
microfluidics
automation
and
workflow
management
software
have
been
the
recipient
government
grants
from
Germany
and
the
United
States
for
various
projects
related
early stage
research
and
development
have
generally
retained
minimum
non exclusive
rights
any
items
enhancements
develop
under
these
grants
The
German
government
requires
that
use
and
market
technology
developed
under
grants
order
retain
our
rights
the
technology
have
also
accepted
some
sponsored
research
contracts
from
private
sources
BSI
Segment
The
research
and
development
performed
the
BSI
Segment
primarily
conducted
our
facilities
Bremen
Ettlingen
Karlsruhe
and
Leipzig
Germany
Faellanden
Switzerland
Wissembourg
France
Billerica
Massachusetts
Madison
Wisconsin
San
Jose
and
Santa
Barbara
California
The
Bruker
BioSpin
Group
maintains
technical
competencies
core
magnetic
resonance
technologies
and
single
and
multimodal
imaging
technologies
and
capabilities
including
NMR
EPR
MRI
MPI
PET
and
Recent
projects
include
the
development
solid
state
dynamic
nuclear
polarization
technologies
ongoing
development
that
enables
gains
sensitivity
for
NMR
high
field
EPR
instrumentation
with
dedicated
cryogen
free
magnets
high
field
magnet
technology
for
preclinical
MRI
basic
NMR
research
and
quadrupole
tuned
cryoprobes
for
biological
research
well
MPI
imaging
for
preclinical
application
Table
Contents
The
Bruker
CALID
Group
maintains
technical
competencies
core
mass
spectrometry
technologies
and
capabilities
including
MALDI
ESI
and
ion
source
TOF
TOF TOF
ion
traps
FTMS
quadrupole
and
IMS
analyzers
and
bioinformatics
Recent
projects
include
the
rapifleX
MALDI
Tissuetyper
which
Bruker
Daltonics
high throughput
MALDI
imaging
solution
that
provides
enhanced
high resolution
molecular
information
and
distribution
tissues
Another
recent
project
includes
the
innovative
timsTOF
mass
spectrometer
for
separation
and
analysis
unresolved
compounds
and
conformations
The
Bruker
CALID
Group
also
maintains
technical
competencies
core
vibrational
spectroscopy
technologies
and
capabilities
including
NIR
and
Raman
The
Bruker
Nano
Group
maintains
technical
competencies
core
ray
technologies
and
capabilities
including
detectors
used
sense
ray
and
ray
diffraction
patterns
ray
sources
and
optics
that
generate
and
focus
the
rays
robotics
and
sample
handling
equipment
that
holds
and
manipulates
the
experimental
material
and
software
that
generates
the
structural
data
Recent
projects
include
refining
next generation
high
brilliancy
optics
and
microsources
developing
new
high power
ray
sources
for
ray
diffraction
and
protein
crystallography
applications
developing
TXRF
system
for
trace
element
analysis
semiconductor
metrology
developing
new
large
solid
angle
high resolution
high throughput
energy
dispersive
ray
detector
for
microanalysis
creating
high
sensitivity
area
detector
system
and
developing
other
solution based
technologies
and
software
applications
including
product
for
ray
scattering
investigations
protein
crystals
The
Bruker
Nano
Group
also
has
competencies
AFM
technology
which
involve
sub angstrom
level
position
and
motion
control
well
sub pico
newton
force
control
The
Bruker
Nano
Group
technologies
also
include
optical
inference
based
microscopy
stylus
profilometry
tribology
testing
nano indentation
optical
fluorescence
two photon
microscopy
multipoint
scanning
microscopy
and
high speed
super resolution
florescence
microscopy
Recent
innovations
include
elemental
analyzer
systems
for
advanced
applications
and
research
and
simultaneous
all optical
stimulation
and
imaging
platforms
for
neuroscience
applications
BEST
Segment
The
research
and
development
performed
the
BEST
Segment
primarily
conducted
our
facilities
Hanau
Bergisch
Gladbach
and
Alzenau
Germany
and
Carteret
New
Jersey
BEST
maintains
technical
competencies
the
production
and
development
low
and
high
temperature
superconducting
materials
and
devices
Intellectual
Property
Our
intellectual
property
consists
patents
copyrights
trade
secrets
know how
and
trademarks
Protection
our
intellectual
property
strategic
priority
for
our
businesses
because
the
length
time
and
expense
associated
with
bringing
new
products
through
the
development
process
and
the
marketplace
have
substantial
patent
portfolio
and
intend
file
additional
patent
applications
appropriate
believe
our
owned
and
licensed
patent
portfolio
provides
with
competitive
advantage
This
portfolio
permits
maintain
access
number
key
technologies
license
our
owned
patent
rights
where
appropriate
intend
enforce
our
patent
rights
against
infringers
necessary
The
patent
positions
life
sciences
tools
companies
involve
complex
legal
and
factual
questions
result
cannot
predict
the
enforceability
our
patents
with
certainty
addition
are
aware
the
existence
from
time
time
patents
certain
countries
which
valid
could
impair
our
ability
manufacture
and
sell
products
these
countries
also
rely
upon
trade
secrets
know how
trademarks
copyright
protection
and
licensing
develop
and
maintain
our
competitive
position
generally
require
the
execution
confidentiality
agreements
our
employees
consultants
and
other
scientific
advisors
These
agreements
provide
that
all
confidential
information
made
known
during
the
course
relationship
with
will
held
Table
Contents
confidence
and
used
only
for
our
benefit
addition
these
agreements
provide
that
own
all
inventions
generated
during
the
course
the
relationship
Government
Contracts
are
party
various
government
contracts
Under
some
these
government
contracts
the
government
may
receive
license
similar
rights
intellectual
property
developed
under
the
contract
However
under
government
contracts
enter
generally
receive
least
non exclusive
rights
any
items
technologies
develop
Although
transact
business
with
various
government
agencies
believe
that
government
contract
such
magnitude
that
renegotiation
profits
termination
the
contract
subcontracts
the
election
the
government
would
have
material
adverse
effect
our
financial
results
Government
Regulation
are
required
comply
with
federal
state
and
local
environmental
protection
regulations
not
expect
this
compliance
have
significant
impact
our
capital
spending
earnings
competitive
position
Prior
introducing
product
the
United
States
our
Bruker
AXS
subsidiary
provides
notice
the
Food
and
Drug
Administration
FDA
the
form
Radiation
Safety
Initial
Product
Abbreviated
Report
which
provides
identification
information
and
operating
characteristics
the
product
the
FDA
finds
that
the
report
complete
provides
approval
the
form
what
known
accession
number
Bruker
AXS
may
not
market
product
until
has
received
accession
number
addition
Bruker
AXS
submits
annual
report
the
FDA
that
includes
the
radiation
safety
history
all
products
sells
the
United
States
Bruker
AXS
required
report
the
FDA
incidents
accidental
exposure
radiation
arising
from
the
manufacture
testing
use
any
its
products
Bruker
AXS
also
reports
installations
its
products
state
government
regulatory
agencies
responsible
for
the
regulation
radiation
emitting
devices
For
sales
Germany
Bruker
AXS
registers
each
system
with
the
local
authorities
some
countries
where
Bruker
AXS
sells
systems
Bruker
AXS
uses
the
license
obtained
from
the
federal
authorities
Germany
assist
obtaining
license
from
the
country
which
the
sale
occurs
addition
indicated
above
are
subject
various
other
foreign
and
domestic
environmental
health
and
safety
laws
and
regulations
connection
with
our
operations
Apart
from
these
areas
are
subject
the
laws
and
regulations
generally
applicable
businesses
the
jurisdictions
which
operate
Our
Bruker
AXS
subsidiary
possesses
low level
radiation
materials
licenses
from
the
Nuclear
Regulatory
Commission
agreement
with
the
State
Wisconsin
for
its
facility
Madison
Wisconsin
from
the
local
radiation
safety
authority
Gewerbeaufsichtsamt
Karlsruhe
for
its
facility
Karlsruhe
Germany
and
from
the
local
radiation
safety
authority
Kanagawa
Prefecture
for
its
facility
Yokohama
Japan
well
from
various
other
countries
which
sells
its
products
Our
Bruker
Daltonics
subsidiary
possesses
low level
radiation
licenses
for
facilities
Billerica
Massachusetts
and
Leipzig
Germany
The
Nuclear
Regulatory
Commission
also
has
regulations
concerning
the
exposure
our
employees
radiation
Certain
our
clinical
products
are
subject
regulation
the
United
States
the
FDA
and
similar
regulatory
bodies
other
countries
where
such
products
are
sold
For
example
our
MALDI
Biotyper
system
subject
regulation
the
FDA
and
our
IVD
Certified
MALDI
BioTyper
system
subject
regulation
the
European
Union
under
the
provisions
Directive
These
and
similar
local
regulations
elsewhere
the
world
govern
wide
variety
product related
activities
from
quality
management
design
and
development
labeling
manufacturing
promotion
sales
and
distribution
such
continually
invest
our
manufacturing
infrastructure
gain
and
maintain
certifications
necessary
for
the
relevant
level
regulatory
clearance
Table
Contents
Working
Capital
Requirements
There
were
credit
terms
extended
customers
that
would
have
material
adverse
effect
our
working
capital
recognize
revenue
from
system
sales
when
persuasive
evidence
arrangement
exists
the
price
fixed
determinable
title
and
risk
loss
has
been
transferred
the
customer
and
collectability
the
resulting
receivable
reasonably
assured
Title
and
risk
loss
generally
transfers
upon
shipment
for
certain
systems
based
upon
customer
acceptance
for
system
that
has
been
delivered
the
customer
and
installed
customer
facility
For
systems
that
include
customer specific
acceptance
criteria
are
required
assess
when
can
demonstrate
the
acceptance
criteria
have
been
met
which
generally
upon
successful
factory
acceptance
testing
customer
acceptance
and
evidence
installation
Systems
that
have
been
shipped
customers
but
not
yet
accepted
the
customer
are
included
finished
goods
transit
Finished
goods
transit
was
million
and
million
December
and
respectively
also
have
well equipped
applications
and
demonstration
facilities
and
qualified
application
personnel
who
assist
customers
and
provide
product
demonstrations
specific
application
areas
total
held
million
and
million
demonstration
inventory
December
and
respectively
Backlog
Our
backlog
consists
firm
orders
under
non cancellable
purchase
orders
received
from
customers
Total
system
backlog
December
and
was
approximately
million
and
million
respectively
anticipate
that
approximately
the
backlog
December
will
filled
experience
variable
and
fluctuating
revenues
the
first
three
quarters
the
year
while
our
fourth
quarter
revenues
have
historically
been
stronger
than
the
rest
the
year
result
backlog
any
particular
date
can
indicative
our
short term
revenue
performance
but
not
necessarily
reliable
indicator
long term
revenue
performance
Employees
December
and
had
approximately
and
full time
employees
worldwide
respectively
these
employees
approximately
and
were
located
the
United
States
December
and
respectively
Our
employees
the
United
States
are
not
unionized
affiliated
with
any
labor
organizations
Employees
based
outside
the
United
States
are
primarily
located
Europe
with
worker
councils
labor
unions
primarily
Germany
and
France
Several
our
international
subsidiaries
are
parties
contracts
with
labor
unions
and
workers
councils
believe
that
have
good
relationships
with
our
employees
and
the
workers
councils
December
had
approximately
employees
production
and
distribution
employees
selling
and
marketing
and
employees
research
and
development
with
general
and
administrative
employees
representing
the
remainder
December
had
approximately
employees
production
and
distribution
employees
selling
and
marketing
and
employees
research
and
development
with
general
and
administrative
employees
representing
the
remainder
Financial
Information
about
Geographic
Areas
and
Segments
Financial
information
about
our
geographic
areas
and
segments
may
found
Note
our
Consolidated
Financial
Statements
this
Annual
Report
Form
included
part
Item
this
report
which
includes
information
about
our
revenues
from
external
customers
measure
profit
and
total
assets
reportable
segment
Table
Contents
Available
Information
are
subject
the
informational
requirements
the
Securities
Exchange
Act
Exchange
Act
Therefore
file
periodic
reports
proxy
statements
and
other
information
with
the
Securities
and
Exchange
Commission
SEC
Such
reports
proxy
statements
and
other
information
may
read
and
copied
visiting
the
Public
Reference
Room
the
SEC
Street
Washington
You
may
obtain
information
the
operation
the
Public
Reference
Room
calling
the
SEC
SEC
addition
the
SEC
maintains
Internet
site
http sec gov
that
contains
reports
proxy
and
information
statements
and
other
information
regarding
issuers
that
file
electronically
Our
website
located
bruker
make
available
free
charge
through
this
website
our
annual
reports
Form
quarterly
reports
Form
current
reports
Form
and
amendments
those
reports
filed
with
furnished
the
SEC
pursuant
Section
the
Exchange
Act
soon
reasonably
practicable
after
they
are
electronically
filed
with
furnished
the
SEC
The
contents
our
website
are
not
incorporated
into
this
report
ITEM
RISK
FACTORS
The
following
risk
factors
should
considered
conjunction
with
the
other
information
included
this
Annual
Report
Form
This
report
may
include
forward looking
statements
that
involve
risks
and
uncertainties
addition
those
risk
factors
discussed
elsewhere
this
report
identify
the
following
risk
factors
which
could
affect
our
actual
results
and
cause
actual
results
differ
materially
from
those
the
forward looking
statements
may
lose
money
when
exchange
foreign
currency
received
from
international
sales
into
Dollars
significant
portion
our
business
conducted
currencies
other
than
the
Dollar
which
our
reporting
currency
result
currency
fluctuations
among
the
Dollar
and
the
currencies
which
business
have
caused
and
will
continue
cause
foreign
currency
translation
gains
and
losses
addition
currency
fluctuations
could
cause
the
price
our
products
more
less
competitive
than
our
principal
competitors
products
Currency
fluctuations
will
increase
decrease
our
cost
structure
relative
those
our
competitors
which
could
lessen
the
demand
for
our
products
and
affect
our
competitive
position
From
time
time
enter
into
certain
hedging
transactions
and
option
and
foreign
currency
exchange
contracts
which
are
intended
offset
some
the
market
risk
associated
with
our
sales
denominated
foreign
currencies
cannot
predict
the
effectiveness
these
transactions
their
impact
upon
our
future
operating
results
and
from
time
time
they
may
negatively
affect
our
quarterly
earnings
Our
reported
financial
results
may
adversely
affected
fluctuations
currency
exchange
rates
addition
the
foreign
currency
exposure
associated
with
differences
between
where
our
products
are
manufactured
and
sold
and
our
competitors
our
exposure
currency
exchange
rate
fluctuations
results
from
the
currency
translation
exposure
associated
with
the
preparation
our
consolidated
financial
statements
well
from
the
exposure
associated
with
transactions
our
subsidiaries
that
are
denominated
currency
other
than
the
respective
subsidiary
functional
currency
While
our
financial
results
are
reported
Dollars
the
financial
statements
many
our
subsidiaries
outside
the
are
prepared
using
the
local
currency
the
functional
currency
During
consolidation
these
results
are
translated
into
Dollars
applying
appropriate
exchange
rates
result
fluctuations
the
exchange
rate
the
Dollar
relative
the
local
currencies
which
our
foreign
subsidiaries
report
could
cause
significant
fluctuations
our
reported
results
Moreover
exchange
rates
vary
revenue
and
other
operating
results
may
differ
materially
from
our
expectations
The
favorable
effects
changes
currency
exchange
rates
increased
our
revenues
Table
Contents
approximately
million
while
unfavorable
foreign
currency
effects
decreased
our
revenues
approximately
million
respectively
Adjustments
resulting
from
financial
statement
translations
are
included
separate
component
shareholders
equity
the
year
ended
December
recorded
net
gains
from
currency
translation
adjustments
million
the
year
ended
December
recorded
net
losses
from
currency
translation
adjustments
million
Additionally
the
extent
monetary
assets
and
liabilities
including
cash
and
debt
are
held
different
currency
than
the
reporting
subsidiary
functional
currency
fluctuations
currency
exchange
rates
may
have
significant
impact
our
reported
financial
results
and
may
lead
increased
earnings
volatility
may
record
significant
gains
losses
related
both
the
translation
assets
and
liabilities
held
our
subsidiaries
into
local
currencies
and
the
remeasurement
inter company
receivables
and
loan
balances
Unfavorable
economic
political
conditions
the
countries
which
operate
may
have
adverse
impact
our
business
results
financial
condition
Our
businesses
and
results
operations
are
affected
international
national
and
regional
economic
and
political
conditions
Our
businesses
financial
results
may
adversely
impacted
unfavorable
changes
economic
political
conditions
the
countries
and
markets
which
operate
including
among
others
adverse
changes
interest
rates
tax
rates
volatility
financial
and
commodity
markets
contraction
the
availability
credit
the
marketplace
and
changes
capital
spending
patterns
Our
revenue
from
operations
represented
approximately
and
total
consolidated
revenue
for
fiscal
and
respectively
Our
revenue
from
operations
Europe
represented
approximately
and
total
consolidated
revenue
for
the
corresponding
periods
Our
revenue
from
operations
the
Asia
Pacific
region
represented
approximately
and
total
consolidated
revenue
for
the
corresponding
periods
Economic
factors
that
could
adversely
influence
demand
for
the
Company
products
include
uncertainty
about
global
economic
conditions
leading
reduced
levels
investment
changes
government
spending
levels
and
priorities
the
size
and
availability
government
budgets
customers
and
suppliers
access
credit
and
other
macroeconomic
factors
affecting
government
academic
industrial
spending
behavior
Slower
economic
growth
deterioration
economic
conditions
could
result
decrease
government
funding
for
scientific
research
delay
orders
from
current
potential
customers
reduction
purchases
our
products
cannot
predict
how
changes
economic
conditions
political
instability
will
affect
our
customers
and
suppliers
how
any
negative
impact
our
customers
and
suppliers
might
adversely
impact
our
business
results
financial
condition
The
effect
comprehensive
tax
reform
legislation
uncertain
December
the
President
the
United
States
signed
the
Tax
Cuts
and
Jobs
Act
the
Tax
Act
which
enacted
wide
range
changes
the
income
tax
system
many
which
differ
significantly
from
the
provisions
the
previous
tax
law
The
Tax
Act
among
other
things
permanently
reduces
the
corporate
income
tax
rate
beginning
and
provides
for
more
general
changes
the
taxation
corporations
including
changes
the
deductibility
interest
expense
the
adoption
modified
territorial
tax
system
assessing
repatriation
tax
toll charge
undistributed
earnings
and
profits
owned
foreign
corporations
and
broadening
the
corporate
tax
base
through
the
elimination
reduction
deductions
exclusions
and
credits
have
not
yet
completed
our
assessment
the
tax
effects
associated
with
the
enactment
the
Tax
Act
however
reasonable
estimates
have
been
made
the
effects
the
Tax
Act
the
Table
Contents
Company
existing
deferred
tax
balances
and
the
one time
transition
tax
undistributed
earnings
and
profits
our
foreign
subsidiaries
Changes
the
tax
rates
and
laws
are
accounted
for
the
period
enactment
and
these
estimates
are
reflected
our
financial
statements
for
the
period
ended
December
The
actual
results
the
implementation
the
Tax
Act
may
materially
differ
from
our
current
estimate
due
among
other
things
further
guidance
that
may
issued
tax
authorities
regulatory
bodies
including
the
SEC
and
the
Financial
Accounting
Standards
Board
FASB
interpret
the
Tax
Act
will
continue
analyze
the
Tax
Act
and
any
additional
guidance
that
may
issued
and
finalize
the
full
effects
applying
the
new
legislation
future
periods
Any
revisions
our
current
estimates
could
materially
affect
our
results
operations
cash
flow
and
financial
position
derive
significant
portion
our
revenue
from
international
sales
and
are
subject
the
risks
doing
business
foreign
countries
International
sales
account
and
are
expected
continue
account
for
significant
portion
our
total
revenues
Our
revenue
from
non
operations
represented
approximately
and
our
total
consolidated
revenue
for
fiscal
and
respectively
Our
international
operations
are
and
will
continue
subject
variety
risks
associated
with
conducting
business
internationally
many
which
are
beyond
our
control
These
risks
which
may
adversely
affect
our
ability
achieve
and
maintain
profitability
and
our
ability
sell
our
products
internationally
include
changes
foreign
currency
translation
rates
changes
regulatory
requirements
legislation
and
regulation
including
tariffs
relating
the
import
export
high
technology
products
the
imposition
government
controls
political
and
economic
instability
including
international
hostilities
acts
terrorism
and
governmental
restrictions
inflation
trade
relationships
and
military
and
political
alliances
costs
and
risks
deploying
systems
foreign
countries
compliance
with
export
laws
and
controls
and
trade
embargoes
multiple
jurisdictions
limited
intellectual
property
rights
the
burden
complying
with
wide
variety
complex
foreign
laws
and
treaties
including
unfavorable
labor
regulations
specifically
those
applicable
our
European
operations
and
compliance
with
and
local
laws
affecting
the
activities
companies
abroad
including
the
United
States
Foreign
Corrupt
Practices
Act
FCPA
and
local
anti bribery
laws
must
also
comply
with
the
recently
enacted
European
Union
General
Data
Protection
Regulation
GDPR
All
European
Union
member
states
must
comply
with
GDPR
May
The
goal
the
regulation
increase
individual
rights
and
protections
for
personal
data
located
originating
from
the
European
Union
GDPR
extraterritorial
that
applies
all
business
within
the
European
Union
and
any
business
located
outside
the
European
Union
that
processes
personal
data
individuals
located
within
the
European
Union
There
are
significant
fines
associated
with
non compliance
While
the
impact
these
factors
difficult
predict
any
one
more
these
factors
could
adversely
affect
our
operations
the
future
Table
Contents
are
not
able
successfully
integrate
the
businesses
acquire
through
mergers
acquisitions
strategic
alliances
may
not
able
realize
all
the
cost
savings
and
other
benefits
that
expect
result
from
the
transactions
and
our
financial
results
may
different
than
expected
Our
strategy
includes
expanding
our
technology
base
and
product
offerings
through
selected
mergers
acquisitions
and
strategic
alliances
For
example
from
December
have
acquired
businesses
expand
our
technologies
and
product
offerings
Successful
integration
the
businesses
acquire
involves
number
risks
including
among
others
risks
related
coordinating
consolidating
geographically
separate
organizations
and
integrating
personnel
with
different
business
backgrounds
and
corporate
cultures
integrating
previously
autonomous
departments
sales
and
marketing
distribution
accounting
and
administrative
functions
and
information
and
management
systems
diversion
resources
and
management
time
disruption
our
ongoing
business
potential
impairment
relationships
with
customers
result
changes
management
otherwise
arising
out
such
transactions
and
retention
key
employees
the
acquired
businesses
within
the
first
one
two
years
after
the
acquisition
including
the
risk
that
they
may
compete
with
subsequently
may
have
difficulty
developing
manufacturing
and
marketing
the
products
newly
acquired
company
business
way
that
enhances
the
performance
our
combined
businesses
product
lines
result
may
not
realize
the
value
from
expected
synergies
Acquisitions
have
resulted
and
may
the
future
result
unexpected
significant
costs
and
expenses
the
future
may
required
record
charges
earnings
during
the
period
determine
there
impairment
goodwill
intangible
assets
the
full
amount
the
value
the
assets
may
difficult
for
implement
our
strategies
for
improving
margins
profitability
and
cash
flow
are
pursuing
number
strategies
improve
our
financial
performance
including
implementing
various
productivity
improvement
initiatives
both
BSI
and
BEST
effort
streamline
our
operations
These
initiatives
include
the
outsourcing
manufacturing
activities
consolidating
transferring
ceasing
operations
certain
facilities
applying
lean
manufacturing
and
six
sigma
concepts
our
operations
implementing
ERP
and
other
information
technology
systems
and
applying
shared
service
approach
various
functions
may
not
able
successfully
implement
these
strategies
and
these
efforts
may
not
result
the
expected
improvement
our
margins
profitability
cash
flow
Anticipated
benefits
our
operating
and
financial
performance
might
reduced
delayed
result
difficulties
implementing
these
initiatives
which
may
include
complications
the
transfer
assets
and
production
knowledge
loss
key
employees
and
customers
the
disruption
ongoing
business
and
possible
inconsistencies
standards
controls
and
procedures
Implementation
costs
also
might
exceed
our
expectations
and
further
cost
reduction
measures
might
become
necessary
resulting
additional
future
charges
Our
ability
successfully
implement
these
strategies
and
achieve
our
objectives
will
also
depend
our
ability
identify
attract
and
retain
management
and
other
personnel
with
the
skills
and
experience
needed
effectively
manage
the
process
and
drive
our
operating
performance
improvement
during
and
after
implementation
our
improvement
initiatives
Table
Contents
These
improvement
strategies
may
also
have
unintended
consequences
such
attrition
beyond
our
intended
reduction
workforce
reduced
employee
morale
and
loss
customer
relationships
also
may
undertake
additional
restructuring
activities
the
future
Because
these
and
other
factors
cannot
predict
whether
will
realize
the
purpose
and
anticipated
benefits
our
restructuring
and
related
measures
and
not
our
business
and
results
operations
may
adversely
affected
Goodwill
intangible
assets
and
other
long lived
assets
are
subject
impairment
have
recorded
goodwill
intangible
assets
and
other
long lived
assets
that
must
periodically
evaluated
for
potential
impairment
assess
the
realizability
the
reported
goodwill
intangible
assets
and
other
long lived
assets
annually
well
whenever
events
changes
circumstances
indicate
that
the
assets
may
impaired
These
events
circumstances
generally
include
operating
losses
significant
decline
the
earnings
associated
with
the
reporting
unit
these
assets
are
reported
within
decline
our
stock
price
and
market
capitalization
may
also
cause
consider
whether
goodwill
intangible
assets
and
other
long lived
assets
may
require
impairment
assessment
Our
ability
realize
the
value
these
assets
will
depend
the
future
cash
flows
the
reporting
unit
addition
how
well
integrate
the
businesses
acquire
have
recorded
impairment
losses
million
million
and
million
for
the
years
ended
December
and
respectively
our
products
fail
achieve
and
sustain
sufficient
market
acceptance
across
their
broad
intended
range
applications
will
not
generate
expected
revenue
Our
business
strategy
depends
our
ability
successfully
commercialize
broad
range
products
based
our
technology
platforms
including
magnetic
resonance
technology
pre clinical
imaging
technology
mass
spectrometry
technology
ray
technology
atomic
force
microscopy
technology
stylus
and
optical
metrology
technology
fluorescence
microscopy
technology
infrared
technology
and
superconducting
magnet
technologies
for
use
variety
life
science
chemistry
and
materials
analysis
applications
Some
our
products
have
only
recently
been
commercially
launched
and
have
achieved
only
limited
sales
date
The
commercial
success
our
products
depends
obtaining
and
expanding
market
acceptance
diverse
array
industrial
academic
clinical
pharmaceutical
biotechnology
applied
medical
research
and
governmental
customers
around
the
world
may
fail
achieve
sustain
substantial
market
acceptance
for
our
products
across
the
full
range
our
intended
applications
one
more
our
principal
intended
applications
Any
such
failure
could
decrease
our
sales
and
revenue
succeed
must
convince
substantial
numbers
potential
customers
invest
new
systems
replace
their
existing
techniques
with
techniques
employing
our
systems
Limited
funding
available
for
capital
acquisitions
our
customers
well
our
customers
own
internal
purchasing
approval
policies
could
hinder
market
acceptance
our
products
Our
intended
customers
may
reluctant
make
the
substantial
capital
investment
generally
needed
acquire
our
products
incur
the
training
and
other
costs
involved
with
replacing
their
existing
systems
with
our
products
also
may
not
able
convince
our
intended
customers
that
our
systems
are
attractive
and
cost effective
alternative
other
technologies
and
systems
for
the
acquisition
analysis
and
management
molecular
cellular
and
microscopic
information
Additionally
ethical
and
other
concerns
surrounding
the
use
genetic
information
gene
therapy
genetically
modified
organisms
become
widespread
may
have
less
demand
for
our
products
Because
these
and
other
factors
our
products
may
fail
gain
sustain
market
acceptance
Our
products
compete
markets
that
are
subject
rapid
technological
change
and
one
more
the
technologies
underlying
our
products
could
made
obsolete
new
technology
The
market
for
discovery
and
analysis
tools
characterized
rapid
technological
change
and
frequent
new
product
introductions
Rapidly
changing
technology
could
make
some
our
entire
Table
Contents
product
lines
obsolete
unless
are
able
continually
improve
our
existing
products
and
develop
new
products
Because
substantially
all
our
products
are
based
our
technology
platforms
including
magnetic
resonance
technology
mass
spectrometry
technology
ray
technology
atomic
force
microscopy
technology
fluorescence
microscopy
technology
stylus
and
optical
metrology
technology
and
infrared
technology
are
particularly
vulnerable
any
technological
advances
that
would
make
these
techniques
obsolete
the
basis
for
analytical
systems
any
our
markets
meet
the
evolving
needs
our
customers
must
rapidly
and
continually
enhance
our
current
and
planned
products
and
services
and
develop
and
introduce
new
products
and
services
addition
our
product
lines
are
based
complex
technologies
that
are
subject
rapid
change
new
technologies
are
developed
and
introduced
the
marketplace
may
have
difficulty
keeping
abreast
the
rapid
changes
affecting
each
the
different
markets
serve
intend
serve
fail
develop
and
introduce
products
timely
manner
response
changing
technology
market
demands
the
requirements
our
customers
our
product
sales
may
decline
and
could
experience
significant
losses
Currently
our
backlog
have
orders
totaling
million
for
ultra high
field
magnets
are
unable
reach
the
technical
feasibility
for
these
magnets
will
unable
fulfill
customer
orders
where
alternate
arrangements
have
not
been
provided
for
customer
contracts
Additional
risks
include
extraordinary
warranty
expenses
rework
and
potential
inventory
write offs
Our
business
could
harmed
our
collaborations
fail
advance
our
product
development
Demand
for
our
products
will
depend
part
upon
the
extent
which
our
collaborations
with
pharmaceutical
biotechnology
and
proteomics
companies
are
successful
developing
helping
develop
new
products
and
new
applications
for
our
existing
products
addition
collaborate
with
academic
institutions
and
government
research
laboratories
product
development
have
limited
control
over
the
resources
that
any
collaborator
may
devote
our
products
Any
our
present
future
collaborators
may
not
perform
their
obligations
expected
fail
enter
into
maintain
appropriate
collaboration
agreements
any
these
events
occur
may
not
able
develop
some
our
new
products
which
could
materially
impede
our
ability
generate
revenue
profits
face
substantial
competition
face
substantial
competition
our
industries
and
expect
that
competition
all
our
markets
will
increase
further
Currently
our
principal
competition
comes
from
established
companies
providing
products
using
existing
technologies
that
perform
many
the
same
functions
for
which
market
our
products
number
our
competitors
have
expanded
their
market
share
recent
years
through
business
combinations
Other
companies
also
may
choose
enter
our
fields
the
future
Our
competitors
may
develop
market
products
that
are
more
effective
commercially
attractive
than
our
current
future
products
that
may
render
our
products
obsolete
Competition
has
the
past
subjected
and
likely
the
future
subject
our
products
pricing
pressure
Many
our
competitors
have
more
experience
the
market
and
substantially
greater
financial
operational
marketing
and
technical
resources
than
which
could
give
them
competitive
advantage
areas
such
research
and
development
production
marketing
and
distribution
Our
ability
compete
successfully
will
depend
part
our
ability
develop
proprietary
products
that
reach
the
market
timely
manner
and
are
technologically
superior
less
expensive
than
more
cost effective
than
other
currently
marketed
products
lose
our
strategic
partners
our
marketing
and
sales
efforts
could
impaired
substantial
portion
our
sales
selected
products
consists
sales
third
parties
who
incorporate
our
products
into
their
systems
These
third
parties
are
responsible
for
the
marketing
and
sales
their
systems
have
little
control
over
their
marketing
and
sales
activities
how
they
Table
Contents
use
their
resources
Our
present
future
strategic
partners
may
may
not
purchase
sufficient
quantities
products
from
perform
appropriate
marketing
and
sales
activities
addition
are
unable
maintain
our
relationships
with
strategic
partners
our
businesses
may
suffer
Failures
our
present
future
strategic
partners
our
inability
maintain
enter
into
new
arrangements
with
strategic
partners
for
product
distribution
could
materially
impede
the
growth
our
businesses
and
our
ability
generate
sufficient
revenue
and
profits
face
risks
related
sales
through
distributors
and
other
third
parties
that
not
control
which
could
harm
our
business
sell
some
products
through
third
party
agents
including
distributors
and
value added
resellers
This
exposes
various
risks
including
competitive
pressure
concentration
sales
volumes
credit
risks
and
compliance
risks
may
rely
one
few
key
distributors
for
product
market
and
the
loss
these
distributors
could
reduce
our
revenue
and
net
earnings
Distributors
may
also
face
financial
difficulties
including
bankruptcy
which
could
harm
our
collection
accounts
receivables
Risks
related
our
use
distributors
may
reduce
sales
increase
expenses
and
weaken
our
competitive
position
Moreover
violations
the
FCPA
similar
anti bribery
laws
distributors
other
third
party
agents
could
materially
and
adversely
impact
our
business
and
results
operations
Dependence
contract
manufacturing
may
adversely
affect
our
ability
bring
products
market
and
damage
our
reputation
part
our
efforts
streamline
our
operations
and
reduce
our
operating
costs
outsource
aspects
our
manufacturing
processes
and
continue
evaluate
additional
outsourcing
our
contract
manufacturers
fail
perform
their
obligations
timely
manner
satisfactory
quality
levels
our
ability
bring
products
market
and
our
reputation
could
suffer
For
example
during
market
upturn
our
contract
manufacturers
may
unable
meet
our
demand
requirements
which
may
preclude
from
fulfilling
our
customers
orders
timely
basis
The
ability
these
manufacturers
perform
largely
outside
our
control
Additionally
changing
replacing
our
contract
manufacturers
could
cause
disruptions
delays
Problems
with
outsourced
manufacturing
could
result
lower
revenues
and
unexecuted
efficiencies
and
adversely
affect
our
financial
condition
and
results
operations
investment
life
and
material
science
research
spending
declines
our
ability
generate
revenue
may
suffer
are
dependent
both
directly
and
indirectly
upon
general
investment
life
science
research
particularly
the
research
and
development
budgets
the
pharmaceutical
and
biotechnology
industries
and
material
science
research
well
upon
the
financial
condition
and
funding
priorities
various
governments
and
government
agencies
Since
our
inception
both
and
our
academic
collaborators
and
customers
have
benefited
from
various
governmental
contracts
and
research
grants
Whether
our
academic
collaborators
will
continue
able
attract
these
grants
depends
not
only
the
quality
our
products
but
also
general
spending
patterns
public
institutions
Any
reduction
the
capital
resources
government
funding
our
customers
could
reduce
our
sales
and
impede
our
ability
generate
revenue
significant
portion
our
sales
are
capital
purchases
our
customers
The
spending
policies
our
customers
could
have
significant
effect
the
demand
for
our
products
These
policies
are
based
wide
variety
factors
including
the
resources
available
make
purchases
the
spending
priorities
among
various
types
equipment
policies
regarding
spending
during
recessionary
periods
and
changes
the
political
climate
Any
changes
capital
spending
changes
the
capital
budgets
our
Table
Contents
customers
could
significantly
reduce
demand
for
our
products
The
capital
resources
our
life
science
and
other
corporate
customers
may
limited
the
availability
equity
debt
financing
Any
significant
decline
research
and
development
expenditures
our
life
science
and
material
science
customers
could
significantly
decrease
our
sales
addition
substantial
portion
our
sales
are
non profit
and
government
entities
which
are
dependent
government
support
for
scientific
research
Any
decline
this
support
could
decrease
the
ability
these
customers
purchase
our
products
Disruptions
any
our
manufacturing
facilities
could
adversely
affect
our
business
have
manufacturing
facilities
located
the
United
States
Europe
and
Israel
Many
our
products
are
developed
and
manufactured
single
locations
with
limited
alternate
facilities
experience
any
significant
disruption
those
facilities
for
any
reason
such
strikes
other
labor
unrest
power
interruptions
fire
earthquakes
other
events
beyond
our
control
may
unable
manufacture
the
relevant
products
previous
levels
all
reduction
interruption
manufacturing
could
harm
our
customer
relationships
impede
our
ability
generate
revenues
from
our
backlog
obtain
new
orders
and
could
have
material
adverse
effect
our
business
results
operations
financial
condition
and
cash
flows
employees
were
engage
strike
other
work
stoppage
interruption
our
business
results
operations
financial
condition
and
liquidity
could
materially
adversely
affected
Some
our
employees
are
represented
workers
councils
and
labor
unions
certain
jurisdictions
primarily
Germany
and
France
Although
believe
that
our
relations
with
our
employees
are
satisfactory
disputes
with
these
employees
arise
our
workers
engage
strike
other
work
stoppage
interruption
could
experience
significant
disruption
inefficiencies
our
operations
incur
higher
labor
costs
which
could
have
material
adverse
effect
our
business
results
operations
financial
condition
and
liquidity
Our
operations
are
dependent
upon
limited
number
suppliers
and
contract
manufacturers
currently
purchase
components
used
our
products
from
limited
number
outside
suppliers
Our
reliance
limited
number
suppliers
could
result
time
delays
associated
with
redesigning
product
due
inability
obtain
adequate
supply
required
components
and
reduced
control
over
pricing
quality
and
timely
delivery
Any
these
factors
could
adversely
affect
our
revenues
and
profitability
particular
our
ray
microanalysis
business
which
manufactures
and
sells
accessories
for
electron
microscopes
partially
dependent
cooperation
from
larger
manufacturers
electron
microscopes
Additionally
our
elemental
analysis
business
purchases
certain
optical
detectors
from
single
supplier
PerkinElmer
Inc
the
sole
supplier
these
detector
components
Bruker
CALID
purchases
detectors
and
power
supplies
from
sole
limited
source
suppliers
and
its
focal
plane
array
detectors
from
single
supplier
Lockheed
Martin
Corporation
Similarly
Bruker
BioSpin
obtains
various
components
from
sole
limited
source
suppliers
and
BEST
obtains
various
raw
materials
and
uses
key
production
equipment
from
sole
limited
source
suppliers
contract
manufacturers
There
are
limited
any
available
alternatives
these
suppliers
The
existence
shortages
these
components
the
failure
delivery
with
regard
these
components
could
have
material
adverse
effect
upon
our
revenues
and
margins
addition
price
increases
from
these
suppliers
contract
manufacturers
could
have
material
adverse
effect
upon
our
gross
margins
Because
the
scarcity
some
components
may
unable
obtain
adequate
supply
components
may
required
pay
higher
prices
purchase
components
lesser
quality
Any
delay
interruption
the
supply
these
other
components
could
impair
our
ability
manufacture
and
deliver
our
products
harm
our
reputation
and
cause
reduction
our
revenues
addition
any
increase
the
cost
the
components
that
use
our
products
could
make
our
products
less
competitive
and
decrease
our
gross
profits
may
not
able
obtain
sufficient
Table
Contents
quantities
required
components
the
same
substantially
the
same
terms
Additionally
consolidation
among
our
suppliers
could
result
other
sole
source
suppliers
for
the
future
Supply
shortages
and
increasing
prices
raw
materials
could
adversely
affect
the
gross
profit
the
Bruker
BioSpin
Group
and
our
Bruker
Energy
Supercon
Technologies
business
The
last
few
years
have
seen
periodic
supply
shortages
and
sharp
increases
the
prices
for
various
raw
materials
part
due
high
demand
from
developing
countries
Bruker
BioSpin
and
BEST
rely
some
these
materials
for
the
production
their
products
particular
for
its
superconducting
magnet
production
both
for
the
horizontal
and
vertical
magnet
series
Bruker
BioSpin
relies
the
availability
copper
steel
and
the
metallic
raw
materials
for
traditional
lowtemperature
superconducting
wires
Similarly
BEST
relies
the
availability
niobium
titanium
for
its
production
low temperature
superconducting
materials
and
devices
Higher
prices
for
these
commodities
will
increase
the
production
cost
superconducting
wires
and
superconducting
magnets
and
may
adversely
affect
gross
profits
The
prices
copper
and
certain
other
raw
materials
used
for
superconductors
have
increased
significantly
over
the
last
decade
Since
copper
main
constituent
low
temperature
superconductors
this
may
affect
the
price
superconducting
wire
This
type
increase
would
have
immediate
effect
the
production
costs
superconducting
magnets
and
may
negatively
affect
the
profit
margins
for
those
products
addition
increase
raw
material
cost
affects
the
production
cost
the
superconducting
wire
produced
BEST
and
superconducting
wire
used
Bruker
BioSpin
Bruker
BioSpin
and
its
customers
also
rely
liquid
helium
operate
its
superconducting
magnets
Helium
controlled
the
Federal
Helium
Reserve
and
subject
price
changes
Shortages
liquid
helium
associated
with
federal
price
controls
could
have
adverse
impact
producing
and
operating
BioSpin
superconducting
magnets
and
may
also
negatively
impact
the
profit
margins
for
those
products
Regulations
related
conflict
minerals
may
cause
incur
additional
expenses
and
could
limit
the
supply
and
increase
the
cost
certain
metals
used
manufacturing
our
products
Regulations
require
disclosures
public
companies
specified
minerals
known
conflict
minerals
that
are
necessary
the
functionality
production
products
manufactured
contracted
manufactured
This
requires
the
performance
due
diligence
determine
whether
not
such
minerals
originate
from
the
Democratic
Republic
Congo
adjoining
country
These
regulations
could
affect
sourcing
competitive
prices
and
availability
sufficient
quantities
certain
minerals
used
the
manufacture
our
products
including
tantalum
tin
gold
and
tungsten
The
number
suppliers
who
provide
conflict free
minerals
may
limited
addition
there
may
material
costs
associated
with
complying
with
the
disclosure
requirements
such
costs
related
determining
the
source
certain
minerals
used
our
products
well
costs
possible
changes
products
processes
sources
supply
consequence
such
verification
activities
our
supply
chain
complex
and
use
contract
manufacturers
for
some
our
products
may
not
able
sufficiently
verify
the
origins
the
relevant
minerals
used
our
products
through
the
due
diligence
procedures
that
implement
which
may
harm
our
reputation
addition
may
encounter
challenges
satisfy
those
customers
who
require
that
all
the
components
our
products
certified
conflict free
which
could
place
competitive
disadvantage
are
unable
Table
Contents
fail
maintain
effective
system
internal
controls
may
not
able
accurately
report
our
financial
results
which
could
lead
loss
investor
confidence
our
financial
statements
and
have
adverse
effect
our
stock
price
Effective
internal
controls
are
necessary
for
provide
reliable
and
accurate
financial
statements
and
effectively
prevent
fraud
devote
significant
resources
and
time
comply
with
the
internal
control
over
financial
reporting
requirements
the
Sarbanes
Oxley
Act
and
continue
enhance
our
controls
However
cannot
certain
that
will
able
prevent
future
significant
deficiencies
material
weaknesses
the
year
ended
December
remediated
the
previously
disclosed
material
weakness
our
internal
controls
over
the
accounting
for
income
taxes
Inadequate
internal
controls
could
cause
investors
lose
confidence
our
reported
financial
information
which
could
have
negative
effect
investor
confidence
our
financial
statements
the
trading
price
our
stock
and
our
access
capital
Our
manufacture
and
sale
products
could
lead
product
liability
claims
for
which
could
have
substantial
liability
The
manufacture
and
sale
our
products
expose
product
liability
claims
any
our
products
cause
injury
are
found
otherwise
unsuitable
during
manufacturing
marketing
sale
customer
use
particular
one
our
CBRNE
detection
products
malfunctions
this
could
lead
civilian
military
casualties
time
unrest
exposing
increased
potential
for
high profile
liability
our
CBRNE
detection
products
malfunction
generating
falsepositive
potential
threat
could
exposed
liabilities
associated
with
actions
taken
that
otherwise
would
not
have
been
required
Additionally
the
nuclear
magnetic
resonance
research
magnetic
resonance
imaging
Fourier
transform
mass
spectrometry
and
certain
electron
paramagnetic
resonance
magnets
Bruker
BioSpin
utilize
high
magnet
fields
and
cryogenics
operate
approximately
Kelvin
the
temperature
liquid
helium
There
inherent
risk
potential
product
liability
due
the
existence
these
high
magnetic
fields
associated
stray
fields
outside
the
magnet
and
the
handling
the
cryogens
associated
with
superconducting
magnets
addition
our
MALDI
Biotyper
product
has
IVD
mark
and
used
for
the
identification
microorganisms
Misidentification
false negative
certain
bacteria
yeasts
fungi
could
lead
inappropriate
treatment
for
patients
and
could
expose
product
liability
claims
successful
product
liability
claim
brought
against
excess
outside
the
coverage
our
insurance
coverage
could
have
material
adverse
effect
our
business
financial
condition
and
results
operations
may
not
able
maintain
product
liability
insurance
acceptable
terms
all
and
insurance
may
not
provide
adequate
coverage
against
potential
liabilities
Responding
claims
relating
improper
handling
storage
disposal
hazardous
chemicals
and
radioactive
and
biological
materials
which
use
could
time
consuming
and
costly
use
controlled
hazardous
and
radioactive
materials
our
business
and
generate
wastes
that
are
regulated
hazardous
wastes
under
federal
and
Massachusetts
California
New
Jersey
Washington
and
Wisconsin
state
environmental
and
atomic
energy
regulatory
laws
and
under
equivalent
provisions
law
those
and
other
jurisdictions
which
our
research
and
manufacturing
facilities
are
located
Our
use
these
substances
and
materials
subject
stringent
and
periodically
changing
regulation
that
can
impose
costly
compliance
obligations
and
have
the
potential
adversely
affect
our
manufacturing
activities
The
risk
accidental
contamination
injury
from
these
materials
cannot
completely
eliminated
accident
with
these
substances
occurs
could
held
liable
for
any
damages
that
result
addition
incurring
clean
costs
and
liabilities
which
can
substantial
Additionally
accident
could
damage
our
research
and
manufacturing
facilities
resulting
delays
and
increased
costs
Table
Contents
are
subject
environmental
laws
and
regulations
which
may
impose
significant
compliance
other
costs
Our
manufacturing
product
development
and
research
and
development
operations
and
processes
involve
the
controlled
use
certain
hazardous
materials
addition
own
and
lease
number
facilities
some
which
have
been
operation
for
many
decades
where
others
may
have
used
substances
generated
and
disposed
wastes
which
are
considered
hazardous
may
considered
hazardous
the
future
also
have
acquired
various
companies
which
historically
may
have
used
certain
hazardous
materials
and
which
may
have
owned
and
leased
facilities
which
hazardous
materials
have
been
used
For
all
these
reasons
are
subject
federal
state
foreign
and
local
laws
and
regulations
governing
the
use
manufacture
storage
transportation
handling
treatment
remediation
and
disposal
hazardous
materials
and
certain
waste
products
have
potential
liability
under
these
laws
and
regulations
with
respect
the
remediation
past
contamination
certain
the
facilities
now
own
lease
Additionally
the
future
our
facilities
and
the
disposal
sites
owned
others
which
send
sent
waste
may
identified
contaminated
and
require
remediation
Accordingly
may
become
subject
additional
compliance
costs
environmental
liabilities
which
may
significant
and
could
materially
harm
our
results
operations
financial
condition
addition
the
risks
applicable
our
life
science
and
materials
analysis
products
our
CBRNE
detection
products
are
subject
number
additional
risks
including
lengthy
product
development
and
contract
negotiation
periods
and
certain
risks
inherent
long term
government
contracts
Our
CBRNE
detection
products
are
subject
many
the
same
risks
associated
with
our
life
science
products
including
vulnerability
rapid
technological
change
dependence
mass
spectrometry
and
other
technologies
and
substantial
competition
addition
our
CBRNE
detection
products
and
certain
products
are
generally
sold
government
agencies
under
long term
contracts
These
contracts
generally
involve
lengthy
pre contract
negotiations
and
product
development
may
required
devote
substantial
working
capital
and
other
resources
prior
obtaining
product
orders
result
may
incur
substantial
costs
before
recognize
revenue
from
these
products
Moreover
return
for
larger
longer term
contracts
our
customers
for
these
products
often
demand
more
stringent
acceptance
criteria
These
criteria
may
also
cause
delays
our
ability
recognize
revenue
from
sales
these
products
Furthermore
may
not
able
accurately
predict
advance
our
costs
fulfill
our
obligations
under
these
long term
contracts
fail
accurately
predict
our
costs
due
inflation
other
factors
could
incur
significant
losses
Also
the
presence
absence
such
contracts
may
cause
substantial
variation
our
results
operations
between
fiscal
periods
and
result
our
results
operations
for
any
given
fiscal
period
may
not
predictive
our
results
for
subsequent
fiscal
periods
The
resulting
uncertainty
may
have
adverse
impact
our
stock
price
are
subject
existing
and
potential
additional
regulation
and
government
inquiry
which
can
impose
burdens
our
operations
and
narrow
the
markets
for
our
products
are
subject
both
directly
and
indirectly
the
adverse
impact
existing
and
potential
future
government
regulation
our
operations
and
markets
For
example
exportation
our
products
particularly
our
CBRNE
detection
products
subject
strict
regulatory
control
number
jurisdictions
The
failure
satisfy
export
control
criteria
obtain
necessary
clearances
could
delay
prevent
shipment
products
which
could
adversely
affect
our
revenues
and
profitability
addition
result
our
international
operations
are
subject
compliance
with
various
laws
and
regulations
including
the
FCPA
and
local
antibribery
laws
the
jurisdictions
which
business
which
generally
prohibit
companies
and
their
intermediaries
agents
from
engaging
bribery
making
improper
payments
foreign
officials
their
agents
The
FCPA
also
requires
proper
record
keeping
and
characterization
such
payments
our
reports
filed
with
the
SEC
Table
Contents
Despite
maintaining
policies
and
procedures
that
require
our
employees
comply
with
these
laws
and
our
standards
ethical
conduct
cannot
ensure
that
these
policies
and
procedures
will
always
protect
from
intentional
reckless
negligent
acts
committed
our
employees
agents
For
example
resolved
investigation
the
SEC
into
possible
violations
the
FCPA
arising
from
past
conduct
our
subsidiaries
operating
China
connection
with
the
resolution
consented
the
entry
administrative
cease
and
desist
order
the
SEC
concerning
violations
the
books
and
records
and
internal
controls
provisions
the
FCPA
and
paid
aggregate
amount
approximately
million
consisting
million
disgorgement
million
prejudgment
interest
and
million
penalty
also
incurred
legal
and
professional
fees
associated
with
the
investigation
and
settlement
approximately
million
Additionally
resolved
investigation
the
Korea
Fair
Trade
Commission
KFTC
into
improper
bidding
Bruker
Korea
Ltd
Bruker
Korea
and
several
other
companies
connection
with
bids
for
sales
ray
systems
and
connection
with
these
matters
various
Korean
governmental
entities
imposed
suspensions
Bruker
Korea
with
overlapping
suspension
periods
ranging
from
three
six
months
During
the
periods
these
suspensions
which
expired
Bruker
Korea
was
prohibited
from
bidding
for
conducting
sales
Korean
governmental
agencies
October
the
Company
received
notice
investigation
and
subpoena
produce
documents
from
the
Division
Enforcement
the
SEC
The
subpoena
seeks
information
related
employee
terminated
part
restructuring
and
certain
matters
involving
the
Company
policies
and
accounting
practices
related
revenue
recognition
and
restructuring
activities
well
related
financial
reporting
disclosure
and
compliance
matters
since
January
The
subpoena
also
seeks
information
concerning
among
other
things
the
Company
previously
identified
material
weakness
internal
controls
over
the
accounting
for
income
taxes
related
financial
reporting
matters
and
certain
payments
for
non employee
travel
expenses
The
Company
producing
documents
response
the
subpoena
and
intends
continue
cooperate
fully
with
the
SEC
investigation
this
time
the
Company
unable
predict
the
duration
scope
outcome
this
investigation
Moreover
the
life
sciences
industry
which
the
market
for
our
principal
products
has
historically
been
heavily
regulated
There
are
for
example
laws
several
jurisdictions
restricting
research
genetic
engineering
which
can
operate
narrow
our
markets
Given
the
evolving
nature
this
industry
legislative
bodies
regulatory
authorities
may
adopt
additional
regulation
that
adversely
affects
our
market
opportunities
Our
business
also
directly
affected
wide
variety
government
regulations
applicable
business
enterprises
generally
and
companies
operating
the
life
sciences
industry
particular
Our
clinical
products
are
subject
regulation
the
FDA
These
regulations
govern
wide
variety
product
related
activities
from
quality
management
design
and
development
labeling
manufacturing
promotion
sales
and
distribution
any
our
suppliers
distributors
fail
comply
with
FDA
and
other
applicable
regulatory
requirements
are
perceived
potentially
have
failed
comply
may
face
among
other
things
warning
letters
adverse
publicity
affecting
both
and
our
customers
investigations
notices
non compliance
fines
injunctions
and
civil
penalties
import
export
restrictions
partial
suspensions
total
shutdown
production
facilities
the
imposition
operating
restrictions
increased
difficulty
obtaining
required
FDA
clearances
approvals
foreign
equivalents
seizures
recalls
our
products
those
our
customers
the
inability
sell
such
products
Any
such
FDA
actions
could
disrupt
our
business
and
operations
lead
significant
remedial
costs
and
have
material
adverse
impact
our
financial
position
and
results
operations
have
been
are
and
expect
the
future
subject
inquiries
from
the
government
agencies
that
enforce
these
regulations
including
the
Department
State
the
Department
Commerce
the
Food
and
Drug
Administration
the
Internal
Revenue
Service
the
Department
Homeland
Security
the
Department
Justice
the
Securities
and
Exchange
Table
Contents
Commission
the
Federal
Trade
Commission
the
Customs
and
Border
Protection
and
the
Department
Defense
among
others
well
from
state
foreign
governments
and
their
departments
and
agencies
result
from
time
time
the
attention
our
management
and
other
resources
may
diverted
attend
these
inquiries
addition
failure
comply
with
these
regulations
obtain
maintain
necessary
permits
and
licenses
could
result
variety
fines
other
censures
interruption
our
business
operations
which
may
have
negative
impact
our
ability
generate
revenues
and
could
adversely
affect
our
financial
condition
and
results
operations
Our
success
depends
our
ability
operate
without
infringing
misappropriating
the
proprietary
rights
others
Our
commercial
success
depends
avoiding
the
infringement
other
parties
patents
and
proprietary
rights
well
avoiding
the
breach
any
licenses
relating
our
technologies
and
products
Given
that
there
may
patents
which
are
unaware
particularly
the
United
States
where
patent
applications
are
confidential
avoidance
patent
infringement
may
difficult
Various
third
parties
hold
patents
which
may
relate
our
technology
and
may
found
the
future
infringe
these
other
patents
proprietary
rights
third
parties
either
with
products
are
currently
marketing
developing
with
new
products
which
may
develop
the
future
third
party
holding
rights
under
patent
successfully
asserts
infringement
claim
with
respect
any
our
current
future
products
may
prevented
from
manufacturing
marketing
our
infringing
product
the
country
countries
covered
the
patent
infringe
unless
can
obtain
license
from
the
patent
holder
may
not
able
obtain
license
commercially
reasonable
terms
all
especially
the
patent
holder
competitor
addition
even
can
obtain
the
license
may
non exclusive
which
will
permit
others
practice
the
same
technology
licensed
also
may
required
pay
substantial
damages
the
patent
holder
the
event
infringement
Under
some
circumstances
the
United
States
these
damages
could
include
damages
equal
triple
the
actual
damages
the
patent
holder
incurs
have
supplied
infringing
products
third
parties
for
marketing
them
licensed
third
parties
manufacture
use
market
infringing
products
may
obligated
indemnify
these
third
parties
for
any
damages
they
may
required
pay
the
patent
holder
and
for
any
losses
the
third
parties
may
sustain
themselves
the
result
lost
sales
license
payments
they
are
required
make
the
patent
holder
Any
successful
infringement
action
brought
against
may
also
adversely
affect
marketing
the
infringing
product
other
markets
not
covered
the
infringement
action
well
our
marketing
other
products
based
similar
technology
Furthermore
will
suffer
adverse
consequences
from
successful
infringement
action
against
even
the
action
subsequently
reversed
appeal
nullified
through
another
action
resolved
settlement
with
the
patent
holder
The
damages
other
remedies
awarded
any
may
significant
result
any
successful
infringement
action
against
may
harm
our
business
are
unable
effectively
protect
our
intellectual
property
third
parties
may
use
our
technology
which
would
impair
our
ability
compete
our
markets
Our
continued
success
will
depend
significant
part
our
ability
obtain
and
maintain
meaningful
patent
protection
for
our
products
throughout
the
world
rely
patents
protect
significant
part
our
intellectual
property
and
enhance
our
competitive
position
However
our
presently
pending
future
patent
applications
may
not
issue
patents
and
any
patent
previously
issued
may
challenged
invalidated
held
unenforceable
circumvented
Furthermore
the
claims
patents
which
have
been
issued
which
may
issued
the
future
may
not
sufficiently
broad
prevent
third
parties
from
producing
competing
products
similar
our
products
addition
the
laws
various
foreign
countries
which
compete
may
not
protect
our
intellectual
property
the
same
extent
the
laws
the
United
States
Failure
obtain
adequate
patent
protection
for
our
proprietary
technology
could
materially
impair
our
ability
commercially
competitive
Table
Contents
addition
patent
protection
also
rely
the
protection
trade
secrets
know how
and
confidential
and
proprietary
information
maintain
the
confidentiality
trade
secrets
and
proprietary
information
generally
seek
enter
into
confidentiality
agreements
with
our
employees
consultants
and
strategic
partners
upon
the
commencement
relationship
with
However
may
not
obtain
these
agreements
all
circumstances
the
event
unauthorized
use
disclosure
this
information
these
agreements
even
obtained
may
not
provide
meaningful
protection
for
our
trade
secrets
other
confidential
information
addition
adequate
remedies
may
not
exist
the
event
unauthorized
use
disclosure
this
information
The
loss
exposure
our
trade
secrets
and
other
proprietary
information
would
impair
our
competitive
advantages
and
could
have
material
adverse
effect
our
operating
results
financial
condition
and
future
growth
prospects
Furthermore
others
may
have
may
the
future
independently
develop
substantially
similar
superior
know how
and
technology
may
involved
lawsuits
protect
enforce
our
patents
that
are
brought
which
could
expensive
and
time
consuming
and
determined
adversely
could
adversely
affect
our
patent
position
order
protect
enforce
our
patent
rights
may
initiate
patent
litigation
against
third
parties
and
may
similarly
sued
others
may
also
become
subject
interference
proceedings
conducted
the
patent
and
trademark
offices
various
countries
determine
the
priority
inventions
The
defense
and
prosecution
necessary
intellectual
property
suits
interference
proceedings
and
related
legal
and
administrative
proceedings
costly
and
diverts
our
technical
and
management
personnel
from
their
normal
responsibilities
may
not
prevail
any
these
suits
adverse
determination
any
litigation
defense
proceedings
could
put
our
patents
risk
being
invalidated
interpreted
narrowly
and
could
put
our
patent
applications
risk
not
issuing
Furthermore
because
the
substantial
amount
discovery
required
connection
with
intellectual
property
litigation
there
risk
that
some
our
confidential
information
could
compromised
disclosure
during
this
type
litigation
addition
during
the
course
this
kind
litigation
there
could
public
announcements
the
results
hearings
motions
other
interim
proceedings
developments
the
litigation
securities
analysts
investors
perceive
these
results
negative
could
have
substantial
negative
effect
the
trading
price
our
common
stock
rely
information
technology
support
our
operations
and
reporting
environments
security
failure
that
technology
could
impact
our
ability
operate
our
businesses
effectively
adversely
affect
our
financial
results
damage
our
reputation
and
expose
potential
liability
litigation
use
information
systems
carry
out
our
operations
and
maintain
our
business
records
Some
systems
are
internally
managed
and
some
are
maintained
third party
service
providers
and
our
service
providers
employ
what
believe
are
adequate
security
measures
Our
ability
conduct
business
could
materially
and
adversely
affected
these
systems
resources
are
compromised
damaged
fail
This
could
result
cyber incident
natural
disaster
hardware
software
corruption
failure
error
telecommunications
system
failure
service
provider
error
failure
intentional
unintentional
personnel
actions
other
disruption
the
ordinary
course
business
collect
and
store
sensitive
data
including
intellectual
property
other
proprietary
information
and
personally
identifiable
information
this
data
compromised
destroyed
inappropriately
disclosed
could
have
material
adverse
effect
including
damage
our
reputation
loss
customers
significant
expenses
address
and
resolve
the
issues
litigation
other
proceedings
affected
individuals
business
partners
regulatory
authorities
Table
Contents
Our
debt
may
adversely
affect
our
cash
flow
and
may
restrict
our
investment
opportunities
limit
our
activities
December
had
outstanding
aggregate
principal
amount
debt
totaling
approximately
million
including
million
senior
unsecured
notes
million
long term
borrowings
under
our
revolving
loan
facility
and
million
other
debt
offset
unamortized
debt
issuance
costs
for
the
senior
unsecured
notes
million
also
had
the
ability
borrow
additional
million
available
under
our
existing
credit
facility
Most
our
outstanding
debt
the
United
States
and
there
are
substantial
cash
requirements
the
United
States
service
debt
interest
obligations
fund
operations
capital
expenditures
and
our
declared
dividends
and
finance
potential
acquisitions
share
repurchases
Our
ability
satisfy
our
debt
obligations
and
meet
our
other
liquidity
needs
depends
our
future
operating
performance
and
economic
financial
competitive
and
other
factors
beyond
our
control
Our
business
may
not
generate
sufficient
cash
flow
meet
our
debt
obligations
provide
sufficient
funds
for
our
other
objectives
are
unable
service
our
debt
obtain
additional
financing
may
forced
delay
strategic
acquisitions
capital
expenditures
research
and
development
expenditures
suspend
our
dividend
payments
and
share
repurchases
may
not
able
obtain
additional
financing
terms
acceptable
all
Furthermore
majority
our
cash
cash
equivalents
and
short term
investments
generated
from
foreign
operations
with
million
held
foreign
subsidiaries
December
Our
financial
condition
and
results
operations
could
adversely
impacted
are
unable
maintain
sufficient
level
cash
flow
the
United
States
address
our
funding
requirements
through
cash
from
operations
and
timely
repatriation
cash
from
overseas
other
sources
obtained
acceptable
cost
Additionally
the
agreements
governing
our
debt
require
that
maintain
certain
financial
ratios
related
maximum
leverage
and
minimum
interest
coverage
and
contain
negative
covenants
including
among
others
restrictions
liens
indebtedness
the
Company
and
its
subsidiaries
asset
sales
dividends
and
transactions
with
affiliates
Our
ability
comply
with
these
financial
restrictions
and
covenants
dependent
our
future
performance
which
subject
prevailing
economic
conditions
and
other
factors
including
factors
that
are
beyond
our
control
such
foreign
currency
translation
rates
and
interest
rates
Our
failure
comply
with
any
these
restrictions
covenants
may
result
event
default
under
the
applicable
debt
instrument
which
could
permit
acceleration
the
debt
under
the
facility
and
require
prepay
the
debt
before
its
scheduled
due
date
Changes
our
effective
income
tax
rate
could
adversely
affect
our
results
operations
are
subject
income
taxes
both
the
United
States
and
various
foreign
jurisdictions
and
our
domestic
and
international
tax
liabilities
are
largely
dependent
upon
the
distribution
income
among
these
different
jurisdictions
Various
factors
may
have
favorable
unfavorable
effects
our
effective
income
tax
rate
These
factors
include
interpretations
existing
tax
laws
the
accounting
for
stock
options
and
other
share based
compensation
changes
tax
laws
and
rates
including
the
recently
enacted
Tax
Cuts
and
Jobs
Act
future
levels
research
and
development
spending
changes
accounting
standards
changes
the
mix
earnings
the
various
tax
jurisdictions
which
operate
the
outcome
examinations
the
Internal
Revenue
Service
and
other
tax
authorities
the
accuracy
our
estimates
for
unrecognized
tax
benefits
and
realization
deferred
tax
assets
and
changes
overall
levels
pre tax
earnings
Various
international
tax
risks
could
adversely
affect
our
earnings
and
cash
flows
are
subject
international
tax
risks
could
subject
double
taxation
income
related
operations
certain
countries
that
not
have
tax
treaties
with
the
country
the
trading
partner
addition
may
have
higher
effective
income
tax
rate
than
that
other
companies
our
industry
losses
incurred
one
operating
company
are
not
available
offset
the
income
Table
Contents
operating
company
located
another
country
Also
distributions
earnings
and
other
payments
received
from
our
subsidiaries
may
subject
withholding
taxes
imposed
the
countries
where
they
are
operating
are
incorporated
these
foreign
countries
not
have
income
tax
treaties
with
the
United
States
the
countries
where
our
subsidiaries
are
incorporated
could
subject
high
rates
withholding
taxes
these
distributions
and
payments
Additionally
the
amount
the
credit
that
may
claim
against
our
federal
income
tax
for
foreign
income
taxes
paid
accrued
subject
many
limitations
which
may
significantly
restrict
our
ability
claim
credit
for
all
the
foreign
taxes
pay
currently
have
reserves
established
for
potential
tax
liabilities
these
reserves
are
challenged
and
are
unable
successfully
defend
our
tax
positions
negative
impact
our
cash
flows
could
result
The
unpredictability
and
fluctuation
our
quarterly
results
may
adversely
affect
the
trading
price
our
common
stock
Our
revenues
and
results
operations
have
the
past
and
will
the
future
vary
from
quarter
quarter
due
number
factors
many
which
are
outside
our
control
and
any
which
may
cause
our
stock
price
fluctuate
The
primary
factors
that
may
affect
include
the
following
the
timing
sales
our
products
and
services
the
timing
recognizing
revenue
and
deferred
revenue
under
GAAP
changes
our
pricing
policies
the
pricing
policies
our
competitors
increases
sales
and
marketing
product
development
administration
expenses
the
mix
services
provided
and
third party
contractors
our
ability
attain
and
maintain
quality
levels
for
our
products
costs
related
acquisitions
technology
businesses
and
the
effectiveness
transactions
entered
into
hedge
the
risks
associated
with
foreign
currency
and
interest
rate
fluctuations
can
experience
quarter quarter
fluctuations
our
operating
results
result
various
factors
some
which
are
outside
our
control
such
the
timing
governmental
stimulus
programs
and
academic
research
budgets
the
time
takes
between
the
date
customer
orders
and
deposits
are
received
systems
are
shipped
and
accepted
our
customers
and
full
payment
received
the
time
takes
satisfy
local
customs
requirements
and
other
export import
requirements
the
time
takes
for
customers
construct
prepare
their
facilities
for
our
products
and
the
time
required
obtain
governmental
licenses
These
factors
have
the
past
affected
the
amount
and
timing
revenue
recognized
sales
our
products
and
receipt
related
payments
and
will
continue
the
future
Accordingly
our
operating
results
any
particular
quarter
may
not
necessarily
indication
any
future
quarter
operating
performance
Historically
have
higher
levels
revenue
the
fourth
quarter
the
year
compared
the
first
second
and
third
quarters
which
believe
primarily
the
result
our
customers
budgeting
cycles
Quarter quarter
comparisons
our
results
operations
should
not
relied
upon
indication
our
future
performance
likely
that
some
future
quarters
our
results
operations
Table
Contents
may
below
the
expectations
public
market
analysts
and
investors
this
event
the
price
our
common
stock
may
fall
Existing
stockholders
have
significant
influence
over
March
Laukien
family
members
including
our
Chairman
President
and
Chief
Executive
Officer
Frank
Laukien
and
Director
Joerg
Laukien
owned
the
aggregate
approximately
our
outstanding
common
stock
result
these
stockholders
will
able
exercise
substantial
influence
over
all
matters
requiring
stockholder
approval
including
the
election
directors
and
approval
significant
corporate
transactions
This
could
have
the
effect
delaying
preventing
change
control
our
company
and
will
make
some
transactions
difficult
accomplish
without
the
support
these
stockholders
Other
companies
may
have
difficulty
acquiring
even
doing
would
benefit
our
stockholders
due
provisions
under
our
corporate
charter
and
bylaws
well
Delaware
law
Provisions
our
certificate
incorporation
amended
and
our
bylaws
well
Delaware
law
could
make
more
difficult
for
other
companies
acquire
even
doing
would
benefit
our
stockholders
Our
certificate
incorporation
amended
and
bylaws
contain
the
following
provisions
among
others
which
may
inhibit
acquisition
our
company
third
party
staggered
Board
Directors
where
stockholders
elect
only
minority
the
board
each
year
advance
notification
procedures
for
matters
brought
before
stockholder
meetings
limitation
who
may
call
stockholder
meetings
and
the
ability
our
Board
Directors
issue
shares
preferred
stock
without
stockholder
vote
ITEM
UNRESOLVED
STAFF
COMMENTS
have
not
received
any
written
comments
from
the
staff
the
Securities
and
Exchange
Commission
regarding
our
periodic
current
reports
that
believe
are
material
were
issued
not
less
than
days
before
the
end
our
fiscal
year
end
and
remain
unresolved
ITEM
PROPERTIES
believe
that
our
existing
principal
facilities
are
well
maintained
and
good
operating
condition
and
that
they
are
adequate
for
our
foreseeable
business
needs
addition
the
principal
facilities
noted
below
lease
additional
facilities
for
sales
applications
and
service
support
various
countries
throughout
the
world
including
Australia
Austria
Belgium
Brazil
China
Czech
Republic
Estonia
France
Germany
Hong
Kong
India
Israel
Italy
Japan
Malaysia
Mexico
Netherlands
Poland
Portugal
Russia
Singapore
South
Africa
South
Korea
Spain
Sweden
Switzerland
Taiwan
Thailand
Turkey
Ukraine
the
United
Kingdom
and
the
United
States
should
require
additional
alternative
facilities
believe
that
such
facilities
can
obtained
short
notice
competitive
rates
The
location
and
general
character
our
principal
properties
operating
segment
are
follows
BSI
Segment
Bruker
BioSpin
five
principal
facilities
are
located
Rheinstetten
Ettlingen
and
Karlsruhe
Germany
Faellanden
Switzerland
and
Wissembourg
France
These
facilities
which
incorporate
Table
Contents
manufacturing
research
and
development
application
and
demonstration
marketing
and
sales
and
administration
functions
for
the
businesses
Bruker
BioSpin
include
owned
square
foot
facility
Rheinstetten
Germany
owned
square
foot
facility
Ettlingen
Germany
owned
square
foot
facility
Karlsruhe
Germany
owned
square
foot
facility
and
leased
square
foot
facility
Faellanden
Switzerland
and
owned
square
foot
facility
and
leased
square
foot
facility
Wissembourg
France
Bruker
CALID
three
principal
facilities
are
located
Bremen
Ettlingen
and
Leipzig
Germany
These
facilities
which
incorporate
manufacturing
research
and
development
application
and
demonstration
marketing
and
sales
and
administration
functions
for
the
mass
spectrometry
and
CBRNE
businesses
Bruker
CALID
include
owned
square
foot
facility
Bremen
Germany
owned
square
foot
facility
Ettlingen
Germany
and
owned
square
foot
facility
Leipzig
Germany
Bruker
Nano
five
principal
facilities
are
located
Karlsruhe
and
Berlin
Germany
Migdal
Emek
Israel
Madison
Wisconsin
and
Santa
Barbara
California
These
facilities
which
incorporate
manufacturing
research
and
development
application
and
demonstration
marketing
and
sales
and
administration
functions
for
the
businesses
Bruker
Nano
include
owned
square
foot
facility
and
owned
square
foot
facility
Karlsruhe
Germany
owned
square
foot
facility
Santa
Barbara
California
owned
square
foot
facility
Berlin
Germany
owned
square
foot
facility
Madison
Wisconsin
and
leased
square
foot
facility
Migdal
Emek
Israel
BEST
Segment
BEST
five
principal
facilities
are
located
Hanau
Bergisch
Gladbach
and
Alzenau
Germany
Carteret
New
Jersey
and
Perth
Scotland
These
facilities
which
incorporate
manufacturing
research
and
development
application
and
demonstration
marketing
and
sales
and
administration
functions
for
the
business
BEST
include
owned
square
foot
facility
Perth
Scotland
leased
square
foot
facility
Hanau
Germany
leased
square
foot
facility
Bergisch
Gladbach
Germany
leased
square
foot
facility
Carteret
New
Jersey
and
leased
square
foot
facility
Alzenau
Germany
Table
Contents
ITEM
LEGAL
PROCEEDINGS
are
involved
lawsuits
claims
and
proceedings
including
but
not
limited
patent
and
commercial
matters
which
arise
the
ordinary
course
business
There
are
such
matters
pending
that
currently
believe
are
reasonably
possible
having
material
impact
our
business
our
consolidated
financial
statements
addition
from
time
time
the
Company
the
subject
investigations
national
state
and
local
government
agencies
the
United
States
and
other
countries
which
operates
involving
among
other
things
regulatory
financial
reporting
marketing
and
other
business
practices
These
governmental
investigations
may
result
the
commencement
civil
and
criminal
proceedings
fines
penalties
and
administrative
remedies
and
may
have
material
adverse
effect
our
financial
position
results
operations
and
business
October
received
notice
investigation
and
subpoena
produce
documents
from
the
Division
Enforcement
the
SEC
The
subpoena
seeks
information
related
employee
terminated
part
restructuring
and
certain
matters
involving
the
Company
policies
and
accounting
practices
related
revenue
recognition
and
restructuring
activities
well
related
financial
reporting
disclosure
and
compliance
matters
since
January
The
subpoena
also
seeks
information
concerning
among
other
things
the
Company
previously
identified
material
weakness
internal
controls
over
the
accounting
for
income
taxes
related
financial
reporting
matters
and
certain
payments
for
non employee
travel
expenses
The
Company
producing
documents
response
the
subpoena
and
intends
continue
cooperate
fully
with
the
SEC
investigation
this
time
are
unable
predict
the
duration
scope
outcome
this
investigation
ITEM
MINE
SAFETY
DISCLOSURE
Not
applicable
Table
Contents
PART
ITEM
MARKET
FOR
REGISTRANT
COMMON
EQUITY
RELATED
STOCKHOLDER
MATTERS
AND
ISSUER
PURCHASES
EQUITY
SECURITIES
Market
Prices
Our
common
stock
traded
the
Nasdaq
Global
Select
Market
under
the
symbol
BRKR
The
following
table
sets
forth
for
the
period
indicated
the
high
and
low
sales
prices
for
our
common
stock
reported
the
Nasdaq
Global
Select
Market
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
High
Low
March
there
were
approximately
holders
record
our
common
stock
This
number
does
not
include
individual
beneficial
owners
shares
held
nominee
name
within
clearinghouse
positions
brokerage
firms
and
banks
Dividends
February
announced
the
establishment
dividend
policy
and
the
declaration
our
Board
Directors
initial
quarterly
cash
dividend
the
amount
per
share
our
issued
and
outstanding
common
stock
Cash
dividends
paid
and
totaled
per
share
each
March
June
September
and
December
Under
the
dividend
policy
will
target
cash
dividend
our
stockholders
the
amount
per
share
per
annum
payable
equal
quarterly
installments
Subsequent
dividend
declarations
and
the
establishment
record
and
payment
dates
for
such
future
dividend
payments
any
are
subject
the
Board
Directors
continuing
determination
that
the
dividend
policy
the
best
interests
our
stockholders
The
dividend
policy
may
suspended
cancelled
the
discretion
the
Board
Directors
any
time
are
compliance
with
restrictions
that
the
terms
certain
debt
facilities
place
the
amount
cash
dividends
that
could
potentially
pay
Recent
Sales
Unregistered
Securities
There
were
unregistered
sales
equity
securities
during
the
fourth
quarter
Table
Contents
Issuer
Purchases
Equity
Securities
The
following
table
sets
forth
all
purchases
made
behalf
the
Company
any
affiliated
purchaser
defined
Rule
under
the
Exchange
Act
shares
our
common
stock
during
each
month
the
fourth
quarter
Period
Total
Number
Shares
Purchased
October
October
November
November
December
December
Total
Number
Shares
Purchased
Part
Publicly
Announced
Plans
Programs
Average
Price
Paid
per
Share
Maximum
Number
Shares
approximate
dollar
value
that
May
Yet
Purchased
Under
the
Plans
Programs
Includes
shares
repurchased
under
million
share
repurchase
program
approved
the
Board
Directors
and
announced
May
the
Repurchase
Program
under
which
repurchases
common
stock
may
occur
from
time
time
amounts
prices
and
such
times
the
Company
deems
appropriate
subject
market
conditions
legal
requirements
and
other
considerations
Represents
shares
repurchased
under
the
Repurchase
Program
The
Repurchase
Program
authorizes
purchases
million
the
Company
common
stock
over
two year
period
commencing
May
December
shares
common
stock
with
aggregate
cost
approximately
million
have
been
repurchased
The
remaining
authorization
under
the
Repurchase
Program
million
March
The
Repurchase
Program
expires
May
and
can
suspended
modified
terminated
any
time
without
prior
notice
Table
Contents
Stock
Price
Performance
Graph
The
graph
below
shows
the
cumulative
stockholder
return
assuming
the
investment
and
the
reinvestment
any
dividends
thereafter
for
the
period
beginning
December
and
ending
December
for
our
common
stock
stocks
traded
Nasdaq
and
peer
group
consisting
Public
Companies
with
Standard
Industry
Classification
SIC
code
Laboratory
Analytical
Instruments
The
stock
price
performance
Bruker
Corporation
shown
the
following
graph
not
indicative
future
stock
price
performance
Comparison
Year
Cumulative
Total
Return
Assumes
Initial
Investment
December
Cumulative
Total
Return
Index
for
Bruker
Corporation
NASDAQ
Stock
Market
companies
SIC
Code
Laborartory
Analytical
Instruments
The
data
for
this
performance
graph
was
compiled
Zack
Investment
Research
Inc
and
used
with
their
permission
Table
Contents
ITEM
SELECTED
FINANCIAL
DATA
The
consolidated
statements
income
and
comprehensive
income
data
for
each
the
years
ended
December
and
and
the
consolidated
balance
sheet
data
December
and
have
been
derived
from
our
audited
consolidated
financial
statements
included
Item
this
Annual
Report
Form
The
data
presented
below
was
derived
from
consolidated
financial
statements
that
were
prepared
accordance
with
generally
accepted
accounting
principles
and
should
read
with
the
consolidated
and
combined
financial
statements
including
the
notes
thereto
and
Management
Discussion
and
Analysis
Financial
Condition
and
Results
Operations
included
elsewhere
this
Annual
Report
Form
Consolidated Combined
Statements
Income
Data
Product
revenue
Service
revenue
Other
revenue
Total
revenue
Total
costs
and
operating
expenses
Operating
income
Net
income
attributable
Bruker
Corporation
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
Cash
dividends
declared
per
common
share
Year
Ended
December
millions
except
per
share
data
includes
million
restructuring
costs
and
million
impairment
other
long lived
assets
and
includes
million
incremental
income
tax
provision
related
the
Tax
Act
includes
million
restructuring
costs
and
million
impairment
other
long lived
assets
includes
million
restructuring
costs
and
million
impairment
goodwill
definite lived
intangible
assets
and
other
long lived
assets
includes
million
restructuring
costs
and
million
impairment
definite lived
intangible
assets
and
other
long lived
assets
Table
Contents
includes
million
restructuring
costs
Consolidated Combined
Balance
Sheet
Data
Cash
and
cash
equivalents
Short term
investments
Working
capital
Total
assets
Total
debt
Other
long term
liabilities
Total
shareholders
equity
Year
Ended
December
millions
the
Company
adopted
Accounting
Standards
Update
Simplifying the Presentation Debt Issuance Costs
and
reclassified
the
debt
issuance
costs
associated
with
the
senior
unsecured
notes
reduction
the
carrying
amount
debt
instead
other
asset
each
the
years
presented
above
The
impact
was
million
million
million
and
million
each
the
years
ended
December
and
respectively
the
Company
commenced
program
enter
into
time
deposits
with
varying
maturity
dates
well
call
deposits
Based
the
call
and
maturity
dates
certain
these
investments
have
been
classified
short term
investments
Working
capital
defined
the
above
table
current
assets
less
current
liabilites
Table
Contents
ITEM
MANAGEMENT
DISCUSSION
AND
ANALYSIS
FINANCIAL
CONDITION
AND
RESULTS
OPERATIONS
The
following
Management
Discussion
and
Analysis
Financial
Condition
and
Results
Operations
describes
the
principal
factors
affecting
the
results
our
operations
financial
condition
and
changes
financial
condition
well
our
critical
accounting
policies
and
estimates
Our
organized
follows
Overview
This
section
provides
brief
discussion
our
reportable
segments
results
operations
significant
recent
developments
our
businesses
and
challenges
and
risks
that
may
impact
our
businesses
the
future
Results Operations
This
section
provides
our
analysis
the
significant
line
items
our
consolidated
statements
income
and
comprehensive
income
for
the
year
ended
December
compared
the
year
ended
December
and
for
the
year
ended
December
compared
the
year
ended
December
Liquidity and Capital Resources
This
section
provides
analysis
our
liquidity
and
cash
flow
and
discussion
our
outstanding
debt
and
commitments
Critical Accounting Policies and Estimates
This
section
discusses
the
accounting
estimates
that
are
considered
important
our
financial
condition
and
results
operations
and
require
exercise
subjective
complex
judgments
their
application
All
our
significant
accounting
policies
are
summarized
Note
our
consolidated
financial
statements
Item
this
Annual
Report
Form
Recent Accounting Pronouncements
This
section
provides
summary
recent
accounting
pronouncements
and
discusses
their
potential
impact
our
consolidated
financial
statements
Transactions with Related Parties
This
section
summarizes
transactions
with
related
parties
Statements
contained
Management
Discussion
and
Analysis
Financial
Condition
and
Results
Operations
which
express
that
believe
anticipate
plan
expect
seek
estimate
should
well
other
statements
which
are
not
historical
fact
are
forward looking
statements
within
the
meaning
the
Private
Securities
Litigation
Reform
Act
Actual
events
results
may
differ
materially
from
those
set
forth
forward looking
statements
Certain
factors
that
might
cause
such
difference
are
discussed
Risk
Factors
and
Management
Discussion
and
Analysis
Financial
Condition
and
Results
Operations
this
Annual
Report
Form
for
the
year
ended
December
Although
our
consolidated
financial
statements
have
been
prepared
accordance
with
generally
accepted
accounting
principles
the
United
States
America
GAAP
believe
describing
revenue
and
expenses
excluding
the
effects
foreign
currency
acquisitions
and
divestitures
well
certain
other
charges
net
provides
meaningful
supplemental
information
regarding
our
performance
Specifically
management
believes
that
free
cash
flow
and
organic
revenue
both
non GAAP
financial
measures
well
non GAAP
gross
profit
margin
and
non GAAP
operating
margin
provide
relevant
and
useful
information
which
widely
used
equity
analysts
investors
and
competitors
our
industry
well
our
management
assessing
both
consolidated
and
business
unit
performance
define
the
term
organic
revenue
GAAP
revenue
excluding
the
effect
foreign
currency
translation
changes
and
the
effect
acquisitions
and
divestitures
define
the
term
non GAAP
gross
profit
margin
GAAP
gross
profit
margin
with
certain
non GAAP
measures
excluded
and
non GAAP
operating
margin
GAAP
operating
margin
with
certain
non GAAP
measures
excluded
These
non GAAP
measures
exclude
costs
related
restructuring
actions
acquisition
and
related
integration
expenses
amortization
acquired
intangible
assets
and
other
costs
that
are
infrequent
non recurring
nature
and
believe
these
are
useful
measures
evaluate
our
continuing
business
Table
Contents
define
free
cash
flow
net
cash
provided
operating
activities
less
additions
property
plant
and
equipment
believe
free
cash
flow
useful
measure
evaluate
our
business
indicates
the
amount
cash
generated
after
additions
property
plant
and
equipment
which
available
for
among
other
things
investments
our
business
acquisitions
share
repurchases
dividends
and
repayment
debt
use
these
non GAAP
financial
measures
evaluate
our
period over period
operating
performance
because
our
management
believes
they
provide
more
comparable
measures
our
continuing
business
because
they
adjust
for
certain
items
that
are
not
reflective
the
underlying
performance
our
business
These
measures
may
also
useful
investors
evaluating
the
underlying
operating
performance
our
business
regularly
use
these
non GAAP
financial
measures
internally
understand
manage
and
evaluate
our
business
results
and
make
operating
decisions
also
measure
our
employees
and
compensate
them
part
based
such
non GAAP
measures
and
use
this
information
for
our
planning
and
forecasting
activities
The
presentation
these
non GAAP
financial
measures
not
intended
substitute
for
superior
the
financial
information
prepared
and
presented
accordance
with
GAAP
and
may
different
from
non GAAP
financial
measures
used
other
companies
and
therefore
may
not
comparable
among
companies
OVERVIEW
are
organized
into
four
operating
segments
the
Bruker
BioSpin
Group
the
Bruker
CALID
Group
the
Bruker
Nano
Group
and
the
Bruker
Energy
Supercon
Technologies
BEST
Segment
For
the
year
ended
December
our
revenue
increased
million
million
compared
million
for
the
year
ended
December
Included
revenue
were
increase
approximately
million
attributable
our
recent
acquisitions
and
increase
approximately
million
from
the
impact
foreign
currency
translation
caused
the
weakening
the
Dollar
versus
the
Euro
and
other
currencies
Excluding
the
effects
foreign
currency
translation
and
our
recent
acquisitions
our
organic
revenue
non GAAP
measure
increased
million
Our
gross
profit
margin
remained
approximately
consistent
during
the
year
ended
December
compared
during
the
year
ended
December
The
positive
effect
higher
sales
resulting
from
improvements
European
and
Industrial
end
markets
was
offset
primarily
unfavorable
business
and
product
mix
caused
higher
revenues
our
now
larger
BEST
segment
which
has
lower
gross
profit
margins
and
unfavorable
mix
within
the
BioSpin
Group
Our
operating
margin
increased
for
the
year
ended
December
from
during
the
year
ended
December
demonstrating
operating
leverage
following
Bruker
multi year
operational
transformation
while
appropriately
investing
our
six
strategic
growth
areas
The
operating
margin
increased
due
primarily
positive
operating
leverage
higher
sales
cost
discipline
and
savings
from
restructuring
initiatives
These
factors
more
than
offset
dilution
from
recent
acquisitions
and
foreign
currency
translations
effects
The
income
tax
provision
the
years
ended
December
and
was
million
and
million
respectively
representing
effective
tax
rates
and
respectively
The
increase
our
effective
tax
rate
for
the
year
ended
December
compared
was
primarily
attributable
the
impact
tax
reform
offset
the
release
our
remaining
valuation
allowances
and
the
recognition
previously
unrecognized
tax
benefits
due
the
closure
tax
audits
Our
tax
rate
may
change
over
time
the
amount
and
mix
jurisdictional
income
changes
December
Enactment
Date
the
President
the
United
States
signed
tax
reform
legislation
Tax
Act
which
enacted
wide
range
changes
the
corporate
income
tax
Table
Contents
system
many
which
differ
significantly
from
the
provisions
the
previous
tax
law
have
not
yet
completed
the
assessment
the
tax
effects
associated
with
the
enactment
the
Tax
Act
However
reasonable
estimate
has
been
made
the
effects
the
existing
deferred
tax
balances
and
the
one time
transition
tax
Changes
the
tax
rates
and
laws
are
accounted
for
the
period
enactment
Therefore
during
the
fourth
quarter
recorded
incremental
income
tax
provision
million
which
primarily
comprised
the
following
estimated
income
tax
provision
million
for
the
federal
and
state
impacts
the
one time
deemed
repatriation
pre
accordance
with
the
Tax
Act
the
federal
portion
the
toll
charge
liability
may
paid
over
eight
years
Such
liability
can
reduced
certain
credits
Accordingly
have
recorded
million
and
million
long term
income
tax
liabilities
and
accrued
income
taxes
current
respectively
December
estimated
net
income
tax
benefit
million
for
the
remeasurement
our
deferred
tax
assets
and
liabilities
the
newly
enacted
tax
rate
and
result
the
Tax
Act
and
our
expectations
about
distributing
certain
cash
balances
from
its
foreign
subsidiaries
the
United
States
also
recorded
estimated
income
tax
provisions
for
estimated
state
income
taxes
and
foreign
withholding
taxes
million
The
actual
results
the
implementation
the
Tax
Act
may
materially
differ
from
our
current
estimate
due
among
other
things
further
guidance
that
may
issued
tax
authorities
regulatory
bodies
including
the
SEC
and
the
FASB
interpret
the
Tax
Act
will
continue
analyze
the
Tax
Act
and
any
additional
guidance
that
may
issued
and
finalize
the
full
effects
applying
the
new
legislation
the
measurement
period
Earnings
per
share
decreased
from
per
diluted
share
for
the
year
ended
December
when
compared
the
year
ended
December
The
decrease
was
primarily
due
the
impact
tax
reform
which
resulted
significantly
higher
effective
tax
rate
for
the
year
ended
December
Operating
cash
flow
for
the
year
ended
December
was
source
cash
million
For
the
year
ended
December
our
free
cash
flow
non GAAP
measure
was
million
calculated
follows
Net
cash
provided
operating
activities
Less
Purchases
property
plant
and
equipment
Free
Cash
Flow
Year
Ended
December
For
the
year
ended
December
our
free
cash
flow
was
higher
than
for
the
year
ended
December
primarily
attributable
higher
net
earnings
adjusted
for
non cash
items
lower
inventory
levels
and
timing
employee
payments
These
effects
were
partially
offset
increase
accounts
receivables
caused
proportionately
higher
sales
late
the
fourth
quarter
May
our
Board
Directors
approved
share
repurchase
program
the
Repurchase
Program
that
authorized
repurchases
million
common
stock
over
two
years
total
shares
were
repurchased
aggregate
cost
million
the
twelve
months
ended
December
February
announced
the
establishment
dividend
policy
and
the
declaration
our
Board
Directors
initial
quarterly
cash
dividend
the
amount
per
share
our
issued
and
outstanding
common
stock
Dividends
amounting
million
and
million
were
Table
Contents
paid
during
the
years
ended
December
and
respectively
Future
dividend
payments
any
are
subject
approval
our
Board
Directors
are
targeting
cash
dividend
our
shareholders
the
amount
per
share
per
annum
payable
equal
quarterly
installments
the
years
ended
December
and
completed
various
acquisitions
that
complemented
our
existing
market
offerings
and
added
aftermarket
and
software
capabilities
our
existing
microbiology
business
The
impact
the
acquired
companies
revenues
net
income
and
total
assets
was
not
material
can
experience
quarter quarter
fluctuations
our
operating
results
result
various
factors
some
which
are
outside
our
control
such
the
timing
governmental
stimulus
programs
and
academic
research
budgets
the
time
takes
between
the
date
customer
orders
and
deposits
are
received
systems
are
shipped
and
accepted
our
customers
and
full
payment
received
the
time
takes
satisfy
local
customs
requirements
and
other
export import
requirements
the
time
takes
for
customers
construct
prepare
their
facilities
for
our
products
and
the
time
required
obtain
governmental
licenses
These
factors
have
the
past
affected
the
amount
and
timing
revenue
recognized
sales
our
products
and
receipt
related
payments
and
will
continue
the
future
Accordingly
our
operating
results
any
particular
quarter
may
not
necessarily
indication
any
future
quarter
operating
performance
Table
Contents
RESULTS
OPERATIONS
Year Ended December Compared the Year Ended December
Consolidated
Results
The
following
table
presents
our
results
for
the
years
ended
December
and
dollars
millions
except
per
share
data
Year
Ended
December
Product
revenue
Service
revenue
Other
revenue
Total
revenue
Cost
product
revenue
Cost
service
revenue
Cost
other
revenue
Total
cost
revenue
Gross
profit
Operating
expenses
Selling
general
and
administrative
Research
and
development
Other
charges
Total
operating
expenses
Operating
income
Interest
and
other
income
expense
net
Income
before
income
taxes
and
noncontrolling
interest
consolidated
subsidiaries
Income
tax
provision
Consolidated
net
income
Net
income
attributable
noncontrolling
interest
consolidated
subsidiaries
Net
income
attributable
Bruker
Corporation
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
Weighted
average
common
shares
outstanding
Basic
Diluted
Revenue
For
the
year
ended
December
our
revenue
increased
million
million
compared
million
for
the
year
ended
December
Included
revenue
were
increase
approximately
million
attributable
our
recent
acquisitions
and
Table
Contents
increase
approximately
million
from
the
impact
foreign
currency
translation
caused
the
weakening
the
Dollar
versus
the
Euro
and
other
currencies
Excluding
the
effects
foreign
currency
translation
and
our
recent
acquisitions
our
organic
revenue
non GAAP
measure
increased
million
Gross
Profit
Our
gross
profit
for
the
year
ended
December
was
million
resulting
gross
profit
margin
compared
million
resulting
gross
profit
margin
for
the
year
ended
December
Included
gross
profit
were
various
charges
for
amortization
acquisition related
intangible
assets
and
other
acquisition related
costs
and
restructuring
costs
totaling
million
and
million
for
the
years
ended
December
and
respectively
Excluding
these
charges
our
non GAAP
gross
profit
margins
was
each
the
years
ended
December
and
Selling
General
and
Administrative
Our
selling
general
and
administrative
expenses
for
the
year
ended
December
increased
million
revenue
from
million
revenue
for
the
year
ended
December
The
increase
was
primarily
caused
the
effect
recent
acquisitions
our
Bruker
Nano
Group
and
Bruker
CALID
Group
The
decrease
selling
general
and
administrative
expenses
percentage
revenue
was
attributable
cost
control
discipline
and
savings
associated
with
restructuring
initiatives
Research
and
Development
Our
research
and
development
expenses
for
the
year
ended
December
increased
million
revenue
from
million
revenue
for
the
year
ended
December
The
increase
was
primarily
caused
the
effect
recent
acquisitions
our
Bruker
Nano
Group
and
Bruker
CALID
Group
Other
Charges
Net
Other
charges
net
was
million
for
the
year
ended
December
which
million
related
the
BSI
Segment
and
million
related
the
BEST
Segment
The
charges
consisted
primarily
million
restructuring
costs
related
closing
facilities
and
implementing
outsourcing
and
other
restructuring
initiatives
million
related
primarily
additional
contingent
consideration
recognized
for
the
acquisition
Jordan
Valley
Semiconductors
Ltd
Jordan
Valley
based
upon
increase
revenue
levels
the
acquired
business
which
increased
the
amount
expected
earn
out
payments
million
costs
associated
with
our
global
information
technology
transformation
initiative
and
impairment
charges
million
comprised
other
long lived
assets
related
the
restructuring
actions
Other
charges
net
was
million
for
the
year
ended
December
which
million
related
the
BSI
Segment
and
million
related
the
BEST
Segment
The
charges
consisted
primarily
million
restructuring
costs
related
closing
facilities
and
implementing
outsourcing
and
other
restructuring
initiatives
million
related
primarily
additional
contingent
consideration
recognized
for
the
Jordan
Valley
acquisition
based
upon
increase
revenue
levels
the
acquired
business
which
increased
the
amount
expected
earn
out
payments
million
costs
associated
with
our
global
transformation
initiative
and
impairment
charges
million
comprised
other
long lived
assets
related
the
restructuring
actions
within
the
Bruker
CALID
and
Bruker
Nano
Groups
during
the
year
Table
Contents
expect
incur
million
expense
related
various
outsourcing
initiatives
and
other
restructuring
activities
that
were
implemented
will
commence
December
and
performed
our
annual
goodwill
and
indefinite lived
intangible
impairment
evaluation
and
concluded
the
fair
values
each
our
reporting
units
were
significantly
greater
than
their
carrying
amounts
and
therefore
additional
impairment
required
will
continue
monitor
goodwill
and
long lived
intangible
assets
well
long lived
tangible
assets
for
possible
future
impairment
Operating
Income
Operating
income
for
the
year
ended
December
was
million
resulting
operating
margin
compared
income
from
operations
million
resulting
operating
margin
for
the
year
ended
December
The
operating
margin
increased
due
primarily
positive
operating
leverage
higher
revenues
cost
discipline
and
savings
from
restructuring
initiatives
These
factors
more
than
offset
dilution
from
recent
acquisitions
and
foreign
currency
translation
effects
Included
operating
income
were
various
charges
for
amortization
acquisition related
intangible
assets
and
other
acquisition related
costs
and
restructuring
costs
totaling
million
and
million
for
the
years
ended
December
and
respectively
Excluding
these
charges
our
non GAAP
operating
margins
was
and
the
years
ended
December
and
respectively
Interest
and
Other
Income
Expense
Net
Interest
and
other
income
expense
net
during
the
year
ended
December
was
million
compared
million
for
the
year
ended
December
During
the
year
ended
December
the
major
components
within
interest
and
other
income
expense
net
were
net
interest
expense
million
and
realized
and
unrealized
losses
foreign
currency
denominated
transactions
million
partially
offset
million
proceeds
from
cargo
insurance
settlement
and
gain
acquisition
million
The
million
gain
acquisition
related
the
acquisition
MERLIN
Diagnostika
GmbH
within
the
BSI
Segment
the
value
the
assets
purchased
exceeded
the
consideration
paid
During
the
year
ended
December
the
major
components
within
interest
and
other
income
expense
net
were
gain
acquisition
million
realized
and
unrealized
gains
foreign
currency
denominated
transactions
million
partially
offset
net
interest
expense
million
The
million
gain
acquisition
related
the
acquisition
Oxford
Instruments
Superconducting
Wire
LLC
OST
within
the
BEST
Segment
the
value
the
assets
purchased
exceeded
the
consideration
paid
expect
incur
approximately
million
interest
expense
Income
Tax
Provision
The
income
tax
provision
the
years
ended
December
and
was
million
and
million
respectively
representing
effective
tax
rates
and
respectively
The
increase
our
effective
tax
rate
for
the
year
ended
December
compared
was
primarily
attributable
impact
tax
reform
which
was
offset
the
release
our
remaining
valuation
allowances
and
the
recognition
previously
unrecognized
tax
benefits
due
the
closure
tax
audits
Our
tax
rate
may
change
over
time
the
amount
and
mix
jurisdictional
income
changes
expect
our
effective
income
tax
rate
approximately
for
the
year
ended
December
Table
Contents
December
Enactment
Date
the
President
the
United
States
signed
tax
reform
legislation
Tax
Act
which
enacted
wide
range
changes
the
corporate
income
tax
system
many
which
differ
significantly
from
the
provisions
the
previous
tax
law
have
not
yet
completed
the
assessment
the
tax
effects
associated
with
the
enactment
the
Tax
Act
However
reasonable
estimate
has
been
made
the
effects
the
existing
deferred
tax
balances
and
the
one time
transition
tax
Changes
the
tax
rates
and
laws
are
accounted
for
the
period
enactment
Therefore
during
the
fourth
quarter
recorded
incremental
income
tax
provision
million
which
primarily
comprised
the
following
estimated
income
tax
provision
million
for
the
federal
and
state
impacts
the
one time
deemed
repatriation
pre
accordance
with
the
Tax
Act
the
federal
portion
the
toll
charge
liability
may
paid
over
eight
years
Such
liability
can
reduced
certain
credits
Accordingly
have
recorded
million
and
million
long term
income
tax
liabilities
and
accrued
income
taxes
current
respectively
December
estimated
net
income
tax
benefit
million
for
the
remeasurement
our
deferred
tax
assets
and
liabilities
the
newly
enacted
tax
rate
and
result
the
Tax
Act
and
our
expectations
about
distributing
certain
cash
balances
from
its
foreign
subsidiaries
the
United
States
also
recorded
estimated
income
tax
provisions
for
estimated
state
income
taxes
and
foreign
withholding
taxes
million
The
actual
results
the
implementation
the
Tax
Act
may
materially
differ
from
our
current
estimate
due
among
other
things
further
guidance
that
may
issued
tax
authorities
regulatory
bodies
including
the
SEC
and
the
FASB
interpret
the
Tax
Act
will
continue
analyze
the
Tax
Act
and
any
additional
guidance
that
may
issued
and
finalize
the
full
effects
applying
the
new
legislation
the
measurement
period
The
majority
the
Company
earnings
are
derived
Germany
and
Switzerland
Accounting
for
the
various
federal
and
local
taxing
authorities
the
statutory
rates
for
were
approximately
and
for
Germany
and
Switzerland
respectively
The
mix
earnings
those
two
jurisdictions
resulted
reduction
from
the
statutory
rate
The
Company
has
not
been
party
any
tax
holiday
agreements
Net
Income
Attributable
Noncontrolling
Interests
Net
income
attributable
noncontrolling
interests
for
the
year
ended
December
was
million
compared
million
for
the
year
ended
December
The
net
income
attributable
noncontrolling
interests
represented
the
minority
shareholders
proportionate
share
the
net
income
recorded
our
majority owned
indirect
subsidiaries
Net
Income
Attributable
Bruker
Corporation
Our
net
income
attributable
Bruker
Corporation
for
the
year
ended
December
was
million
per
diluted
share
compared
net
income
million
per
diluted
share
for
The
decrease
for
the
year
ended
December
was
primarily
caused
the
impact
tax
reform
noted
above
Table
Contents
Segment
Results
Revenue
The
following
table
presents
revenue
change
revenue
and
revenue
growth
reportable
segment
for
the
years
ended
December
and
dollars
millions
BSI
BEST
Eliminations
Dollar
Change
Percentage
Change
Represents
product
and
service
revenue
between
reportable
segments
BSI
Segment
Revenues
For
financial
reporting
purposes
aggregate
the
Bruker
BioSpin
Bruker
CALID
and
Bruker
Nano
operating
segments
into
the
Bruker
Scientific
Instruments
BSI
reportable
segment
which
represented
approximately
the
Company
revenues
during
the
year
ended
December
This
aggregation
reflects
these
operating
segments
similar
economic
characteristics
production
processes
customer
services
provided
types
and
classes
customers
methods
distribution
and
regulatory
environments
Our
BEST
Segment
our
other
reportable
segment
and
represents
the
remainder
our
revenues
BSI
Segment
revenue
increased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
Included
revenue
was
increase
approximately
million
related
our
recent
acquisitions
and
approximately
million
from
the
impact
foreign
currency
translation
caused
the
weakening
the
Dollar
versus
the
Euro
and
other
currencies
Excluding
the
effects
foreign
currency
translation
and
our
recent
acquisitions
organic
revenue
non GAAP
measure
increased
million
Bruker
BioSpin
Group
revenue
increased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
Bruker
BioSpin
Group
revenue
increased
despite
challenging
comparison
the
year
ended
December
benefited
from
the
sale
the
first
shielded
ultra high
field
one
gigahertz
NMR
system
and
higher
levels
high
field
NMR
systems
The
increase
revenue
was
primarily
attributable
the
service
and
aftermarket
business
the
Bruker
BioSpin
Group
and
foreign
currency
translations
Bruker
CALID
Group
revenue
increased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
Bruker
CALID
Group
increase
was
primarily
the
result
improved
academic
end
markets
particularly
for
mass
spectrometry
products
and
within
Europe
and
infrared
and
Raman
technologies
used
applied
and
industrial
end
markets
and
the
contributions
acquisitions
and
foreign
currency
translation
effects
These
increases
were
partly
offset
lower
CBRNE
revenue
which
benefited
from
significant
contract
the
year
ended
December
Bruker
Nano
Group
revenue
increased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
Bruker
Nano
Group
revenue
increase
was
primarily
result
recent
acquisitions
growth
within
the
academic
and
industrial
markets
for
ray
and
nano
surfaces
products
and
growth
semiconductor
metrology
markets
Table
Contents
System
revenue
and
aftermarket
revenue
percentage
total
BSI
Segment
revenue
were
follows
during
the
years
ended
December
and
dollars
millions
System
revenue
Aftermarket
revenue
Total
revenue
Revenue
Percentage
Segment
Revenue
Revenue
Percentage
Segment
Revenue
BEST
Segment
Revenues
BEST
Segment
revenue
increased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
increase
revenue
resulted
from
the
OST
acquisition
which
was
completed
the
fourth
quarter
and
organic
revenue
growth
caused
higher
shipments
superconductors
large
magnetic
resonance
imaging
customers
System
and
wire
revenue
and
aftermarket
revenue
percentage
total
BEST
Segment
revenue
were
follows
during
the
years
ended
December
and
dollars
millions
System
and
wire
revenue
Aftermarket
revenue
Total
revenue
Percentage
Revenue
Segment
Revenue
Percentage
Revenue
Segment
Revenue
Gross
Profit
and
Operating
Expenses
For
the
year
ended
December
gross
profit
margin
the
BSI
Segment
increased
from
the
year
ended
December
The
increase
gross
margin
was
caused
primarily
higher
sales
attributable
improved
European
and
industrial
end
markets
and
operating
cost
improvements
resulting
from
recent
restructuring
and
operational
initiatives
product
mix
favoring
less
profitable
lower
field
NMR
systems
within
the
BioSpin
Group
was
offset
the
year
over
year
BSI
Segment
gross
margin
expansion
The
BEST
Segment
gross
profit
margin
decreased
from
for
the
year
ended
December
Lower
gross
margins
resulted
primarily
from
the
impact
the
OST
acquisition
Integration
plans
for
the
BEST
Segment
OST
business
include
commercial
and
productivity
improvement
actions
designed
achieve
pre acquisition
gross
profit
margin
levels
For
the
year
ended
December
selling
general
and
administrative
expenses
and
research
and
development
expenses
the
BSI
Segment
increased
million
segment
revenue
from
million
segment
revenue
for
the
comparable
period
Selling
general
and
administrative
expenses
and
research
and
development
expenses
the
BEST
Segment
increased
million
segment
revenue
compared
million
segment
revenue
The
decrease
BEST
Segment
operating
expenses
percent
revenue
was
primarily
attributable
the
increased
revenue
during
the
year
ended
December
Table
Contents
Operating
Income
The
following
table
presents
operating
income
and
operating
margins
revenue
reportable
segment
for
the
years
ended
December
and
dollars
millions
Operating
Income
BSI
BEST
Corporate
eliminations
and
other
Total
operating
income
Percentage
Segment
Revenue
Operating
Income
Percentage
Segment
Revenue
Represents
corporate
costs
and
eliminations
not
allocated
the
reportable
segments
BSI
Segment
operating
income
for
the
year
ended
December
was
million
resulting
operating
margin
compared
income
from
operations
million
resulting
operating
margin
for
the
year
ended
December
Our
operating
margin
increased
primarily
because
the
gross
profit
improvements
noted
above
well
operational
improvements
result
our
restructuring
initiatives
BEST
Segment
operating
income
for
the
year
ended
December
was
million
resulting
operating
margin
compared
operating
income
million
resulting
operating
margin
for
the
year
ended
December
The
decrease
operating
margin
was
primarily
the
result
the
gross
margin
deterioration
noted
above
Table
Contents
Year Ended December Compared the Year Ended December
Consolidated
Results
The
following
table
presents
our
results
for
the
years
ended
December
and
dollars
millions
except
per
share
data
Year
Ended
December
Product
revenue
Service
revenue
Other
revenue
Total
revenue
Cost
product
revenue
Cost
service
revenue
Cost
other
revenue
Total
cost
revenue
Gross
profit
Operating
expenses
Selling
general
and
administrative
Research
and
development
Other
charges
Total
operating
expenses
Operating
income
Interest
and
other
income
expense
net
Income
before
income
taxes
and
noncontrolling
interest
consolidated
subsidiaries
Income
tax
provision
Consolidated
net
income
Net
income
attributable
noncontrolling
interest
consolidated
subsidiaries
Net
income
attributable
Bruker
Corporation
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
Weighted
average
common
shares
outstanding
Basic
Diluted
Revenue
For
the
year
ended
December
our
revenue
decreased
million
million
compared
million
for
the
year
ended
December
Included
revenue
was
increase
approximately
million
attributable
primarily
the
acquisition
Jordan
Valley
and
decrease
approximately
million
from
the
impact
foreign
currency
translation
caused
the
strengthening
the
Dollar
versus
the
Euro
Swiss
Franc
and
other
Table
Contents
currencies
Excluding
the
effects
foreign
currency
translation
and
our
recent
acquisitions
our
organic
revenue
non GAAP
measure
decreased
million
Gross
Profit
Our
gross
profit
for
the
year
ended
December
was
million
resulting
gross
profit
margin
compared
million
resulting
gross
profit
margin
for
the
year
ended
December
The
increase
our
gross
profit
margin
was
caused
primarily
operating
cost
improvements
result
recent
restructuring
and
operational
initiatives
the
impact
pricing
increases
and
favorable
business
mix
within
the
Bruker
BioSpin
Group
and
the
impact
the
Jordan
Valley
acquisition
The
favorable
effect
these
items
was
partially
offset
weakness
Bruker
Nano
Group
industrial
market
segments
and
delays
European
academic
funding
within
our
Bruker
CALID
and
Bruker
Nano
Groups
during
the
first
three
quarters
Selling
General
and
Administrative
Our
selling
general
and
administrative
expenses
for
the
year
ended
December
decreased
million
revenue
from
million
revenue
for
the
year
ended
December
Selling
general
and
administrative
expenses
remained
consistent
percentage
revenue
compared
the
year
ended
December
the
favorable
impacts
our
outsourcing
and
restructuring
initiatives
was
offset
additional
expenses
incurred
related
our
acquisition
Jordan
Valley
and
other
recent
acquisitions
Research
and
Development
Our
research
and
development
expenses
for
the
year
ended
December
increased
million
revenue
from
million
revenue
for
the
year
ended
December
The
increase
was
attributable
new
initiatives
related
our
recent
acquisitions
and
our
expanded
technological
portfolio
Other
Charges
Net
Other
charges
net
was
million
for
the
year
ended
December
which
million
related
the
BSI
Segment
and
million
related
the
BEST
Segment
The
charges
consisted
primarily
million
restructuring
costs
related
closing
facilities
and
implementing
outsourcing
and
other
restructuring
initiatives
million
related
primarily
additional
contingent
consideration
recognized
for
Jordan
Valley
based
upon
increase
revenue
levels
the
acquired
business
which
increased
the
amount
expected
earn
out
payments
million
costs
associated
with
our
global
information
technology
transformation
initiative
and
impairment
charges
million
comprised
other
long lived
assets
related
the
restructuring
actions
within
the
Bruker
CALID
and
Bruker
Nano
Groups
during
the
year
Other
charges
net
was
million
for
the
year
ended
December
and
related
almost
entirely
the
BSI
Segment
The
charges
consisted
primarily
million
one time
non cash
settlement
charge
the
plan
assets
and
pension
obligations
for
the
retirees
and
other
certain
members
the
population
within
our
pension
plan
Switzerland
were
transferred
outside
insurance
provider
million
restructuring
costs
related
closing
facilities
and
implementing
outsourcing
and
other
restructuring
initiatives
million
costs
associated
with
our
global
transformation
initiative
and
impairment
charges
million
comprised
goodwill
definite lived
intangible
assets
and
other
long lived
assets
related
the
restructuring
actions
within
the
Bruker
BioSpin
Group
partially
offset
million
contingent
consideration
reversals
was
determined
that
certain
financial
targets
related
the
applicable
acquisitions
would
not
meet
the
required
thresholds
for
payment
Table
Contents
December
and
performed
our
annual
goodwill
and
indefinite lived
intangible
impairment
evaluation
and
concluded
the
fair
values
each
our
reporting
units
were
significantly
greater
than
their
carrying
amounts
and
therefore
additional
impairment
required
Operating
Income
Operating
income
for
the
year
ended
December
was
million
resulting
operating
margin
compared
income
from
operations
million
resulting
operating
margin
for
the
year
ended
December
The
increase
operating
margin
was
primarily
attributable
the
gross
margin
improvements
discussed
above
operating
cost
improvements
result
our
restructuring
initiatives
and
prudent
cost
controls
Interest
and
Other
Income
Expense
Net
Interest
and
other
income
expense
net
during
the
year
ended
December
was
million
compared
million
for
the
year
ended
December
During
the
year
ended
December
the
major
components
within
interest
and
other
income
expense
net
were
gain
acquisition
million
realized
and
unrealized
gains
foreign
currency
denominated
transactions
million
partially
offset
net
interest
expense
million
The
million
gain
acquisition
related
the
acquisition
OST
within
the
BEST
Segment
the
value
the
assets
purchased
exceeded
the
consideration
paid
During
the
year
ended
December
the
major
components
within
interest
and
other
income
expense
net
were
net
interest
expense
million
and
realized
and
unrealized
losses
foreign
currency
denominated
transactions
million
Income
Tax
Provision
The
income
tax
provision
each
the
years
ended
December
and
was
million
representing
effective
tax
rates
and
respectively
The
decrease
our
effective
tax
rate
for
the
year
ended
December
compared
was
primarily
attributable
the
release
our
remaining
valuation
allowances
and
the
recognition
previously
unrecognized
tax
benefits
due
the
closure
tax
audits
Our
tax
rate
may
change
over
time
the
amount
and
mix
jurisdictional
income
changes
Net
Income
Attributable
Noncontrolling
Interests
Net
income
attributable
noncontrolling
interests
for
the
year
ended
December
was
million
compared
million
for
the
year
ended
December
The
net
income
attributable
noncontrolling
interests
represented
the
minority
shareholders
proportionate
share
the
net
income
recorded
our
majority owned
indirect
subsidiaries
Net
Income
Attributable
Bruker
Corporation
Our
net
income
attributable
Bruker
Corporation
for
the
year
ended
December
was
million
per
diluted
share
compared
net
income
million
per
diluted
share
for
The
increase
for
the
year
ended
December
was
primarily
caused
increased
gross
profit
operating
profit
improvements
lower
effective
tax
rate
and
the
positive
impact
foreign
currency
translation
and
our
share
repurchase
program
Table
Contents
Segment
Results
Revenue
The
following
table
presents
revenue
change
revenue
and
revenue
growth
reportable
segment
for
the
years
ended
December
and
dollars
millions
BSI
BEST
Eliminations
Dollar
Change
Percentage
Change
Represents
product
and
service
revenue
between
reportable
segments
BSI
Segment
Revenues
For
financial
reporting
purposes
aggregate
the
Bruker
BioSpin
Bruker
CALID
and
Bruker
Nano
operating
segments
into
the
Bruker
Scientific
Instruments
BSI
reportable
segment
which
represented
approximately
the
Company
revenues
during
the
year
ended
December
This
aggregation
reflects
these
operating
segments
similar
economic
characteristics
production
processes
customer
services
provided
types
and
classes
customers
methods
distribution
and
regulatory
environments
Our
BEST
Segment
our
other
reportable
segment
and
represents
the
remainder
our
revenues
BSI
Segment
revenue
decreased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
Included
revenue
was
increase
approximately
million
related
the
acquisition
Jordan
Valley
offset
part
approximately
million
from
the
impact
foreign
currency
translation
caused
the
strengthening
the
Dollar
versus
the
Euro
Swiss
Franc
and
other
currencies
Excluding
the
effects
foreign
currency
translation
and
our
recent
acquisitions
our
organic
revenue
non GAAP
measure
decreased
million
Bruker
BioSpin
Group
revenue
increased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
Bruker
BioSpin
Group
increase
revenue
was
primarily
due
increased
pricing
and
the
recognition
revenues
from
the
sale
the
first
shielded
ultra high
field
gigahertz
nuclear
magnetic
resonance
system
Bruker
CALID
Group
revenue
decreased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
Bruker
CALID
Group
experienced
lower
revenue
primarily
due
delays
European
academic
funding
the
first
three
quarters
and
lower
sales
our
MALDI
Biotyper
China
and
the
United
States
the
first
half
Bruker
Nano
Group
revenue
decreased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
Bruker
Nano
Group
experienced
lower
revenue
primarily
due
delays
European
academic
funding
the
first
three
quarters
well
continued
weaker
demand
within
global
industrial
markets
Table
Contents
System
revenue
and
aftermarket
revenue
percentage
total
BSI
Segment
revenue
were
follows
during
the
years
ended
December
and
dollars
millions
System
revenue
Aftermarket
revenue
Total
revenue
Revenue
Percentage
Segment
Revenue
Revenue
Percentage
Segment
Revenue
BEST
Segment
Revenues
BEST
Segment
revenue
decreased
million
million
for
the
year
ended
December
compared
million
for
the
year
ended
December
The
decline
revenue
was
primarily
attributable
the
completion
and
final
acceptance
the
ROSATOM
pilot
line
Russia
and
high
margin
customer
projects
DESY
particle
acceleration
and
ITER
magnetic
fusion
the
year
ended
December
System
and
wire
revenue
and
aftermarket
revenue
percentage
total
BEST
Segment
revenue
were
follows
during
the
years
ended
December
and
dollars
millions
Percentage
Segment
Revenue
Revenue
System
and
wire
revenue
Aftermarket
and
other
revenue
Total
revenue
Percentage
Segment
Revenue
Revenue
Gross
Profit
and
Operating
Expenses
For
the
year
ended
December
gross
profit
margin
the
BSI
Segment
increased
from
the
year
ended
December
The
increase
gross
margin
percentage
was
caused
primarily
operating
cost
improvements
resulting
from
recent
restructuring
and
operational
initiatives
the
impact
pricing
increases
within
the
Bruker
BioSpin
Group
and
the
impact
the
Jordan
Valley
acquisition
within
the
Bruker
Nano
Group
These
effects
were
partially
offset
revenue
weakness
certain
Bruker
Nano
and
Bruker
CALID
Group
market
segments
resulting
from
delays
European
academic
funding
during
the
first
three
quarters
The
BEST
Segment
gross
profit
margin
decreased
from
for
the
year
ended
December
Lower
gross
margins
resulted
primarily
from
the
completion
the
ROSATOM
pilot
line
and
the
DESY
and
ITER
orders
For
the
year
ended
December
selling
general
and
administrative
expenses
and
research
and
development
expenses
the
BSI
Segment
remained
consistent
million
segment
revenue
from
million
segment
revenue
for
the
comparable
period
Selling
general
and
administrative
expenses
and
research
and
development
expenses
the
BEST
Segment
increased
million
segment
revenue
compared
million
segment
revenue
The
increase
BEST
Segment
operating
expenses
was
primarily
attributable
increased
costs
associated
with
selective
research
and
development
initiatives
Table
Contents
Operating
Income
The
following
table
presents
operating
income
and
operating
margins
revenue
reportable
segment
for
the
years
ended
December
and
dollars
millions
Percentage
Operating
Segment
Income
Revenue
BSI
BEST
Corporate
eliminations
and
other
Total
operating
income
Percentage
Operating
Segment
Income
Revenue
Represents
corporate
costs
and
eliminations
not
allocated
the
reportable
segments
BSI
operating
income
for
the
year
ended
December
was
million
resulting
operating
margin
compared
income
from
operations
million
resulting
operating
margin
for
the
year
ended
December
Our
operating
margin
increased
primarily
because
the
gross
profit
improvements
noted
above
well
operational
improvements
result
our
restructuring
initiatives
BEST
operating
income
for
the
year
ended
December
was
million
resulting
operating
margin
compared
operating
income
million
resulting
operating
margin
for
the
year
ended
December
The
decrease
operating
margin
primarily
the
result
the
decreased
gross
margins
result
the
completion
the
ROSATOM
pilot
line
and
the
DESY
and
ITER
projects
LIQUIDITY
AND
CAPITAL
RESOURCES
currently
anticipate
that
our
existing
cash
and
credit
facilities
will
sufficient
support
our
operating
and
investing
needs
for
least
the
next
twelve
months
Our
future
cash
requirements
could
affected
acquisitions
that
may
complete
repurchases
our
common
stock
the
payment
dividends
the
future
Historically
have
financed
our
growth
and
liquidity
needs
through
cash
flow
generation
and
combination
debt
financings
and
issuances
common
stock
the
future
there
are
assurances
that
additional
financing
alternatives
will
available
required
available
will
obtained
terms
favorable
During
the
year
ended
December
net
cash
provided
operating
activities
was
million
resulting
primarily
from
consolidated
net
income
adjusted
for
non cash
items
million
offset
net
increase
operating
assets
and
liabilities
net
acquisitions
and
divestitures
million
The
increase
operating
assets
and
liabilities
net
acquisitions
and
divestitures
for
the
year
ended
December
was
primarily
caused
increase
accounts
receivables
caused
proportionately
higher
sales
late
the
fourth
quarter
which
was
offset
part
the
income
tax
accruals
the
fourth
quarter
related
tax
reform
legislation
well
higher
compensation
and
restructuring
accruals
During
the
year
ended
December
net
cash
provided
operating
activities
was
million
resulting
primarily
from
consolidated
net
income
adjusted
for
non cash
items
million
offset
net
increase
operating
assets
and
liabilities
net
acquisitions
and
divestitures
million
The
increase
operating
assets
and
liabilities
net
acquisitions
and
divestitures
for
the
year
ended
December
was
primarily
caused
the
timing
customer
payments
the
fourth
quarter
included
higher
than
normal
collections
receivables
increase
inventory
result
inventory
build
for
orders
with
the
Bruker
BioSpin
Table
Contents
Group
and
BEST
Segment
income
tax
payments
for
audit
settlements
and
withholding
tax
payments
made
the
first
quarter
related
the
Company
European
cash
repatriation
During
the
year
ended
December
net
cash
used
investing
activities
was
million
compared
net
cash
used
investing
activities
million
during
the
year
ended
December
Cash
used
investing
activities
during
the
year
ended
December
was
primarily
due
the
net
cash
paid
for
acquisitions
million
and
net
capital
expenditures
million
These
activities
were
offset
part
net
cash
proceeds
short term
investments
million
During
the
year
ended
December
net
cash
used
investing
activities
was
million
compared
net
cash
used
investing
activities
million
during
the
year
ended
December
Cash
used
investing
activities
during
the
year
ended
December
was
primarily
caused
net
capital
expenditures
million
and
cash
paid
for
acquisitions
net
cash
acquired
million
offset
part
maturities
net
purchases
short term
investments
million
expect
capital
expenditures
amount
approximately
million
During
the
year
ended
December
net
cash
used
financing
activities
was
million
compared
net
cash
used
financing
activities
million
during
the
year
ended
December
Cash
used
financing
activities
during
the
year
ended
December
was
primarily
caused
the
repurchase
common
stock
million
million
repayments
under
the
revolving
line
credit
million
used
for
the
payment
dividends
and
million
repayments
under
the
Note
Purchase
Agreement
These
cash
uses
were
partially
offset
borrowings
million
under
the
revolving
line
credit
and
million
proceeds
from
the
issuance
common
stock
connection
with
stock
option
exercises
Cash
used
financing
activities
during
the
year
ended
December
was
primarily
caused
the
repurchase
common
stock
million
and
million
used
for
the
payment
dividends
partially
offset
borrowings
million
under
the
revolving
line
credit
and
million
proceeds
from
the
issuance
common
stock
connection
with
stock
option
exercises
May
our
Board
Directors
approved
share
repurchase
program
the
Repurchase
Program
under
which
repurchases
common
stock
the
amount
million
may
occur
from
time
time
amounts
prices
and
such
times
deem
appropriate
subject
market
conditions
legal
requirements
and
other
considerations
total
shares
were
repurchased
aggregate
cost
million
December
under
this
Repurchase
Program
intend
fund
any
additional
repurchases
from
cash
hand
future
cash
flows
from
operations
and
available
borrowings
under
our
revolving
credit
facility
The
repurchased
shares
are
reflected
within
Treasury
stock
the
accompanying
consolidated
balance
sheet
December
Cash
cash
equivalents
and
short term
investments
December
and
totaled
million
and
million
respectively
which
million
and
million
respectively
related
cash
cash
equivalents
and
short term
investments
held
outside
the
our
foreign
subsidiaries
most
significantly
the
Netherlands
and
Switzerland
December
and
accordance
with
the
Tax
Act
recorded
state
and
foreign
withholding
taxes
the
cash
and
liquid
assets
portion
the
unremitted
earnings
and
profits
foreign
subsidiaries
expected
repatriated
from
its
foreign
subsidiaries
the
United
States
continue
indefinitely
reinvested
amounting
million
non cash
that
related
the
Tax
Act
deemed
repatriation
this
ultimately
distributed
the
United
States
the
form
dividends
otherwise
would
likely
subject
additional
withholding
tax
will
continue
evaluate
our
assertions
the
cumulative
historical
outside
basis
differences
our
foreign
subsidiaries
December
expect
finalize
its
analysis
and
accounting
related
the
toll
charge
and
any
remaining
outside
basis
differences
our
foreign
subsidiaries
during
the
Table
Contents
measurement
period
estimate
the
amount
unrecognized
deferred
withholding
taxes
the
undistributed
approximately
million
December
December
had
approximately
million
net
operating
loss
carryforwards
available
reduce
state
taxable
income
also
had
approximately
million
German
Trade
Tax
and
Corporate
Income
Tax
net
operating
losses
that
are
carried
forward
indefinitely
Additionally
had
million
other
foreign
net
operating
losses
that
are
expected
expire
various
times
beginning
also
had
state
research
and
development
tax
credits
million
Utilization
these
credits
and
state
net
operating
losses
may
subject
annual
limitations
due
the
ownership
percentage
change
limitations
provided
the
Internal
Revenue
Code
Section
and
similar
state
provisions
the
event
deemed
change
control
under
Internal
Revenue
Code
Section
annual
limitation
the
utilization
net
operating
losses
and
credits
may
result
the
expiration
all
portion
the
net
operating
loss
and
credit
carryforwards
Uncertain
tax
contingencies
are
positions
taken
expected
taken
income
tax
return
that
may
result
additional
payments
tax
authorities
tax
authority
agrees
with
the
tax
position
taken
expected
taken
the
applicable
statute
limitations
expires
then
additional
payments
will
not
necessary
December
had
outstanding
debt
totaling
million
consisting
million
outstanding
under
the
Note
Purchase
Agreement
described
below
million
outstanding
under
the
revolving
loan
component
the
Credit
Agreement
described
below
and
million
under
capital
lease
obligations
and
other
loans
These
amounts
were
offset
unamortized
debt
issuance
costs
under
the
Note
Purchase
Agreement
million
December
had
outstanding
debt
totaling
million
consisting
million
outstanding
under
the
Note
Purchase
Agreement
described
below
million
outstanding
under
the
revolving
loan
component
the
Credit
Agreement
described
below
and
million
under
capital
lease
obligations
and
other
loans
These
amounts
were
offset
unamortized
debt
issuance
costs
under
the
Note
Purchase
Agreement
million
The
following
summary
the
maximum
commitments
and
the
net
amounts
available
under
the
Credit
Agreement
and
other
lines
credit
with
various
financial
institutions
located
primarily
Germany
and
Switzerland
that
are
unsecured
and
typically
due
upon
demand
with
interest
payable
monthly
December
millions
Credit
Agreement
Other
lines
credit
Total
revolving
loans
Weighted
Average
Interest
Rate
Total
Amount
Committed
Lenders
Outstanding
Borrowings
Outstanding
Letters
Total
Amount
Credit
Available
October
entered
into
revolving
credit
agreement
referred
the
Credit
Agreement
and
terminated
the
prior
credit
agreement
The
Credit
Agreement
provides
maximum
commitment
the
revolving
credit
line
million
and
maturity
date
October
Borrowings
under
the
revolving
credit
line
the
Credit
Agreement
accrue
interest
the
Company
option
either
the
greatest
the
prime
rate
the
federal
funds
rate
plus
and
iii
adjusted
LIBOR
plus
plus
margins
ranging
from
LIBOR
plus
margins
ranging
from
There
also
facility
fee
ranging
from
Borrowings
under
the
Credit
Agreement
are
secured
guarantees
from
certain
material
subsidiaries
defined
the
Credit
Agreement
The
Credit
Agreement
also
requires
maintain
certain
financial
ratios
related
maximum
leverage
and
minimum
interest
coverage
Table
Contents
Specifically
our
leverage
ratio
cannot
exceed
and
our
interest
coverage
ratio
cannot
less
than
addition
the
financial
ratios
the
Credit
Agreement
contains
negative
covenants
including
among
others
restrictions
liens
indebtedness
the
Company
and
its
subsidiaries
asset
sales
dividends
and
transactions
with
affiliates
Failure
comply
with
any
these
restrictions
covenants
may
result
event
default
the
Credit
Agreement
which
could
permit
acceleration
the
debt
and
require
prepay
the
debt
before
its
scheduled
due
date
December
were
compliance
with
the
covenants
defined
the
Credit
Agreement
our
leverage
ratio
was
and
our
interest
coverage
ratio
was
January
entered
into
note
purchase
agreement
referred
the
Note
Purchase
Agreement
with
group
accredited
institutional
investors
Under
the
Note
Purchase
Agreement
issued
and
sold
million
senior
notes
which
consist
the
following
million
Series
senior
notes
due
January
million
Series
senior
notes
due
January
million
Series
senior
notes
due
January
and
million
Series
senior
notes
due
January
January
the
outstanding
million
principal
amount
Tranche
the
Senior
Notes
was
repaid
accordance
with
the
terms
the
Note
Purchase
Agreement
Under
the
terms
the
Note
Purchase
Agreement
may
issue
and
sell
additional
senior
notes
aggregate
principal
amount
million
subject
certain
conditions
Interest
the
Senior
Notes
payable
semi annually
January
and
July
each
year
The
Senior
Notes
are
unsecured
obligations
ours
and
are
fully
and
unconditionally
guaranteed
certain
our
direct
and
indirect
subsidiaries
The
Senior
Notes
rank
pari
passu
right
repayment
with
our
other
senior
unsecured
indebtedness
may
prepay
some
all
the
Senior
Notes
any
time
amount
not
less
than
the
original
aggregate
principal
amount
the
Senior
Notes
prepaid
price
equal
the
sum
the
principal
amount
thereof
plus
accrued
and
unpaid
interest
and
the
applicable
make whole
amount
upon
not
less
than
and
more
than
days
written
notice
the
holders
the
Senior
Notes
the
event
change
control
the
Company
defined
the
Note
Purchase
Agreement
may
required
prepay
the
Notes
price
equal
the
principal
amount
thereof
plus
accrued
and
unpaid
interest
The
Note
Purchase
Agreement
contains
affirmative
covenants
including
without
limitation
maintenance
corporate
existence
compliance
with
laws
maintenance
insurance
and
properties
payment
taxes
addition
subsidiary
guarantors
and
furnishing
notices
and
other
information
The
Note
Purchase
Agreement
also
contains
certain
restrictive
covenants
that
restrict
our
ability
among
other
things
incur
liens
transfer
sell
assets
engage
certain
mergers
and
consolidations
and
enter
into
transactions
with
affiliates
The
Note
Purchase
Agreement
also
includes
customary
representations
and
warranties
and
events
default
the
case
event
default
arising
from
specified
events
bankruptcy
insolvency
all
outstanding
Senior
Notes
will
become
due
and
payable
immediately
without
further
action
notice
the
case
payment
events
defaults
any
holder
Senior
Notes
affected
thereby
may
declare
all
Senior
Notes
held
due
and
payable
immediately
the
case
any
other
event
default
majority
the
holders
the
Senior
Notes
may
declare
all
the
Senior
Notes
due
and
payable
immediately
Pursuant
the
Note
Purchase
Agreement
long
any
Senior
Notes
are
outstanding
will
not
permit
our
leverage
ratio
determined
pursuant
the
Note
Purchase
Agreement
the
end
any
fiscal
quarter
exceed
our
interest
coverage
ratio
determined
pursuant
the
Note
Purchase
Agreement
the
end
any
fiscal
quarter
for
any
period
four
consecutive
fiscal
quarters
less
than
iii
priority
debt
Table
Contents
any
time
exceed
consolidated
net
worth
determined
pursuant
the
Note
Purchase
Agreement
December
were
compliance
with
the
covenants
the
Note
Purchase
Agreement
Our
leverage
ratio
defined
the
Note
Purchase
Agreement
was
and
our
interest
coverage
ratio
defined
the
Note
Purchase
Agreement
was
The
following
table
summarizes
maturities
for
our
significant
financial
obligations
December
dollars
millions
Contractual
Obligations
Revolving
lines
credit
Other
long term
debt
including
current
portion
Interest
payable
long term
debt
and
revolving
lines
credit
Unconditional
purchase
commitments
Acquisition related
contingent
consideration
Operating
lease
obligations
Tax
Act
impact
Pension
liabilities
Uncertain
tax
contingencies
Total
Less
than
Year
More
than
Years
Years
Years
Unconditional
purchase
commitments
include
agreements
purchase
goods
services
fixed
assets
that
are
enforceable
and
legally
binding
and
that
specify
all
significant
terms
including
fixed
minimum
quantities
purchased
fixed
minimum
variable
price
provisions
and
the
approximate
timing
the
transaction
Purchase
commitments
exclude
agreements
that
are
cancellable
any
time
without
penalty
Acquisition related
contingent
considerations
represents
the
estimated
fair
value
future
payments
the
former
shareholders
applicable
acquired
companies
based
achieving
annual
revenue
and
gross
margin
targets
certain
years
specified
the
purchase
and
sale
agreements
CRITICAL
ACCOUNTING
POLICIES
AND
ESTIMATES
This
discussion
and
analysis
our
financial
condition
and
results
operations
based
upon
our
consolidated
financial
statements
which
have
been
prepared
accordance
with
accounting
principles
generally
accepted
the
United
States
America
GAAP
The
preparation
these
financial
statements
requires
that
make
estimates
and
assumptions
that
affect
the
reported
amounts
assets
and
liabilities
and
the
disclosure
contingent
assets
and
liabilities
the
date
the
financial
statements
and
reported
amounts
revenues
and
expenses
during
the
reporting
period
ongoing
basis
management
evaluates
its
estimates
and
judgments
including
those
related
revenue
recognition
the
expensing
and
capitalization
software
development
costs
stock based
compensation
expense
restructuring
and
other
related
charges
income
taxes
including
the
recoverability
deferred
tax
assets
allowances
for
doubtful
accounts
inventory
reductions
for
excess
and
obsolete
inventories
estimated
fair
values
long lived
assets
used
measure
the
recoverability
long lived
assets
intangible
assets
and
goodwill
expected
future
cash
flows
used
measure
the
recoverability
intangible
assets
and
long lived
assets
warranty
costs
derivative
financial
instruments
and
contingent
liabilities
base
our
estimates
and
judgments
our
historical
experience
current
market
and
economic
conditions
industry
trends
and
other
assumptions
that
believe
are
reasonable
and
form
Table
Contents
the
basis
for
making
judgments
about
the
carrying
value
assets
and
liabilities
that
are
not
readily
apparent
from
other
sources
Actual
results
could
differ
from
these
estimates
believe
the
following
critical
accounting
policies
and
estimates
both
those
most
important
the
portrayal
our
financial
position
and
results
operations
and
those
that
require
the
most
estimation
and
subjective
judgment
Revenue recognition
recognize
revenue
from
system
sales
when
persuasive
evidence
arrangement
exists
the
price
fixed
determinable
title
and
risk
loss
has
been
transferred
the
customer
and
collectability
the
resulting
receivable
reasonably
assured
Title
and
risk
loss
generally
transfers
upon
shipment
for
certain
systems
based
upon
customer
acceptance
for
system
that
has
been
delivered
the
customer
and
installed
customer
facility
For
systems
that
include
customer specific
acceptance
criteria
are
required
assess
when
can
demonstrate
the
acceptance
criteria
has
been
met
which
generally
upon
successful
factory
acceptance
testing
customer
acceptance
and
evidence
installation
When
products
are
sold
through
independent
distributor
strategic
distribution
partner
who
assumes
responsibility
for
installation
recognize
the
system
sale
when
the
product
has
been
shipped
and
title
and
risk
loss
have
been
transferred
the
distributor
Our
distributors
not
have
price
protection
rights
rights
return
however
our
products
are
typically
warranted
free
from
defect
for
period
one
year
Revenue
deferred
until
cash
received
when
collectability
not
reasonably
assured
when
the
price
not
fixed
determinable
For
transactions
that
include
multiple
elements
arrangement
consideration
allocated
each
element
using
the
fair
value
hierarchy
required
ASU
limit
the
amount
revenue
recognized
for
delivered
elements
the
amount
that
not
contingent
the
future
delivery
products
services
future
performance
obligations
subject
customer specific
return
refund
privileges
determine
the
fair
value
products
and
services
based
upon
vendor
specific
objective
evidence
VSOE
determine
VSOE
based
normal
selling
pricing
and
discounting
practices
for
the
specific
product
service
when
sold
stand alone
basis
determining
VSOE
our
policy
requires
substantial
majority
selling
prices
for
product
service
within
reasonably
narrow
range
also
consider
the
class
customer
method
distribution
and
the
geographies
into
which
products
and
services
are
being
sold
when
determining
VSOE
VSOE
cannot
established
attempt
establish
the
selling
price
based
third party
evidence
TPE
VSOE
cannot
established
instances
where
product
service
has
not
been
sold
separately
stand alone
sales
are
too
infrequent
product
pricing
not
within
sufficiently
narrow
range
TPE
determined
based
competitor
prices
for
similar
deliverables
when
sold
separately
When
cannot
determine
VSOE
TPE
use
estimated
selling
price
ESP
our
allocation
arrangement
consideration
The
objective
ESP
determine
the
price
which
would
typically
transact
stand alone
sale
the
product
service
ESP
determined
considering
number
factors
including
our
pricing
policies
internal
costs
and
gross
profit
objectives
method
distribution
market
research
and
information
recent
technological
trends
competitive
landscape
and
geographies
analyze
the
selling
prices
used
our
allocation
arrangement
consideration
minimum
annual
basis
Selling
prices
will
analyzed
more
frequently
significant
change
our
business
occurs
other
factors
necessitate
more
frequent
analysis
experience
significant
variances
our
selling
prices
Revenue
from
accessories
and
consumable
parts
generally
recognized
upon
shipping
terms
Service
revenue
recognized
the
services
are
performed
ratably
over
the
contractual
obligation
Table
Contents
and
includes
maintenance
contracts
extended
warranty
training
application
support
and
demand
services
also
have
contracts
for
which
apply
the
percentage completion
model
and
completed
contract
model
revenue
recognition
Application
the
percentage completion
method
requires
make
reasonable
estimates
the
extent
progress
toward
completion
the
contract
and
the
total
costs
will
incur
under
the
contract
and
losses
are
recorded
immediately
when
estimate
that
contracts
will
ultimately
result
loss
Changes
the
estimates
could
affect
the
timing
revenue
recognition
Other
revenues
are
primarily
comprised
development
arrangements
recognized
cost plus fixed fee
basis
and
licensing
arrangements
recognized
ratably
over
the
term
the
related
contracts
Income taxes
The
determination
income
tax
expense
requires
make
certain
estimates
and
judgments
concerning
the
annual
effective
tax
rate
the
calculation
deferred
tax
assets
and
liabilities
the
forecasted
profitability
our
subsidiaries
certain
geographic
jurisdictions
well
the
deductions
carryforwards
and
credits
that
are
available
reduce
taxable
income
Deferred
tax
assets
and
liabilities
arise
from
differences
the
timing
the
recognition
revenue
and
expenses
for
financial
statement
and
tax
purposes
Deferred
tax
assets
and
liabilities
are
measured
using
the
tax
rates
effect
for
the
year
which
these
temporary
differences
are
expected
settled
estimate
the
degree
which
tax
assets
and
loss
carryforwards
will
result
benefit
based
expected
profitability
tax
jurisdiction
and
provide
valuation
allowance
for
tax
assets
and
loss
carryforwards
that
believe
will
more
likely
than
not
unused
becomes
more
likely
than
not
that
tax
asset
loss
carryforward
will
used
for
which
valuation
allowance
has
been
provided
reverse
the
related
valuation
allowance
our
actual
future
taxable
income
tax
jurisdiction
differs
from
estimates
additional
allowances
reversals
valuation
allowance
may
necessary
addition
only
recognize
benefits
for
tax
positions
that
believe
are
more
likely
than
not
being
sustained
upon
review
taxing
authority
with
knowledge
all
relevant
information
reevaluate
our
uncertain
tax
positions
quarterly
basis
and
any
changes
these
positions
result
tax
audits
tax
laws
other
facts
and
circumstances
could
result
additional
charges
credits
operations
The
expiration
statutes
limitations
affecting
estimates
made
for
uncertain
tax
positions
can
cause
higher
earnings
December
Enactment
Date
the
President
the
United
States
signed
tax
reform
legislation
Tax
Act
which
enacted
wide
range
changes
the
corporate
income
tax
system
many
which
differ
significantly
from
the
provisions
the
previous
tax
law
have
not
yet
completed
the
assessment
the
tax
effects
associated
with
the
enactment
the
Tax
Act
however
reasonable
estimate
has
been
made
the
effects
the
existing
deferred
tax
balances
and
the
one time
transition
tax
Changes
the
tax
rates
and
laws
are
accounted
for
the
period
enactment
The
actual
results
the
implementation
the
Tax
Act
may
materially
differ
from
our
current
estimate
due
among
other
things
further
guidance
that
may
issued
tax
authorities
regulatory
bodies
including
the
SEC
and
the
FASB
interpret
the
Tax
Act
will
continue
analyze
the
Tax
Act
and
any
additional
guidance
that
may
issued
and
finalize
the
full
effects
applying
the
new
legislation
the
measurement
period
Inventories
Inventories
are
stated
the
lower
cost
and
net
realizable
value
with
costs
determined
the
first
first out
method
for
majority
subsidiaries
and
average
cost
for
certain
other
subsidiaries
record
provisions
account
for
excess
and
obsolete
inventory
reflect
the
expected
nonsaleable
non refundable
inventory
based
evaluation
slow
moving
products
products
longer
offered
for
sale
Inventories
also
include
demonstration
units
located
our
demonstration
laboratories
installed
the
sites
potential
customers
consider
our
demonstration
units
available
for
sale
and
have
history
selling
these
demonstration
units
Table
Contents
reduce
the
carrying
value
demonstration
inventories
for
differences
between
cost
and
estimated
net
realizable
value
taking
into
consideration
usage
the
preceding
twelve
months
expected
demand
technological
obsolescence
and
other
information
including
the
physical
condition
the
unit
ultimate
usage
demand
varies
significantly
from
expected
usage
demand
additional
write downs
may
required
resulting
additional
charges
operations
Goodwill other intangible assets and other long lived assets
evaluate
goodwill
for
impairment
annually
and
when
events
occur
circumstances
change
test
goodwill
for
impairment
the
reporting
unit
level
which
the
operating
segment
one
level
below
operating
segment
Under
GAAP
have
the
option
performing
qualitative
assessment
determine
whether
further
impairment
testing
necessary
before
performing
two step
quantitative
assessment
The
qualitative
assessment
requires
significant
judgments
about
macro economic
conditions
including
the
entity
operating
environment
its
industry
and
other
market
considerations
entity specific
events
related
financial
performance
loss
key
personnel
and
other
events
that
could
impact
the
reporting
unit
result
our
qualitative
assessment
more likely than not
that
the
fair
value
reporting
unit
less
than
its
carrying
amount
the
quantitative
impairment
test
will
required
Otherwise
further
testing
required
quantitative
impairment
test
performed
the
first
step
involves
comparing
the
fair
values
the
applicable
reporting
units
with
their
aggregate
carrying
values
including
goodwill
generally
determine
the
fair
value
our
reporting
units
using
weighting
both
the
market
approach
and
the
income
approach
methodologies
The
income
approach
valuation
methodology
includes
discounted
cash
flow
estimates
Estimating
the
fair
value
the
reporting
units
requires
significant
judgment
about
the
future
cash
flows
the
carrying
amount
reporting
unit
exceeds
the
fair
value
the
reporting
unit
perform
the
second
step
the
goodwill
impairment
test
measure
the
amount
the
impairment
the
second
step
the
goodwill
impairment
test
compare
the
implied
fair
value
the
reporting
unit
goodwill
with
the
carrying
value
that
goodwill
December
performed
our
annual
goodwill
and
indefinite lived
intangible
impairment
evaluation
using
qualitative
impairment
test
and
concluded
the
fair
values
each
our
reporting
units
were
significantly
greater
than
their
carrying
amounts
and
therefore
additional
impairment
was
required
also
review
definite lived
intangible
assets
and
other
long lived
assets
when
indications
potential
impairment
exist
Should
the
fair
value
our
longlived
assets
decline
because
reduced
operating
performance
market
declines
other
indicators
impairment
charge
operations
for
impairment
may
necessary
RECENT
ACCOUNTING
PRONOUNCEMENTS
January
the
Financial
Accounting
Standards
Board
FASB
issued
Accounting
Standards
Update
ASU
Intangibles Goodwill and
Other Topic Simplifying the Test for Goodwill Impairment The
new
standard
simplifies
the
subsequent
measurement
goodwill
eliminating
the
second
step
the
goodwill
impairment
test
This
ASU
will
applied
prospectively
and
effective
for
annual
interim
goodwill
impairment
tests
fiscal
years
beginning
after
December
The
adoption
this
standard
not
expected
have
material
impact
our
financial
position
results
operations
statements
cash
flows
upon
adoption
January
the
FASB
issued
ASU
Business Combinations Topic Clarifying the Definition Business This
new
standard
clarifies
the
definition
business
and
provides
screen
determine
when
integrated
set
assets
and
activities
not
business
The
screen
requires
that
when
substantially
all
the
fair
value
the
gross
assets
acquired
disposed
concentrated
single
identifiable
asset
group
similar
identifiable
assets
the
set
not
business
This
new
standard
was
adopted
the
effective
date
January
have
evaluated
the
provisions
this
standard
and
have
determined
that
the
impact
adoption
ASU
was
not
material
our
consolidated
financial
statements
Table
Contents
October
the
FASB
issued
ASU
Income Taxes Topic Intra Entity Transfer Assets Other than Inventory
The
new
standard
requires
recognition
current
and
deferred
income
taxes
resulting
from
intra entity
transfer
any
asset
excluding
inventory
when
the
transfer
occurs
This
change
from
existing
GAAP
which
prohibits
recognition
current
and
deferred
income
taxes
until
the
asset
sold
third
party
This
new
standard
was
adopted
the
effective
date
January
have
evaluated
the
provisions
this
standard
and
have
determined
that
the
impact
adoption
ASU
was
not
material
our
consolidated
financial
statements
February
the
FASB
issued
ASU
Leases
The
new
standard
provides
guidance
the
recognition
measurement
presentation
and
disclosure
leases
The
new
standard
supersedes
present
GAAP
guidance
leases
and
requires
substantially
all
leases
reported
the
balance
sheet
right use
assets
and
lease
liabilities
well
additional
disclosures
The
new
standard
effective
January
and
early
adoption
permitted
are
evaluating
the
provisions
this
standard
including
which
period
adopt
and
have
not
determined
what
impact
the
adoption
ASU
will
have
our
consolidated
financial
statements
May
the
FASB
issued
ASU
Revenue from Contracts with Customers which
supersedes
the
revenue
recognition
requirements
under
Accounting
Standards
Codification
ASC
Topic
The
new
guidance
was
the
result
joint
project
between
the
FASB
and
the
International
Accounting
Standards
Board
clarify
the
principles
for
recognizing
revenue
and
develop
common
revenue
standards
for
GAAP
and
International
Financial
Reporting
Standards
The
core
principle
the
new
guidance
that
revenue
should
recognized
depict
the
transfer
promised
goods
services
customers
amount
that
reflects
the
consideration
which
the
entity
expects
entitled
exchange
for
those
goods
services
August
the
FASB
elected
defer
the
effective
date
ASU
one
year
annual
periods
beginning
after
December
with
early
application
permitted
the
original
effective
date
The
new
guidance
may
applied
retrospective
basis
for
all
prior
periods
presented
modified
retrospective
basis
with
the
cumulative
effect
the
new
guidance
the
date
initial
application
The
new
guidance
will
effective
for
January
and
currently
intend
use
the
modified
retrospective
transition
method
have
substantially
completed
the
impact
assessment
phase
our
evaluation
ASU
Under
the
new
guidance
there
are
specific
criteria
determine
performance
obligation
should
recognized
over
time
point
time
Accordingly
have
identified
certain
project based
orders
the
BEST
Segment
and
CBRNE
detection
orders
the
Bruker
CALID
Group
for
which
the
timing
when
recognize
revenue
may
impacted
Due
the
complexity
these
project based
orders
revenue
recognition
under
the
new
standard
highly
dependent
specific
contract
terms
During
the
fourth
quarter
have
substantially
completed
the
assessment
over
the
impact
that
this
new
standard
will
have
our
consolidated
balance
sheets
preliminarily
expect
recognize
adjustment
approximately
million
retained
earnings
January
reflect
the
cumulative
effect
the
accounting
changes
made
upon
the
adoption
the
standard
The
finalization
the
assessment
may
result
significant
changes
the
estimates
that
may
materially
impact
the
preliminary
estimate
the
cumulative
effect
TRANSACTIONS
WITH
RELATED
PARTIES
lease
certain
office
space
from
certain
our
principal
shareholders
including
director
and
executive
officer
and
another
member
our
Board
Directors
and
members
their
immediate
families
which
have
expiration
dates
ranging
from
Total
rent
expense
under
these
leases
was
million
million
and
million
for
the
years
ended
December
and
respectively
Table
Contents
During
the
years
ended
December
and
recorded
revenue
million
million
and
million
respectively
arising
from
commercial
transactions
with
life
sciences
company
which
member
our
Board
Directors
Chairman
and
Chief
Executive
Officer
During
the
year
ended
December
and
recorded
revenue
million
and
million
respectively
from
commercial
transactions
with
thermal
analysis
company
for
which
member
our
Board
Directors
serves
consultant
ITEM
QUANTITATIVE
AND
QUALITATIVE
DISCLOSURES
ABOUT
MARKET
RISK
are
potentially
exposed
market
risks
associated
with
changes
foreign
currency
translation
rates
interest
rates
and
commodity
prices
selectively
use
financial
instruments
reduce
these
risks
All
transactions
related
risk
management
techniques
are
authorized
and
executed
pursuant
our
policies
and
procedures
Analytical
techniques
used
manage
and
monitor
foreign
currency
translation
and
interest
rate
risk
include
market
valuations
and
sensitivity
analysis
Impact
Foreign
Currencies
generate
substantial
portion
our
revenues
international
markets
principally
Germany
and
other
countries
the
European
Union
Switzerland
and
Japan
which
exposes
our
operations
the
risk
exchange
rate
fluctuations
The
impact
currency
exchange
rate
movement
can
positive
negative
any
period
Our
costs
related
sales
foreign
currencies
are
largely
denominated
the
same
respective
currencies
limiting
our
transaction
risk
exposure
However
for
foreign
currency
denominated
sales
certain
regions
such
Japan
where
not
incur
significant
costs
denominated
Japanese
Yen
are
more
exposed
the
impact
foreign
currency
fluctuations
For
sales
not
denominated
Dollars
there
increase
the
rate
which
foreign
currency
exchanged
for
Dollars
will
require
more
the
foreign
currency
equal
specified
amount
Dollars
than
before
the
rate
increase
such
cases
price
our
products
the
foreign
currency
will
receive
less
Dollars
than
would
have
received
before
the
rate
increase
went
into
effect
price
our
products
Dollars
and
competitors
price
their
products
local
currency
increase
the
relative
strength
the
Dollar
could
result
our
prices
not
being
competitive
market
where
business
transacted
the
local
currency
the
years
ended
December
and
our
revenue
geography
was
follows
dollars
millions
United
States
Europe
Asia
Pacific
Rest
world
Total
revenue
Revenue
Percentage
Revenue
Revenue
Percentage
Revenue
Changes
foreign
currency
exchange
rates
increased
our
revenue
approximately
the
year
ended
December
and
decreased
our
revenue
approximately
the
year
ended
December
Assets
and
liabilities
our
foreign
subsidiaries
where
the
functional
currency
the
local
currency
are
translated
into
Dollars
using
year end
exchange
rates
historical
rates
appropriate
Revenues
and
expenses
foreign
subsidiaries
are
translated
the
average
exchange
rates
effect
during
the
year
Adjustments
resulting
from
financial
statement
translations
are
included
separate
component
shareholders
equity
the
year
ended
December
recorded
net
gains
from
currency
translation
adjustments
million
the
year
ended
December
Table
Contents
recorded
net
losses
from
currency
translation
million
depreciation
functional
currencies
relative
the
Dollar
December
would
have
resulted
reduction
shareholders
equity
approximately
million
Gains
and
losses
resulting
from
foreign
currency
transactions
are
reported
interest
and
other
income
expense
net
the
consolidated
statements
income
and
comprehensive
income
Our
foreign
currency
translation
gains
losses
net
were
million
and
million
for
years
ended
December
and
respectively
From
time
time
have
entered
into
foreign
currency
contracts
order
minimize
the
volatility
that
fluctuations
exchange
rates
have
our
cash
flows
related
purchases
and
sales
denominated
foreign
currencies
Under
these
arrangements
agree
purchase
fixed
amount
foreign
currency
exchange
for
fixed
amount
Dollars
other
currencies
specified
dates
typically
with
maturities
less
than
twelve
months
These
transactions
not
qualify
for
hedge
accounting
and
accordingly
the
instrument
recorded
fair
value
with
the
corresponding
gains
and
losses
recorded
interest
and
other
income
expense
net
the
consolidated
statements
income
and
comprehensive
income
December
and
had
foreign
currency
contracts
with
notional
amounts
aggregating
million
and
million
respectively
December
the
Company
had
the
following
notional
amounts
outstanding
under
foreign
currency
contracts
millions
Buy
December
Euro
Notional
Amount
Buy
Currency
Sell
Maturity
Notional
Amount
Dollars
Fair
Value
Assets
Fair
Value
Liabilities
Dollars
January
Swiss
Francs
Dollars
January
Singapore
Dolar
Dollars
January
Euro
Polish
Zloty
January
Based
the
contractual
maturities
these
contracts
and
exchange
rates
December
anticipate
that
these
contracts
will
result
net
cash
inflows
million
December
assuming
all
other
variables
are
constant
the
Dollar
weakened
the
market
value
our
foreign
currency
contracts
would
have
increased
approximately
million
and
the
Dollar
strengthened
the
market
value
our
foreign
currency
contracts
would
have
decreased
approximately
million
will
continue
evaluate
our
currency
risks
and
the
future
may
utilize
foreign
currency
contracts
more
frequently
part
transactional
hedging
program
Impact
Interest
Rates
regularly
invest
excess
cash
short term
investments
that
are
subject
changes
interest
rates
believe
that
the
market
risk
arising
from
holding
these
financial
instruments
minimal
because
our
policy
investing
short term
financial
instruments
issued
highly
rated
financial
institutions
Our
exposure
related
adverse
movements
interest
rates
derived
primarily
from
outstanding
floating
rate
debt
instruments
that
are
indexed
short term
market
rates
currently
have
approximately
equal
levels
fixed
and
floating
rate
debt
which
limits
our
exposure
adverse
movements
interest
rates
Table
Contents
Impact
Commodity
Prices
are
exposed
certain
commodity
risks
associated
with
prices
for
various
raw
materials
The
prices
copper
and
certain
other
raw
materials
particularly
niobium tin
used
manufacture
superconductors
have
increased
significantly
over
the
last
decade
Copper
and
niobium tin
are
the
main
components
low
temperature
superconductors
and
continued
commodity
price
increases
for
copper
and
niobium
well
other
raw
materials
may
negatively
affect
our
profitability
Periodically
enter
into
commodity
forward
purchase
contracts
minimize
the
volatility
that
fluctuations
the
price
copper
have
our
sales
these
products
December
and
had
fixed
price
commodity
contracts
with
notional
amounts
aggregating
million
and
million
respectively
The
fair
value
the
fixed
price
commodity
contracts
December
and
was
million
and
million
respectively
will
continue
evaluate
our
commodity
risks
and
may
utilize
commodity
forward
purchase
contracts
more
frequently
the
future
Inflation
not
believe
inflation
had
material
impact
our
business
operating
results
during
any
the
periods
presented
Table
Contents
ITEM
FINANCIAL
STATEMENTS
AND
SUPPLEMENTARY
DATA
Index
Consolidated
Financial
Statements
Reports
Independent
Registered
Public
Accounting
Firms
Page
Consolidated
Balance
Sheets
December
and
Consolidated
Statements
Income
and
Comprehensive
Income
for
the
years
ended
December
and
Consolidated
Statements
Shareholders
Equity
for
the
years
ended
December
and
Consolidated
Statements
Cash
Flows
for
the
years
ended
December
and
Notes
Consolidated
Financial
Statements
Table
Contents
Report
Independent
Registered
Public
Accounting
Firm
the
Board
Directors
and
Shareholders
Bruker
Corporation
Opinions
the
Financial
Statements
and
Internal
Control
over
Financial
Reporting
have
audited
the
accompanying
consolidated
balance
sheets
Bruker
Corporation
and
its
subsidiaries
December
and
and
the
related
consolidated
statements
income
and
comprehensive
income
shareholders
equity
and
cash
flows
for
the
years
then
ended
including
the
related
notes
collectively
referred
the
consolidated
financial
statements
also
have
audited
the
Company
internal
control
over
financial
reporting
December
based
criteria
established
Internal Control Integrated Framework
issued
the
Committee
Sponsoring
Organizations
the
Treadway
Commission
COSO
our
opinion
the
consolidated
financial
statements
referred
above
present
fairly
all
material
respects
the
financial
position
the
Company
December
and
and
the
results
their
operations
and
their
cash
flows
for
the
years
then
ended
conformity
with
accounting
principles
generally
accepted
the
United
States
America
Also
our
opinion
the
Company
maintained
all
material
respects
effective
internal
control
over
financial
reporting
December
based
criteria
established
Internal Control Integrated Framework
issued
the
COSO
Change Accounting Principles
discussed
Notes
and
the
consolidated
financial
statements
respectively
the
Company
changed
the
manner
which
accounts
for
the
measurement
inventory
and
the
manner
which
accounts
for
the
income
tax
effects
share
based
payment
transactions
Basis
for
Opinions
The
Company
management
responsible
for
these
consolidated
financial
statements
for
maintaining
effective
internal
control
over
financial
reporting
and
for
its
assessment
the
effectiveness
internal
control
over
financial
reporting
included
Management
Report
Internal
Control
over
Financial
Reporting
appearing
under
Item
Our
responsibility
express
opinions
the
Company
consolidated
financial
statements
and
the
Company
internal
control
over
financial
reporting
based
our
audits
are
public
accounting
firm
registered
with
the
Public
Company
Accounting
Oversight
Board
United
States
PCAOB
and
are
required
independent
with
respect
the
Company
accordance
with
the
federal
securities
laws
and
the
applicable
rules
and
regulations
the
Securities
and
Exchange
Commission
and
the
PCAOB
conducted
our
audits
accordance
with
the
standards
the
PCAOB
Those
standards
require
that
plan
and
perform
the
audits
obtain
reasonable
assurance
about
whether
the
consolidated
financial
statements
are
free
material
misstatement
whether
due
error
fraud
and
whether
effective
internal
control
over
financial
reporting
was
maintained
all
material
respects
Our
audits
the
consolidated
financial
statements
included
performing
procedures
assess
the
risks
material
misstatement
the
consolidated
financial
statements
whether
due
error
fraud
and
performing
procedures
that
respond
those
risks
Such
procedures
included
examining
test
basis
evidence
regarding
the
amounts
and
disclosures
the
consolidated
financial
statements
Our
audits
also
included
evaluating
the
accounting
principles
used
and
significant
estimates
made
management
well
evaluating
the
overall
presentation
the
consolidated
financial
statements
Our
audit
internal
control
over
financial
reporting
included
obtaining
understanding
internal
control
over
financial
reporting
assessing
the
risk
that
material
weakness
exists
and
testing
and
Table
Contents
evaluating
the
design
and
operating
effectiveness
internal
control
based
the
assessed
risk
Our
audits
also
included
performing
such
other
procedures
considered
necessary
the
circumstances
believe
that
our
audits
provide
reasonable
basis
for
our
opinions
described
Management
Report
Internal
Control
over
Financial
Reporting
management
has
excluded
Hysitron
Incorporated
Hysitron
from
its
assessment
internal
control
over
financial
reporting
December
because
was
acquired
the
Company
purchase
business
combination
during
have
also
excluded
Hysitron
from
our
audit
internal
control
over
financial
reporting
Hysitron
wholly owned
subsidiary
whose
total
assets
and
total
revenues
excluded
from
management
assessment
and
our
audit
internal
control
over
financial
reporting
represent
and
respectively
the
related
consolidated
financial
statement
amounts
and
for
the
year
ended
December
Definition
and
Limitations
Internal
Control
over
Financial
Reporting
company
internal
control
over
financial
reporting
process
designed
provide
reasonable
assurance
regarding
the
reliability
financial
reporting
and
the
preparation
financial
statements
for
external
purposes
accordance
with
generally
accepted
accounting
principles
company
internal
control
over
financial
reporting
includes
those
policies
and
procedures
that
pertain
the
maintenance
records
that
reasonable
detail
accurately
and
fairly
reflect
the
transactions
and
dispositions
the
assets
the
company
provide
reasonable
assurance
that
transactions
are
recorded
necessary
permit
preparation
financial
statements
accordance
with
generally
accepted
accounting
principles
and
that
receipts
and
expenditures
the
company
are
being
made
only
accordance
with
authorizations
management
and
directors
the
company
and
iii
provide
reasonable
assurance
regarding
prevention
timely
detection
unauthorized
acquisition
use
disposition
the
company
assets
that
could
have
material
effect
the
financial
statements
Because
its
inherent
limitations
internal
control
over
financial
reporting
may
not
prevent
detect
misstatements
Also
projections
any
evaluation
effectiveness
future
periods
are
subject
the
risk
that
controls
may
become
inadequate
because
changes
conditions
that
the
degree
compliance
with
the
policies
procedures
may
deteriorate
PricewaterhouseCoopers
LLP
Boston
Massachusetts
March
have
served
the
Company
auditor
since
Table
Contents
Report
Independent
Registered
Public
Accounting
Firm
The
Board
Directors
and
Shareholders
Bruker
Corporation
have
audited
the
accompanying
consolidated
statements
income
and
comprehensive
income
loss
shareholders
equity
and
cash
flows
Bruker
Corporation
for
the
year
ended
December
These
financial
statements
are
the
responsibility
the
Company
management
Our
responsibility
express
opinion
these
financial
statements
based
our
audit
conducted
our
audit
accordance
with
the
standards
the
Public
Company
Accounting
Oversight
Board
United
States
Those
standards
require
that
plan
and
perform
the
audit
obtain
reasonable
assurance
about
whether
the
financial
statements
are
free
material
misstatement
audit
includes
examining
test
basis
evidence
supporting
the
amounts
and
disclosures
the
financial
statements
audit
also
includes
assessing
the
accounting
principles
used
and
significant
estimates
made
management
well
evaluating
the
overall
financial
statement
presentation
believe
that
our
audit
provides
reasonable
basis
for
our
opinion
our
opinion
the
financial
statements
referred
above
present
fairly
all
material
respects
the
consolidated
results
Bruker
Corporation
operations
and
its
cash
flows
for
the
year
ended
December
conformity
with
generally
accepted
accounting
principles
Ernst
Young
LLP
Boston
Massachusetts
February
except
for
Note
Summary
Significant
Accounting
Policies Restricted
Cash
which
the
date
March
Table
Contents
BRUKER
CORPORATION
CONSOLIDATED
BALANCE
SHEETS
millions
except
share
and
per
share
data
December
ASSETS
Current
assets
Cash
and
cash
equivalents
Short term
investments
Accounts
receivable
net
Inventories
Other
current
assets
Total
current
assets
Property
plant
and
equipment
net
Goodwill
Intangible
assets
net
Deferred
tax
assets
Other
long term
assets
Total
assets
LIABILITIES
AND
SHAREHOLDERS
EQUITY
Current
liabilities
Current
portion
long term
debt
Accounts
payable
Customer
advances
Other
current
liabilities
Total
current
liabilities
Long term
debt
Long term
deferred
revenue
Deferred
tax
liabilities
Accrued
pension
Other
long term
liabilities
Commitments
and
contingencies
Note
Shareholders
equity
Preferred
stock
par
value
shares
authorized
none
issued
outstanding
December
and
Common
stock
par
value
shares
authorized
and
shares
issued
and
and
outstanding
December
and
respectively
Treasury
stock
cost
and
shares
December
and
respectively
Additional
paid
capital
Retained
earnings
Accumulated
other
comprehensive
loss
Total
shareholders
equity
attributable
Bruker
Corporation
Noncontrolling
interest
consolidated
subsidiaries
Total
shareholders
equity
Total
liabilities
and
shareholders
equity
The
accompanying
notes
are
integral
part
these
consolidated
financial
statements
Table
Contents
BRUKER
CORPORATION
CONSOLIDATED
STATEMENTS
INCOME
AND
COMPREHENSIVE
INCOME
millions
except
per
share
data
Year
Ended
December
Product
revenue
Service
revenue
Other
revenue
Total
revenue
Cost
product
revenue
Cost
service
revenue
Cost
other
revenue
Total
cost
revenue
Gross
profit
Operating
expenses
Selling
general
and
administrative
Research
and
development
Other
charges
net
Total
operating
expenses
Operating
income
Interest
and
other
income
expense
net
Income
before
income
taxes
and
noncontrolling
interest
consolidated
subsidiaries
Income
tax
provision
Consolidated
net
income
Net
income
attributable
noncontrolling
interest
consolidated
subsidiaries
Net
income
attributable
Bruker
Corporation
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
Weighted
average
common
shares
outstanding
Basic
Diluted
Consolidated
net
income
Foreign
currency
translation
adjustments
Pension
liability
adjustments
net
tax
million
million
and
million
respectively
Net
comprehensive
income
Less
Comprehensive
income
attributable
noncontrolling
interests
Comprehensive
income
attributable
Bruker
Corporation
Dividend
declared
per
common
share
The
accompanying
notes
are
integral
part
these
consolidated
financial
statements
Table
Contents
BRUKER
CORPORATION
CONSOLIDATED
STATEMENTS
SHAREHOLDERS
EQUITY
millions
except
share
data
Total
Shareholders
Equity
Accumulated
Attributable
Noncontrolling
Common
Treasury Additional
Other
Interests
Total
Common
Stock
Treasury
Stock
Paid
Retained
Comprehensive
Bruker
Consolidated
Shareholders
Income
Equity
Shares
Amount
Shares
Amount
Capital
Earnings
Corporation
Subsidiaries
Balance
December
Restricted
shares
issued
Restricted
shares
terminated
Stock
options
exercised
Stock
based
compensation
Excess
tax
benefit
related
exercise
stock
awards
Shares
repurchased
Treasury
stock
acquired
Distributions
noncontrolling
interests
Consolidated
net
income
Other
comprehensive
income
loss
Balance
December
Restricted
shares
issued
Restricted
shares
terminated
Stock
options
exercised
Stock
based
compensation
Excess
tax
benefit
related
exercise
stock
awards
Shares
issued
for
acquisition
Shares
repurchased
Treasury
stock
acquired
Distributions
noncontrolling
interests
Cash
dividends
paid
common
stockholders
Consolidated
net
income
Other
comprehensive
income
loss
Balance
December
Restricted
shares
terminated
Stock
options
exercised
Restricted
stock
units
vested
Stock
based
compensation
Excess
tax
benefit
related
exercise
stock
awards
Shares
issued
for
acquisition
Shares
repurchased
Treasury
stock
acquired
Distributions
noncontrolling
interests
Cash
dividends
paid
common
stockholders
Consolidated
net
income
Other
comprehensive
income
loss
Balance
December
The
accompanying
notes
are
integral
part
these
consolidated
financial
statements
Table
Contents
BRUKER
CORPORATION
CONSOLIDATED
STATEMENTS
CASH
FLOWS
millions
Cash
flows
from
operating
activities
Consolidated
net
income
Adjustments
reconcile
consolidated
net
income
cash
flows
from
operating
activities
Depreciation
and
amortization
Stock based
compensation
expense
Deferred
income
taxes
Gain
loss
disposal
product
lines
Impairment
and
other
non cash
expenses
net
Changes
operating
assets
and
liabilities
net
acquisitions
Accounts
receivable
Inventories
Accounts
payable
and
accrued
expenses
Income
taxes
payable
net
Deferred
revenue
Customer
advances
Other
changes
operating
assets
and
liabilities
net
Net
cash
provided
operating
activities
Cash
flows
from
investing
activities
Purchase
short term
investments
Maturity
short term
investments
Cash
paid
for
acquisitions
net
cash
acquired
Proceeds
from
disposal
product
lines
Purchases
property
plant
and
equipment
Proceeds
from
sales
property
plant
and
equipment
Net
cash
used
investing
activities
Cash
flows
from
financing
activities
Repayments
revolving
lines
credit
Proceeds
from
revolving
lines
credit
Repayment
Note
Purchase
Agreement
Repayment
other
debt
net
Proceeds
from
issuance
common
stock
net
Payment
contingent
consideration
Payment
dividends
common
stockholders
Repurchase
common
stock
Cash
payments
noncontrolling
interests
Excess
tax
benefits
related
stock
option
awards
Net
cash
used
financing
activities
Effect
exchange
rate
changes
cash
cash
equivalents
and
restricted
cash
Net
change
cash
cash
equivalents
and
restricted
cash
Cash
cash
equivalents
and
restricted
cash
beginning
year
Cash
cash
equivalents
and
restricted
cash
end
year
Supplemental
cash
flow
information
Cash
paid
for
interest
Cash
paid
for
taxes
Year
Ended
December
The
accompanying
notes
are
integral
part
these
consolidated
financial
statements
Table
Contents
BRUKER
CORPORATION
NOTES
CONSOLIDATED
FINANCIAL
STATEMENTS
Note
Description
Business
Bruker
Corporation
together
with
its
consolidated
subsidiaries
Bruker
the
Company
develops
manufactures
and
distributes
high performance
scientific
instruments
and
analytical
and
diagnostic
solutions
that
enable
its
customers
explore
life
and
materials
microscopic
molecular
and
cellular
levels
Many
the
Company
products
are
used
detect
measure
and
visualize
structural
characteristics
chemical
biological
and
industrial
material
samples
The
Company
products
address
the
rapidly
evolving
needs
diverse
array
customers
life
science
research
pharmaceuticals
biotechnology
applied
markets
cell
biology
clinical
research
microbiology
vitro
diagnostics
nanotechnology
and
materials
science
research
The
Company
has
two
reportable
segments
Bruker Scientific Instruments BSI
which
represented
approximately
and
the
Company
revenues
during
the
year
ended
December
and
respectively
and
Bruker Energy Supercon Technologies BEST
which
represented
the
remainder
the
Company
revenues
Within
BSI
the
Company
organized
into
three
operating
segments
the
Bruker
BioSpin
Group
the
Bruker
CALID
Group
and
the
Bruker
Nano
Group
For
financial
reporting
purposes
the
Bruker
BioSpin
Bruker
CALID
and
Bruker
Nano
operating
segments
are
aggregated
into
the
BSI
reportable
segment
because
each
has
similar
economic
characteristics
production
processes
service
offerings
types
and
classes
customers
methods
distribution
and
regulatory
environments
Bruker BioSpin
The
Bruker
BioSpin
Group
designs
manufactures
and
distributes
enabling
life
science
tools
based
magnetic
resonance
technology
The
majority
the
Bruker
BioSpin
Group
revenues
are
generated
academic
and
government
research
customers
Other
customers
include
pharmaceutical
and
biotechnology
companies
and
nonprofit
laboratories
well
chemical
food
and
beverage
clinical
and
other
industrial
companies
Bruker CALID hemicals pplied Markets ife Science Vitro Diagnostics etection
The
Bruker
CALID
Group
designs
manufactures
and
distributes
life
science
mass
spectrometry
and
ion
mobility
spectrometry
solutions
analytical
and
process
analysis
instruments
and
solutions
based
infrared
and
Raman
molecular
spectroscopy
technologies
and
radiological nuclear
detectors
for
Chemical
Biological
Radiological
Nuclear
and
Explosive
CBRNE
detection
Customers
the
Bruker
CALID
Group
include
academic
institutions
and
medical
schools
pharmaceutical
biotechnology
and
diagnostics
companies
contract
research
organizations
nonprofit
for profit
forensics
laboratories
agriculture
food
and
beverage
safety
laboratories
environmental
and
clinical
microbiology
laboratories
hospitals
and
government
departments
and
agencies
Bruker Nano
The
Bruker
Nano
Group
designs
manufactures
and
distributes
advanced
ray
instruments
atomic
force
microscopy
instrumentation
advanced
fluorescence
optical
microscopy
instruments
analytical
tools
for
electron
microscopes
and
ray
metrology
defect detection
equipment
for
semiconductor
process
control
handheld
portable
and
mobile
ray
fluorescence
spectrometry
instruments
and
spark
optical
emission
spectroscopy
systems
Customers
the
Bruker
Nano
Group
include
academic
institutions
governmental
customers
nanotechnology
companies
semiconductor
companies
raw
material
manufacturers
industrial
companies
biotechnology
and
pharmaceutical
companies
and
other
businesses
involved
materials
analysis
The
Company
BEST
reportable
segment
develops
and
manufactures
superconducting
and
non superconducting
materials
and
devices
for
use
renewable
energy
energy
infrastructure
healthcare
and
big
science
research
The
segment
focuses
metallic
low
temperature
superconductors
for
use
magnetic
resonance
imaging
nuclear
magnetic
resonance
fusion
energy
Table
Contents
research
and
other
applications
well
ceramic
high
temperature
superconductors
primarily
for
energy
grid
and
magnet
applications
Note
Summary
Significant
Accounting
Policies
The
accompanying
consolidated
financial
statements
reflect
the
application
certain
significant
accounting
policies
described
below
and
elsewhere
the
notes
the
consolidated
financial
statements
Principles
Consolidation
The
accompanying
consolidated
financial
statements
include
the
accounts
the
Company
and
all
majority
and
wholly owned
subsidiaries
All
intercompany
accounts
and
transactions
have
been
eliminated
Noncontrolling
Interests
Noncontrolling
interests
represents
the
minority
shareholders
proportionate
share
the
Company
majority owned
subsidiaries
The
portion
net
income
net
loss
attributable
non controlling
interests
presented
net
income
attributable
noncontrolling
interests
consolidated
subsidiaries
the
consolidated
statements
income
and
comprehensive
income
and
the
portion
other
comprehensive
income
these
subsidiaries
presented
the
consolidated
statements
shareholders
equity
Subsequent
Events
The
Company
has
evaluated
all
subsequent
events
and
determined
that
there
are
material
recognized
unrecognized
subsequent
events
any
subsequent
events
required
mentioned
the
footnotes
the
consolidated
financial
statements
Cash
and
Cash
Equivalents
Cash
and
cash
equivalents
primarily
include
cash
hand
money
market
funds
and
time
deposits
with
original
maturities
three
months
less
the
date
acquisition
Time
deposits
represent
amounts
deposit
banks
and
temporarily
invested
instruments
with
maturities
three
months
less
the
time
purchase
Certain
these
investments
represent
deposits
which
are
not
insured
the
FDIC
any
other
government
agency
Cash
equivalents
are
carried
cost
which
approximates
fair
value
Short term
Investments
Short term
investments
represent
time
and
call
deposits
with
original
maturities
greater
than
three
months
the
date
acquisition
Short term
investments
are
classified
available for sale
and
are
reported
fair
value
There
were
unrealized
gains
losses
recorded
December
and
cost
approximates
current
fair
value
Restricted
Cash
November
the
Financial
Accounting
Standards
Board
FASB
issued
Accounting
Standards
Update
ASU
Statement Cash Flows
Restricted Cash
requiring
restricted
cash
and
restricted
cash
equivalents
included
with
cash
and
cash
equivalents
the
statement
cash
flows
when
reconciling
the
beginning period
and
end period
total
amounts
shown
the
statement
cash
flows
The
guidance
effective
for
interim
and
annual
periods
beginning
after
December
with
early
adoption
permitted
The
Company
adopted
this
standard
during
the
first
Table
Contents
quarter
Restricted
cash
now
included
component
cash
cash
equivalents
and
restricted
cash
the
Company
consolidated
statement
cash
flows
The
Company
has
certain
subsidiaries
which
are
required
local
governance
maintain
restricted
cash
balances
cover
future
employee
benefit
payments
Restricted
cash
balances
are
classified
non current
unless
under
the
terms
the
applicable
agreements
the
funds
will
released
from
restrictions
within
one
year
from
the
balance
sheet
date
The
current
and
non current
portion
restricted
cash
recorded
within
other
current
assets
and
other
long term
assets
respectively
the
accompanying
consolidated
balance
sheets
The
inclusion
restricted
cash
increased
the
balances
the
consolidated
statement
cash
flows
follows
Beginning
Balance
Ending
Balance
Derivative
Financial
Instruments
and
Hedging
Activities
All
derivatives
whether
designated
hedging
relationship
not
are
recorded
the
consolidated
balance
sheets
fair
value
The
accounting
for
changes
fair
value
derivative
instrument
depends
whether
has
been
designated
and
qualifies
part
hedging
relationship
and
further
the
type
hedging
relationship
For
those
derivative
instruments
that
are
designated
and
qualify
hedging
instruments
the
Company
must
designate
the
hedging
instrument
based
the
exposure
being
hedged
fair
value
hedge
cash
flow
hedge
foreign
currency
hedge
hedge
net
investment
foreign
operation
Fair
Value
Financial
Instruments
The
Company
applies
the
following
hierarchy
determine
the
fair
value
financial
instruments
which
prioritizes
the
inputs
used
measure
fair
value
into
three
levels
and
bases
the
categorization
within
the
hierarchy
upon
the
lowest
level
input
that
available
and
significant
the
fair
value
measurement
The
levels
the
hierarchy
are
defined
follows
Level
Inputs
the
valuation
methodology
are
quoted
prices
unadjusted
for
identical
assets
liabilities
active
markets
Level
Inputs
the
valuation
methodology
include
quoted
prices
for
similar
assets
and
liabilities
active
markets
and
inputs
that
are
observable
for
the
asset
liability
either
directly
indirectly
for
substantially
the
full
term
the
financial
instrument
Level
Inputs
the
valuation
methodology
are
unobservable
and
significant
the
fair
value
measurement
The
valuation
techniques
that
may
used
the
Company
determine
the
fair
value
Level
and
Level
financial
instruments
are
the
market
approach
the
income
approach
and
the
cost
approach
The
market
approach
uses
prices
and
other
relevant
information
generated
market
transactions
involving
identical
comparable
assets
liabilities
The
income
approach
uses
valuation
techniques
convert
future
amounts
single
present
value
based
current
market
expectations
about
those
future
amounts
including
present
value
techniques
option pricing
models
and
the
excess
earnings
method
The
cost
approach
based
the
amount
that
would
required
replace
the
service
capacity
asset
replacement
cost
The
Company
financial
instruments
consist
primarily
cash
equivalents
short term
investments
restricted
cash
derivative
instruments
consisting
forward
foreign
exchange
contracts
commodity
contracts
derivatives
embedded
certain
purchase
and
sale
contracts
accounts
receivable
accounts
Table
Contents
payable
contingent
consideration
and
long term
debt
The
carrying
amounts
the
Company
cash
equivalents
short term
investments
and
restricted
cash
accounts
receivable
borrowings
under
revolving
credit
agreement
and
accounts
payable
approximate
fair
value
because
their
short term
nature
Derivative
assets
and
liabilities
are
measured
fair
value
recurring
basis
The
Company
long term
debt
consists
principally
private
placement
arrangement
entered
into
with
various
fixed
interest
rates
based
the
maturity
date
and
borrowings
under
revolving
credit
agreement
The
Company
has
evaluated
the
estimated
fair
value
financial
instruments
using
available
market
information
and
management
estimates
The
use
different
market
assumptions
and
estimation
methodologies
could
have
significant
effect
the
estimated
fair
value
amounts
Concentration
Credit
Risk
Financial
instruments
that
subject
the
Company
credit
risk
consist
cash
cash
equivalents
short term
investments
derivative
instruments
accounts
receivables
and
restricted
cash
The
risk
with
respect
cash
cash
equivalents
and
short term
investments
minimized
the
Company
policy
investing
short term
financial
instruments
issued
highly rated
financial
institutions
The
risk
with
respect
derivative
instruments
minimized
the
Company
policy
entering
into
arrangements
with
highly rated
financial
institutions
The
risk
with
respect
accounts
receivables
minimized
the
creditworthiness
and
diversity
the
Company
customers
The
Company
performs
periodic
credit
evaluations
its
customers
financial
condition
and
generally
requires
advanced
deposit
for
portion
the
purchase
price
Credit
losses
have
been
within
management
expectations
and
the
allowance
for
doubtful
accounts
totaled
million
and
million
December
and
respectively
December
and
single
customer
represented
more
the
Company
accounts
receivable
For
the
years
ended
December
and
single
customer
represented
more
the
Company
total
revenue
Inventories
Components
inventory
include
raw
materials
work process
demonstration
units
and
finished
goods
Demonstration
units
include
systems
which
are
located
the
Company
demonstration
laboratories
installed
the
sites
potential
customers
and
are
considered
available
for
sale
Finished
goods
include
intransit
systems
that
have
been
shipped
the
Company
customers
but
not
yet
installed
and
accepted
the
customer
All
inventories
are
stated
the
lower
cost
and
net
realizable
value
Cost
determined
principally
the
first
first out
method
for
majority
subsidiaries
and
average cost
for
certain
other
subsidiaries
The
Company
reduces
the
carrying
value
its
inventories
for
differences
between
cost
and
estimated
net
realizable
value
taking
into
consideration
usage
the
preceding
twelve
months
expected
demand
technological
obsolescence
and
other
information
including
the
physical
condition
demonstration
inventories
The
Company
records
charge
cost
product
revenue
for
the
amount
required
reduce
the
carrying
value
inventory
net
realizable
value
Costs
associated
with
the
procurement
inventories
such
inbound
freight
charges
and
purchasing
and
receiving
costs
are
capitalized
part
inventory
and
are
also
included
the
cost
product
revenue
line
item
within
the
consolidated
statements
income
and
comprehensive
income
Property
Plant
and
Equipment
Property
plant
and
equipment
are
stated
cost
less
accumulated
depreciation
and
amortization
Major
improvements
are
capitalized
while
expenditures
for
maintenance
repairs
and
minor
improvements
are
charged
expense
incurred
When
assets
are
retired
otherwise
disposed
the
assets
and
related
accumulated
depreciation
and
amortization
are
eliminated
from
the
accounts
and
any
resulting
gain
loss
reflected
the
consolidated
statements
income
and
comprehensive
Table
Contents
income
Depreciation
and
amortization
are
calculated
straight line
basis
over
the
estimated
useful
lives
the
assets
follows
Buildings
Machinery
and
equipment
Computer
equipment
and
software
Furniture
and
fixtures
Leasehold
improvements
years
years
years
years
Lesser
years
the
remaining
lease
term
Goodwill
and
Intangible
Assets
Goodwill
and
indefinite lived
intangible
assets
are
not
amortized
but
are
evaluated
for
impairment
annual
basis
interim
basis
when
events
changes
circumstances
indicate
that
the
carrying
value
may
not
recoverable
assessing
the
recoverability
goodwill
and
indefinite lived
intangible
assets
the
Company
must
make
assumptions
regarding
the
estimated
future
cash
flows
and
other
factors
determine
the
fair
value
these
assets
these
estimates
their
related
assumptions
change
the
future
the
Company
may
required
record
impairment
charges
against
these
assets
the
reporting
period
which
the
impairment
determined
The
Company
tests
goodwill
for
impairment
the
reporting
unit
level
which
the
operating
segment
one
level
below
operating
segment
The
Company
has
the
option
performing
qualitative
assessment
determine
whether
further
impairment
testing
necessary
before
performing
the
two step
quantitative
assessment
result
the
qualitative
assessment
more likely than not
that
the
fair
value
reporting
unit
less
than
its
carrying
amount
quantitative
impairment
test
will
required
Otherwise
further
testing
will
required
quantitative
impairment
test
performed
the
first
step
involves
comparing
the
fair
values
the
applicable
reporting
units
with
their
aggregate
carrying
values
including
goodwill
The
Company
generally
determines
fair
value
reporting
units
using
weighting
both
the
market
and
the
income
methodologies
Estimating
the
fair
value
the
reporting
units
requires
significant
judgment
management
the
carrying
amount
reporting
unit
exceeds
the
fair
value
the
reporting
unit
the
Company
performs
the
second
step
the
goodwill
impairment
test
measure
the
amount
the
impairment
the
second
step
the
goodwill
impairment
test
the
Company
compares
the
implied
fair
value
the
reporting
unit
goodwill
with
the
carrying
value
that
goodwill
process
research
and
development
IPR
acquired
part
business
combinations
under
the
acquisition
method
represents
ongoing
development
work
associated
with
enhancements
existing
products
well
the
development
next
generation
products
IPR
initially
capitalized
fair
value
intangible
asset
with
indefinite
life
and
assessed
for
impairment
annual
basis
when
indicators
impairment
are
identified
When
the
IPR
project
complete
reclassified
finite lived
intangible
asset
and
amortized
over
its
estimated
useful
life
IPR
project
abandoned
before
completion
otherwise
determined
impaired
the
value
the
asset
the
amount
the
impairment
charged
the
consolidated
statements
income
and
comprehensive
income
the
period
the
project
abandoned
impaired
Intangible
assets
with
finite
useful
life
are
amortized
straight line
basis
over
their
estimated
useful
lives
follows
Existing
technology
and
related
patents
Customer
and
distributor
relationships
Trade
names
years
years
years
Table
Contents
Impairment
Long Lived
Assets
Impairment
losses
are
recorded
long lived
assets
used
operations
when
indicators
impairment
are
present
and
the
quoted
market
price
available
the
estimated
fair
value
those
assets
are
less
than
the
assets
carrying
value
and
are
not
recoverable
Determination
recoverability
based
estimate
undiscounted
future
cash
flows
resulting
from
the
use
the
asset
and
its
eventual
disposition
the
event
that
such
cash
flows
are
not
expected
sufficient
recover
the
carrying
amount
the
assets
the
assets
are
written down
their
fair
values
Impairment
losses
are
charged
the
consolidated
statements
income
and
comprehensive
income
for
the
difference
between
the
fair
value
and
carrying
value
the
asset
Warranty
Costs
and
Deferred
Revenue
The
Company
typically
provides
one
year
parts
and
labor
warranty
with
the
purchase
equipment
The
anticipated
cost
for
this
warranty
accrued
upon
recognition
the
sale
and
included
current
liability
the
accompanying
consolidated
balance
sheets
The
Company
warranty
reserve
reflects
estimated
material
and
labor
costs
for
potential
product
issues
for
which
the
Company
expects
incur
obligation
The
Company
estimates
anticipated
rates
warranty
claims
and
costs
are
primarily
based
historical
information
The
Company
assesses
the
adequacy
the
warranty
reserve
quarterly
basis
and
adjusts
the
amount
necessary
the
historical
data
used
calculate
the
adequacy
the
warranty
reserve
not
indicative
future
requirements
additional
reduced
warranty
reserves
may
required
The
Company
also
offers
its
customers
extended
warranty
and
service
agreements
extending
beyond
the
initial
warranty
for
fee
These
fees
are
recorded
deferred
revenue
and
recognized
ratably
into
income
over
the
life
the
extended
warranty
contract
service
agreement
Income
Taxes
Deferred
tax
assets
and
liabilities
are
recognized
for
the
expected
future
tax
consequences
temporary
differences
between
the
financial
statement
carrying
amounts
and
the
income
tax
basis
assets
and
liabilities
valuation
allowance
applied
against
any
net
deferred
tax
asset
based
the
available
evidence
more
likely
than
not
that
some
all
the
deferred
tax
assets
will
not
realized
The
Company
records
liabilities
related
uncertain
tax
positions
accordance
with
the
guidance
that
clarifies
the
accounting
for
uncertainty
income
taxes
recognized
Company
financial
statements
This
guidance
prescribes
minimum
recognition
threshold
and
measurement
attribute
for
the
financial
statement
recognition
and
measurement
tax
position
taken
expected
taken
tax
return
The
Company
includes
accrued
interest
and
penalties
related
unrecognized
tax
benefits
and
income
tax
liabilities
when
applicable
income
tax
expense
Customer
Advances
The
Company
typically
requires
advance
deposit
under
the
terms
and
conditions
contracts
with
customers
These
deposits
are
recorded
current
long term
liability
until
revenue
recognized
the
specific
contract
accordance
with
the
Company
revenue
recognition
policy
Revenue
Recognition
The
Company
recognizes
revenue
from
systems
sales
when
persuasive
evidence
arrangement
exists
the
price
fixed
determinable
title
and
risk
loss
has
been
transferred
the
customer
and
collectability
the
resulting
receivable
reasonably
assured
Title
and
risk
loss
generally
transfers
upon
shipment
for
certain
systems
based
upon
customer
acceptance
for
system
that
has
been
Table
Contents
delivered
and
installed
customer
facility
For
systems
that
include
customer specific
acceptance
criteria
the
Company
required
assess
when
can
demonstrate
the
acceptance
criteria
has
been
met
which
generally
upon
successful
factory
acceptance
testing
customer
acceptance
and
evidence
installation
When
products
are
sold
through
independent
distributor
strategic
distribution
partner
who
assumes
responsibility
for
installation
the
Company
recognizes
the
system
sale
when
the
product
has
been
shipped
and
title
and
risk
loss
have
been
transferred
the
distributor
The
Company
distributors
not
have
price
protection
rights
rights
return
however
the
Company
products
are
typically
warranted
free
from
defect
for
period
one
year
Revenue
deferred
until
cash
received
when
collectability
not
reasonably
assured
when
the
price
not
fixed
determinable
For
transactions
that
include
multiple
elements
arrangement
consideration
allocated
each
element
using
the
fair
value
hierarchy
required
ASU
The
Company
limits
the
amount
revenue
recognized
for
delivered
elements
the
amount
that
not
contingent
the
future
delivery
products
services
future
performance
obligations
subject
customer specific
return
refund
privileges
The
Company
determines
the
fair
value
its
products
and
services
based
upon
vendor
specific
objective
evidence
VSOE
The
Company
determines
VSOE
based
its
normal
selling
pricing
and
discounting
practices
for
the
specific
product
service
when
sold
stand alone
basis
determining
VSOE
the
Company
policy
requires
substantial
majority
selling
prices
for
product
service
within
reasonably
narrow
range
The
Company
also
considers
the
class
customer
method
distribution
and
the
geographies
into
which
products
and
services
are
being
sold
when
determining
VSOE
VSOE
cannot
established
the
Company
attempts
establish
the
selling
price
based
third party
evidence
TPE
VSOE
cannot
established
instances
where
product
service
has
not
been
sold
separately
stand alone
sales
are
too
infrequent
product
pricing
not
within
sufficiently
narrow
range
TPE
determined
based
competitor
prices
for
similar
deliverables
when
sold
separately
When
the
Company
cannot
determine
VSOE
TPE
uses
estimated
selling
price
ESP
its
allocation
arrangement
consideration
The
objective
ESP
determine
the
price
which
the
Company
would
typically
transact
stand alone
sale
the
product
service
ESP
determined
considering
number
factors
including
the
Company
pricing
policies
internal
costs
and
gross
profit
objectives
method
distribution
market
research
and
information
recent
technological
trends
competitive
landscape
and
geographies
The
Company
analyzes
the
selling
prices
used
its
allocation
arrangement
consideration
minimum
annual
basis
Selling
prices
will
analyzed
more
frequently
significant
change
the
Company
business
other
factors
necessitate
more
frequent
analysis
the
Company
experiences
significant
variances
its
selling
prices
Revenue
from
accessories
and
parts
generally
recognized
based
shipping
terms
Service
revenue
recognized
the
services
are
performed
ratably
over
the
contractual
obligation
and
includes
maintenance
contracts
extended
warranty
training
application
support
and
demand
services
The
Company
also
has
contracts
for
which
applies
the
percentage completion
model
and
completed
contract
model
revenue
recognition
Application
the
percentage completion
method
requires
the
Company
make
reasonable
estimates
the
extent
progress
toward
completion
the
contract
and
the
total
costs
the
Company
will
incur
under
the
contract
and
losses
are
recorded
immediately
when
estimate
that
contracts
will
ultimately
result
loss
Changes
the
estimates
could
affect
the
timing
revenue
recognition
Table
Contents
Other
revenues
are
primarily
comprised
development
arrangements
recognized
cost plus fixed fee
basis
and
licensing
arrangements
recognized
ratably
over
the
term
the
related
contracts
Shipping
and
Handling
Costs
The
Company
includes
costs
incurred
connection
with
shipping
and
handling
products
within
selling
general
and
administrative
expenses
the
accompanying
consolidated
statements
income
and
comprehensive
income
Shipping
and
handling
costs
were
million
million
and
million
the
years
ended
December
and
respectively
Amounts
billed
customers
connection
with
these
costs
are
included
total
revenues
Research
and
Development
The
Company
commits
substantial
capital
and
resources
internal
and
collaborative
research
and
development
projects
order
provide
innovative
products
and
solutions
their
customers
The
Company
conducts
research
primarily
enhance
system
performance
and
improve
the
reliability
existing
products
and
develop
revolutionary
new
products
and
solutions
Research
and
development
costs
are
expensed
incurred
and
include
salaries
wages
and
other
personnel
related
costs
material
costs
and
depreciation
consulting
costs
and
facility
costs
Capitalized
Software
Purchased
software
capitalized
cost
and
amortized
over
the
estimated
useful
life
which
generally
three
years
Software
developed
for
use
the
Company
products
expensed
incurred
research
and
development
expense
until
technological
feasibility
achieved
Subsequent
the
achievement
technological
feasibility
amounts
are
capitalizable
however
date
such
amounts
have
not
been
material
Advertising
The
Company
expenses
advertising
costs
incurred
Advertising
expenses
were
million
million
and
million
during
the
years
ended
December
and
respectively
Stock Based
Compensation
The
Company
recognizes
stock based
compensation
expense
the
consolidated
statements
income
and
comprehensive
income
based
the
fair
value
the
share based
award
the
grant
date
The
Company
primary
types
share based
compensation
are
stock
options
restricted
stock
awards
and
restricted
stock
units
The
Company
recorded
stock based
compensation
expense
for
the
years
ended
December
and
follows
millions
Stock
options
Restricted
stock
awards
Restricted
stock
units
Total
stock based
compensation
Table
Contents
Costs
product
revenue
Selling
general
and
administrative
Research
and
development
Total
stock based
compensation
Compensation
expense
amortized
straight line
basis
over
the
underlying
vesting
terms
the
share based
award
Stock
options
purchase
the
Company
common
stock
are
periodically
awarded
executive
officers
and
other
employees
the
Company
subject
vesting
period
three
four
years
The
fair
value
each
option
award
estimated
the
date
grant
using
the
Black Scholes
option pricing
model
Assumptions
regarding
volatility
expected
term
dividend
yield
and
risk free
interest
rates
are
required
for
the
Black Scholes
model
and
are
presented
the
table
below
Risk free
interest
rates
Expected
life
Volatility
Expected
dividend
yield
years
years
years
Risk free
interest
rates
are
based
the
yield
zero coupon
Treasury
securities
for
period
that
commensurate
with
the
expected
life
assumption
Expected
life
determined
through
calculation
based
historical
data
and
the
Company
believes
that
this
the
best
estimate
the
expected
term
new
option
Expected
volatility
based
number
factors
but
the
Company
currently
believes
that
the
exclusive
use
its
historical
volatility
results
the
best
estimate
the
expectations
future
volatility
over
the
expected
term
The
expected
dividend
yield
was
included
the
option
pricing
formula
beginning
February
the
Company
adopted
dividend
policy
addition
the
Company
utilizes
estimated
forfeiture
rate
when
calculating
the
stock based
compensation
expense
for
the
period
The
Company
has
applied
estimated
forfeiture
rates
derived
from
analysis
historical
data
and
for
the
years
ended
December
and
respectively
determining
the
expense
recorded
the
accompanying
consolidated
statements
income
and
comprehensive
income
Starting
members
the
Company
Board
Directors
receive
annual
award
restricted
stock
units
which
vest
over
one
year
service
period
Earnings
Per
Share
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
calculated
dividing
net
income
attributable
Bruker
Corporation
the
weighted average
shares
outstanding
during
the
period
The
diluted
net
income
per
share
computation
includes
the
effect
shares
which
would
issuable
upon
the
exercise
outstanding
stock
options
and
the
vesting
restricted
stock
reduced
the
number
shares
which
are
assumed
purchased
the
Company
under
the
treasury
stock
method
Table
Contents
The
following
table
sets
forth
the
computation
basic
and
diluted
weighted
average
shares
outstanding
for
the
years
ended
December
millions
except
per
share
data
Net
income
attributable
Bruker
Corporation
reported
Weighted
average
shares
outstanding
Weighted
average
shares
outstanding basic
Effect
dilutive
securities
Stock
options
restricted
stock
awards
and
restricted
stock
units
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
Stock
options
and
restricted
stock
units
purchase
approximately
million
shares
million
shares
and
million
shares
were
excluded
from
the
computation
diluted
earnings
per
share
for
the
years
ended
December
and
respectively
because
their
effect
would
have
been
anti dilutive
Post
Retirement
Benefit
Plans
The
Company
recognizes
the
over funded
under funded
status
defined
benefit
pension
and
other
postretirement
defined
benefit
plans
asset
liability
respectively
its
consolidated
balance
sheets
and
recognizes
changes
the
funded
status
the
year
which
the
changes
occur
through
other
comprehensive
income
Other
Comprehensive
Income
Loss
Other
comprehensive
income
loss
refers
revenues
expenses
gains
and
losses
that
are
excluded
from
net
income
these
amounts
are
recorded
directly
adjustment
shareholders
equity
net
tax
The
Company
other
comprehensive
income
loss
was
composed
foreign
currency
translation
adjustments
and
pension
liability
adjustments
Foreign
Currency
Translation
Assets
and
liabilities
the
Company
foreign
subsidiaries
where
the
functional
currency
the
local
currency
are
translated
into
Dollars
using
year end
exchange
rates
historical
rates
appropriate
Revenues
and
expenses
foreign
subsidiaries
are
translated
the
average
exchange
rates
effect
during
the
year
Adjustments
resulting
from
financial
statement
translations
are
included
separate
component
shareholders
equity
Gains
and
losses
resulting
from
translation
foreign
currency
monetary
transactions
are
reported
interest
and
other
income
expense
net
the
consolidated
statements
income
and
comprehensive
income
for
all
periods
presented
The
Company
has
certain
intercompany
foreign
currency
transactions
that
are
deemed
long term
investment
nature
Exchange
adjustments
related
those
transactions
are
made
directly
separate
component
shareholders
equity
Risk
and
Uncertainties
The
Company
subject
risks
common
its
industry
including
but
not
limited
global
economic
conditions
rapid
technological
change
government
and
academic
funding
levels
changes
Table
Contents
commodity
prices
spending
patterns
from
its
customers
protection
its
intellectual
property
availability
key
raw
materials
and
components
compliance
with
existing
and
future
regulation
government
agencies
and
fluctuations
foreign
currency
exchange
rates
Loss
Contingencies
Loss
contingency
provisions
are
recorded
the
potential
loss
from
any
claim
asserted
unasserted
legal
proceeding
related
patents
products
and
other
matters
considered
probable
and
the
amount
can
reasonably
estimated
range
loss
can
determined
These
accruals
represent
management
best
estimate
probable
loss
Disclosure
provided
when
reasonably
possible
that
loss
will
incurred
when
reasonably
possible
that
the
amount
loss
will
exceed
the
recorded
provision
Use
Estimates
The
preparation
financial
statements
conformity
with
accounting
principles
generally
accepted
the
United
States
America
requires
management
make
estimates
and
assumptions
that
affect
the
reported
amounts
assets
and
liabilities
and
disclosure
contingent
assets
and
liabilities
the
date
the
financial
statements
and
reported
amounts
revenues
and
expenses
during
the
reporting
period
Significant
estimates
and
judgments
made
management
preparing
these
financial
statements
include
revenue
recognition
allowances
for
doubtful
accounts
write downs
for
excess
and
obsolete
inventory
estimated
fair
values
used
record
impairment
charges
related
intangible
assets
goodwill
and
other
long lived
assets
amortization
periods
expected
future
cash
flows
used
evaluate
the
recoverability
long lived
assets
stock based
compensation
expense
warranty
allowances
restructuring
and
other
related
charges
contingent
liabilities
and
the
recoverability
the
Company
net
deferred
tax
assets
Although
the
Company
regularly
reassesses
the
assumptions
underlying
these
estimates
actual
results
could
differ
materially
from
these
estimates
Changes
estimates
are
recorded
the
period
which
they
become
known
The
Company
bases
its
estimates
historical
experience
and
various
other
assumptions
that
believes
reasonable
under
the
circumstances
Actual
results
may
differ
from
management
estimates
these
results
differ
from
historical
experience
other
assumptions
prove
not
substantially
accurate
even
such
assumptions
were
reasonable
when
made
Note
Acquisitions
May
the
Company
acquired
the
shares
Luxendo
GmbH
Luxendo
privately
held
spin off
the
European
Molecular
Biology
Laboratory
for
purchase
price
Euro
million
approximately
million
with
the
potential
for
additional
consideration
based
revenue
achievements
through
Luxendo
developer
and
manufacturer
proprietary
light sheet
fluorescence
microscopy
instruments
The
Company
believes
the
acquisition
enhances
the
Company
portfolio
swept field
confocal
super resolution
and
multiphoton
fluorescence
microscope
product
lines
for
small
organism
embryology
live cell
imaging
brain
development
and
cleared
brain
tissue
and
optogenetics
applications
Luxendo
located
Heidelberg
Germany
and
being
integrated
into
the
Bruker
Nano
Group
within
the
BSI
reportable
segment
The
acquisition
Luxendo
Table
Contents
was
accounted
for
under
the
acquisition
method
The
components
and
fair
value
allocation
the
consideration
transferred
connection
with
the
acquisition
were
follows
millions
Consideration
Transferred
Cash
paid
Cash
acquired
Contingent
consideration
Total
consideration
transferred
Allocation
Consideration
Transferred
Inventories
Other
current
and
non current
assets
Property
plant
and
equipment
Intangible
assets
Existing
technology
Trade
name
Goodwill
Deferred
taxes
net
Liabilities
assumed
Total
consideration
transferred
The
preliminary
fair
value
allocation
included
contingent
consideration
the
amount
million
which
represented
the
estimated
fair
value
future
payments
the
former
shareholders
Luxendo
based
achieving
annual
revenue
targets
for
the
years
through
The
Company
completed
the
fair
value
allocation
the
third
quarter
The
amortization
period
for
intangible
assets
acquired
connection
with
the
acquisition
Luxendo
years
for
trade
names
and
years
for
technology
The
results
Luxendo
including
the
amount
allocated
goodwill
that
attributable
expected
synergies
and
not
expected
deductible
for
tax
purposes
have
been
included
the
BSI
Segment
from
the
date
acquisition
Pro
forma
financial
information
reflecting
the
acquisition
Luxendo
has
not
been
presented
because
the
impact
revenues
net
income
and
total
assets
not
material
January
the
Company
acquired
the
shares
Hysitron
Incorporated
Hysitron
The
acquisition
adds
Hysitron
nanomechanical
testing
instruments
the
Company
existing
portfolio
atomic
force
microscopes
surface
profilometers
and
tribology
and
mechanical
testing
systems
Hysitron
included
the
Bruker
Nano
Group
within
the
BSI
reportable
segment
The
acquisition
Hysitron
was
accounted
for
under
the
acquisition
method
The
components
and
fair
Table
Contents
value
allocation
the
consideration
transferred
connection
with
the
acquisition
Hysitron
were
follows
millions
Consideration
Transferred
Cash
paid
Cash
acquired
Contingent
consideration
Total
consideration
transferred
Allocation
Consideration
Transferred
Accounts
receivable
net
Inventories
Other
current
assets
Property
plant
and
equipment
Intangible
assets
Customer
relationships
Existing
technology
Trade
name
Other
Goodwill
Deferred
taxes
net
Capital
lease
Liabilities
assumed
Total
consideration
transferred
The
fair
value
allocation
included
contingent
consideration
the
amount
million
which
represented
the
estimated
fair
value
future
payments
the
former
shareholders
Hysitron
based
achieving
annual
revenue
targets
for
the
years
through
The
Company
completed
the
fair
value
allocation
the
second
quarter
The
maximum
potential
future
payments
related
the
contingent
consideration
million
The
amortization
period
for
intangible
assets
acquired
connection
with
Hysitron
years
for
customer
relationships
trademarks
and
other
intangibles
and
years
for
existing
technology
The
results
Hysitron
including
the
amount
allocated
goodwill
that
attributable
expected
synergies
and
not
expected
deductible
for
tax
purposes
have
been
included
the
BSI
Segment
from
the
date
acquisition
Pro
forma
financial
information
reflecting
the
acquisition
Hysitron
has
not
been
presented
because
the
impact
revenues
net
income
and
total
assets
not
material
addition
the
acquisitions
noted
above
the
year
ended
December
the
Company
completed
various
other
acquisitions
that
collectively
complemented
the
Company
existing
product
offerings
added
aftermarket
and
software
capabilities
the
Company
existing
microbiology
business
The
impact
these
acquisitions
individually
and
collectively
revenues
net
income
and
total
assets
was
not
material
Pro
forma
financial
information
reflecting
these
acquisitions
has
not
been
presented
because
the
impact
individually
and
collectively
revenues
net
income
and
total
assets
Table
Contents
not
material
The
following
table
reflects
the
consideration
transferred
and
the
respective
reporting
segment
for
each
the
acquisitions
Name
Acquisition
InVivo
Biotech
Svs
GmbH
SCIILs
GmbH
Hysitron
Incorporated
Luxendo
GmbH
XGLab
the
pTD ePaTOX
business
Analytik
Jena
MERLIN
Diagnostika
GmbH
Date
Acquired
Segment
January
January
January
May
August
August
September
BSI
BSI
BSI
BSI
BSI
BSI
BSI
Consideration
Cash
Consideration
December
acquired
the
stock
Active
Spectrum
Inc
manufacturer
magnetic
resonance
spectroscopy
November
acquired
the
membership
interests
Oxford
Instruments
Superconducting
Wire
LLC
OST
manufacturer
low temperature
superconductors
November
acquired
the
assets
Renishaw
Diagnostics
Ltd
developer
and
producer
molecular
assays
for
applications
microbiology
November
acquired
the
preclinical
imaging
business
OncoVision
leading
provider
innovative
medical
imaging
devices
June
acquired
the
assets
Yingsheng
Technology
Pty
Ltd
which
comprise
technology
for
advanced
minerals
identification
and
characterization
The
products
the
acquired
companies
are
intended
complement
the
Company
existing
product
portfolio
and
technology
base
The
following
table
reflects
the
consideration
transferred
and
the
respective
reporting
segment
for
each
the
acquisitions
Name
Acquisition
Segment
Yingsheng
Technology
Pty
Ltd
Renishaw
Diagnostics
Ltd
Oxford
Instruments
Superconducting
Wire
LLC
Preclinical
Imaging
Business
OncoVision
Active
Spectrum
Inc
BSI
BSI
BEST
BSI
BSI
Consideration
Cash
Consideration
Table
Contents
The
components
and
fair
value
allocation
the
consideration
transferred
connection
with
these
acquisitions
were
follows
millions
Consideration
Transferred
Cash
paid
Cash
acquired
Shares
issued
Contingent
consideration
Total
consideration
transferred
Allocation
Consideration
Transferred
Accounts
receivable
Inventories
Other
current
assets
Property
plant
and
equipment
Intangible
assets
Customer
relationships
Existing
technology
Trade
name
Goodwill
Bargain
purchase
gain
Deferred
taxes
net
Liabilities
assumed
Total
consideration
transferred
The
Company
completed
the
fair
value
allocation
for
these
acquisitions
December
The
fair
value
allocation
included
contingent
consideration
the
amount
million
which
represented
the
estimated
fair
value
future
payments
the
former
shareholders
the
acquired
companies
based
achieving
annual
revenue
and
gross
margin
targets
future
years
The
future
payments
the
contingent
consideration
may
differ
from
the
fair
value
recorded
based
the
financial
results
the
acquired
businesses
The
amortization
period
for
intangible
assets
between
and
years
The
bargain
purchase
gain
million
related
the
acquisition
OST
and
has
been
recorded
within
interest
and
other
income
net
the
consolidated
statements
income
and
comprehensive
income
The
acquisition
resulted
bargain
purchase
gain
because
the
assets
acquired
exceeded
the
consideration
paid
Pro
forma
financial
information
reflecting
these
acquisitions
have
not
been
presented
because
the
impact
revenues
net
income
and
total
assets
not
material
October
the
Company
completed
the
acquisition
Jordan
Valley
Semiconductors
Ltd
Jordan
Valley
company
headquartered
Israel
that
provides
ray
metrology
and
defect detection
equipment
for
semiconductor
process
control
The
acquisition
Jordan
Valley
was
accounted
Table
Contents
for
under
the
acquisition
method
The
components
and
fair
value
allocation
the
consideration
transferred
connection
with
the
acquisition
Jordan
Valley
were
follows
millions
Consideration
Transferred
Cash
paid
Cash
acquired
Contingent
consideration
Total
consideration
transferred
Allocation
Consideration
Transferred
Accounts
receivable
Inventories
Other
current
assets
Property
plant
and
equipment
Intangible
assets
Customer
relationships
Existing
technology
Trade
name
Goodwill
Liabilities
assumed
Total
consideration
transferred
The
Company
completed
the
fair
value
allocation
the
fourth
quarter
The
fair
value
allocation
included
contingent
consideration
the
amount
million
which
represented
the
estimated
fair
value
future
payments
the
former
shareholders
Jordan
Valley
based
achieving
annual
revenue
and
gross
margin
targets
for
the
years
During
the
year
ended
December
the
Company
recorded
additional
million
other
charges
net
for
additional
consideration
based
revenue
and
gross
margin
achievements
The
maximum
potential
future
payments
related
the
contingent
consideration
million
December
The
amortization
period
for
intangible
assets
acquired
connection
with
Jordan
Valley
years
for
customer
relationships
existing
technology
and
trade
name
The
results
Jordan
Valley
including
the
amount
allocated
goodwill
which
attributable
expected
synergies
and
not
expected
deductible
for
tax
purposes
have
been
included
the
BSI
Segment
from
the
date
acquisition
Pro
forma
financial
information
reflecting
the
acquisition
Jordan
Valley
has
not
been
presented
because
the
impact
revenues
net
income
and
total
assets
not
material
Note
Fair
Value
Financial
Instruments
The
Company
measures
the
following
financial
assets
and
liabilities
fair
value
recurring
basis
The
following
tables
set
forth
the
Company
financial
instruments
and
presents
them
within
the
Table
Contents
fair
value
hierarchy
using
the
lowest
level
input
that
significant
the
fair
value
measurement
December
and
millions
December
Assets
Foreign
exchange
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Fixed
price
commodity
contracts
Total
assets
recorded
fair
value
Liabilities
Contingent
consideration
Foreign
exchange
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Total
liabilities
recorded
fair
value
Total
Quoted
Prices
Active
Markets
Available
Level
Significant
Other
Significant
Observable
Unobservable
Inputs
Inputs
Level
Level
December
Assets
Embedded
derivatives
purchase
and
delivery
contracts
Fixed
price
commodity
contracts
Total
assets
recorded
fair
value
Liabilities
Contingent
consideration
Foreign
exchange
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Total
liabilities
recorded
fair
value
Total
Quoted
Prices
Active
Markets
Available
Level
Significant
Other
Significant
Observable
Unobservable
Inputs
Inputs
Level
Level
Derivative
financial
instruments
are
classified
within
level
because
there
not
active
market
for
each
derivative
contract
However
the
inputs
used
calculate
the
value
the
instruments
are
obtained
from
active
markets
The
fair
value
the
long term
fixed
interest
rate
debt
which
has
been
classified
Level
was
million
and
million
December
and
respectively
based
market
and
observable
sources
with
similar
maturity
dates
The
Company
measures
certain
assets
and
liabilities
fair
value
with
changes
fair
value
recognized
earnings
Fair
value
treatment
may
elected
either
upon
initial
recognition
eligible
asset
liability
for
existing
asset
liability
event
triggers
new
basis
accounting
The
Company
did
not
elect
remeasure
any
its
existing
financial
assets
liabilities
during
the
years
ended
December
and
Excluded
from
the
table
above
are
cash
equivalents
restricted
cash
and
short term
investments
the
cost
approximates
current
fair
value
The
Company
has
program
enter
into
time
deposits
and
call
deposit
and
money
market
funds
The
time
and
call
deposits
have
varying
maturity
dates
ranging
from
one
twelve
month
for
which
the
Company
has
the
ability
redeem
the
invested
amounts
over
Table
Contents
period
days
The
Company
has
classified
these
investments
within
cash
and
cash
equivalents
short term
investments
within
the
consolidated
balance
sheets
based
call
and
maturity
dates
There
are
cash
equivalents
million
and
million
restricted
cash
and
million
and
million
short term
investments
outstanding
December
and
respectively
quarterly
basis
the
Company
reviews
its
short term
investments
determine
there
have
been
any
events
that
could
create
impairment
None
were
noted
for
the
years
ended
December
and
part
certain
acquisitions
and
the
Company
recorded
contingent
consideration
liabilities
that
have
been
classified
Level
the
fair
value
hierarchy
The
contingent
consideration
represents
the
estimated
fair
value
future
payments
the
former
shareholders
applicable
acquired
companies
based
achieving
annual
revenue
and
gross
margin
targets
certain
years
specified
the
purchase
and
sale
agreements
The
Company
initially
values
the
contingent
considerations
using
Monte
Carlo
simulation
income
approach
method
The
Monte
Carlo
method
models
future
revenue
and
costs
goods
sold
projections
and
discounts
the
average
results
present
value
The
income
approach
method
involves
calculating
the
earnout
payment
based
the
forecasted
cash
flows
adjusting
the
future
earnout
payment
for
the
risk
reaching
the
projected
financials
and
then
discounting
the
future
payments
present
value
the
counterparty
risk
The
counterparty
risk
considers
the
risk
the
buyer
having
the
cash
make
the
earnout
payments
and
commensurate
with
the
cost
debt
over
appropriate
term
Changes
the
fair
value
the
contingent
consideration
recognized
earnings
for
the
years
ended
December
and
December
were
million
and
million
respectively
These
amounts
were
recorded
other
charges
net
the
consolidated
statements
income
and
comprehensive
income
for
increases
contingent
consideration
representing
expected
achievement
financial
targets
The
following
table
sets
forth
the
changes
contingent
consideration
liabilities
for
the
years
ended
December
and
millions
Balance
December
Current
period
additions
Current
period
adjustments
Balance
December
Current
period
additions
Current
period
adjustments
Current
period
settlements
Foreign
currency
effect
Balance
December
Note
Accounts
Receivable
The
following
summary
trade
accounts
receivable
December
millions
Gross
accounts
receivable
Allowance
for
doubtful
accounts
Accounts
receivable
net
Table
Contents
The
allowance
for
doubtful
accounts
management
estimate
credit
losses
the
accounts
receivable
The
allowance
for
doubtful
accounts
based
number
factors
including
evaluation
customer
credit
worthiness
the
age
the
outstanding
receivable
economic
trends
and
historical
experience
The
allowance
for
doubtful
accounts
reviewed
quarterly
basis
and
changes
estimates
are
reflected
the
period
which
they
become
known
The
Company
records
account
balances
against
the
allowance
after
all
means
collection
have
been
exhausted
and
the
potential
for
recovery
considered
remote
Provisions
for
doubtful
accounts
are
recorded
selling
general
and
administrative
expenses
the
accompanying
consolidated
statements
income
and
comprehensive
income
The
following
summary
the
activity
the
Company
allowance
for
doubtful
accounts
December
millions
Balance
Beginning
Period
Additions
Charged
Expense
Deductions
Amounts
Written
Off
Foreign
Currency
Impact
Balance
End
Period
Note
Inventories
Inventories
consisted
the
following
December
millions
Raw
materials
Work process
Finished
goods
Demonstration
units
Inventories
Finished
goods
include
transit
systems
that
have
been
shipped
the
Company
customers
but
not
yet
installed
and
accepted
the
customer
December
and
inventory transit
was
million
and
million
respectively
July
the
FASB
issued
ASU
Simplifying the Measurement Inventory
This
guidance
eliminates
the
measurement
inventory
market
value
and
inventory
now
measured
the
lower
cost
and
net
realizable
value
The
ASU
defines
net
realizable
value
the
estimated
selling
prices
the
ordinary
course
business
less
reasonably
predictable
costs
completion
disposal
and
transportation
other
changes
were
made
the
current
guidance
inventory
measurement
The
Company
adopted
ASU
prospective
basis
the
first
quarter
Table
Contents
Note
Property
Plant
and
Equipment
Net
The
following
summary
property
plant
and
equipment
net
major
asset
class
December
millions
Land
Building
and
leasehold
improvements
Machinery
equipment
software
and
furniture
and
fixtures
Less
accumulated
depreciation
and
amortization
Property
plant
and
equipment
net
Depreciation
expense
which
includes
the
amortization
leasehold
improvements
for
the
years
ended
December
and
was
million
million
and
million
respectively
During
the
years
ended
December
and
the
Company
recorded
impairment
charges
million
million
and
million
respectively
representing
the
write
down
fair
value
certain
property
plant
and
equipment
net
related
restructuring
and
outsourcing
activities
undertaken
during
the
respective
years
These
impairment
charges
are
recorded
within
other
charges
net
the
accompanying
consolidated
statements
income
and
comprehensive
income
Please
see
Note
other
charges
net
for
additional
details
the
restructuring
activities
Note
Goodwill
and
Intangible
Assets
Goodwill
The
following
table
sets
forth
the
changes
the
carrying
amount
goodwill
for
the
years
ended
December
and
millions
Balance
December
Current
period
additions adjustments
Impairment
Foreign
currency
impact
Balance
December
Current
period
additions adjustments
Foreign
currency
impact
Balance
December
Current
period
additions adjustments
Foreign
currency
impact
Balance
December
December
and
all
goodwill
was
allocated
within
the
BSI
Segment
The
Company
performed
its
annual
impairment
evaluation
using
qualitative
approach
December
and
and
quantitative
approach
December
and
concluded
was
more
likely
than
not
that
goodwill
has
not
been
impaired
Based
the
most
recent
quantitative
analysis
the
fair
values
each
our
reporting
units
was
significantly
greater
than
their
carrying
amounts
and
therefore
additional
impairment
was
required
Table
Contents
Intangible
Assets
The
following
summary
intangible
assets
December
millions
Gross
Net
Gross
Net
Carrying
Accumulated
Carrying
Carrying
Accumulated
Carrying
Amount
Amortization
Amount
Amount
Amortization
Amount
Existing
technology
and
related
patents
Customer
relationships
Non
compete
conracts
Trade
names
Intangible
assets
subject
amortization
process
research
and
development
Intangible
assets
For
the
years
ended
December
and
the
Company
recorded
amortization
expense
approximately
million
million
and
million
respectively
the
consolidated
statements
income
and
comprehensive
income
During
the
year
ended
December
the
Company
recorded
impairment
charge
million
representing
the
impairment
intangible
assets
the
Bruker
BioSpin
Group
related
certain
restructuring
and
outsourcing
activities
during
the
year
The
estimated
future
amortization
expense
related
amortizable
intangible
assets
December
follows
millions
Thereafter
Total
Note
Other
Current
Liabilities
The
following
summary
other
current
liabilities
December
millions
Deferred
revenue
Accrued
compensation
Accrued
warranty
Contingent
consideration
Income
taxes
payable
Other
taxes
payable
Derivative
liabilities
Other
accrued
expenses
Other
current
liabilities
Table
Contents
The
following
table
sets
forth
the
changes
accrued
warranty
for
the
years
ended
December
and
millions
Balance
December
Accruals
for
warranties
issued
during
the
year
Settlements
warranty
claims
Foreign
currency
impact
Balance
December
Accruals
for
warranties
issued
during
the
year
Settlements
warranty
claims
Foreign
currency
impact
Balance
December
Accruals
for
warranties
issued
during
the
year
Settlements
warranty
claims
Foreign
currency
impact
Balance
December
Note
Debt
The
Company
debt
obligations
consist
the
following
December
millions
Dollar
revolving
loan
under
the
Credit
Agreement
Dollar
notes
under
the
Note
Purchase
Agreement
Unamortized
debt
issuance
costs
under
the
Note
Purchase
Agreement
Capital
lease
obligations
and
other
loans
Total
debt
Current
portion
long term
debt
Total
long term
debt
less
current
portion
Credit
Agreements
October
the
Company
entered
into
new
revolving
credit
agreement
referred
the
Credit
Agreement
The
Credit
Agreement
provides
maximum
commitment
the
Company
revolving
credit
line
million
and
maturity
date
October
Borrowings
under
the
revolving
credit
line
the
Credit
Agreement
accrue
interest
the
Company
option
either
the
greatest
the
prime
rate
the
federal
funds
rate
plus
and
iii
adjusted
LIBOR
plus
plus
margins
ranging
from
LIBOR
plus
margins
ranging
from
There
also
facility
fee
ranging
from
Borrowings
under
the
Credit
Agreement
are
secured
guarantees
from
certain
material
subsidiaries
defined
the
Credit
Agreement
The
Credit
Agreement
also
requires
the
Company
maintain
certain
financial
ratios
related
maximum
leverage
and
minimum
interest
coverage
defined
the
Credit
Agreement
Specifically
the
Company
leverage
ratio
cannot
exceed
and
the
Company
interest
coverage
ratio
cannot
less
than
addition
the
financial
ratios
the
Credit
Agreement
contains
negative
covenants
including
among
others
restrictions
liens
indebtedness
the
Company
and
its
subsidiaries
asset
sales
dividends
and
transactions
with
affiliates
Failure
comply
with
any
these
restrictions
covenants
may
result
event
default
the
Credit
Agreement
which
could
permit
acceleration
the
debt
and
require
the
Company
prepay
the
debt
before
its
scheduled
due
date
Table
Contents
December
the
Company
was
compliance
with
the
covenants
the
Credit
Agreement
The
Company
leverage
ratio
defined
the
Credit
Agreement
was
and
interest
coverage
ratio
defined
the
Credit
Agreement
was
The
following
summary
the
maximum
commitments
and
the
net
amounts
available
the
Company
under
the
Credit
Agreement
and
other
lines
credit
with
various
financial
institutions
located
primarily
Germany
and
Switzerland
that
are
unsecured
and
typically
due
upon
demand
with
interest
payable
monthly
December
millions
Credit
Agreement
Other
lines
credit
Total
revolving
loans
Weighted
Average
Total
Amount
Outstanding
Total
Interest
Committed
Outstanding
Letters
Amount
Rate
Lenders
Credit
Borrowings
Available
Note
Purchase
Agreement
January
the
Company
entered
into
note
purchase
agreement
referred
the
Note
Purchase
Agreement
with
group
accredited
institutional
investors
Pursuant
the
Note
Purchase
Agreement
the
Company
issued
and
sold
million
senior
notes
referred
the
Senior
Notes
which
consist
the
following
million
Series
Senior
Notes
Tranche
due
January
million
Series
Senior
Notes
Tranche
due
January
million
Series
Senior
Notes
Tranche
due
January
and
million
Series
Senior
Notes
Tranche
due
January
January
the
outstanding
million
principal
amount
Tranche
the
Senior
Notes
was
repaid
accordance
with
the
terms
the
Note
Purchase
Agreement
Under
the
terms
the
Note
Purchase
Agreement
the
Company
may
issue
and
sell
additional
senior
notes
aggregate
principal
amount
million
subject
certain
conditions
Interest
the
Senior
Notes
payable
semi annually
January
and
July
each
year
The
Senior
Notes
are
unsecured
obligations
the
Company
and
are
fully
and
unconditionally
guaranteed
certain
the
Company
direct
and
indirect
subsidiaries
The
Senior
Notes
rank
pari
passu
right
repayment
with
the
Company
other
senior
unsecured
indebtedness
The
Company
may
prepay
some
all
the
Senior
Notes
any
time
amount
not
less
than
the
original
aggregate
principal
amount
the
Senior
Notes
prepaid
price
equal
the
sum
the
principal
amount
thereof
plus
accrued
and
unpaid
interest
and
the
applicable
make whole
amount
upon
not
less
than
and
more
than
days
written
notice
the
holders
the
Senior
Notes
the
event
change
control
the
Company
defined
the
Note
Purchase
Agreement
the
Company
may
required
prepay
the
Notes
price
equal
the
principal
amount
thereof
plus
accrued
and
unpaid
interest
The
Note
Purchase
Agreement
contains
affirmative
covenants
including
without
limitation
maintenance
corporate
existence
compliance
with
laws
maintenance
insurance
and
properties
payment
taxes
addition
subsidiary
guarantors
and
furnishing
notices
and
other
information
The
Note
Purchase
Agreement
also
contains
certain
restrictive
covenants
that
restrict
the
Company
ability
among
other
things
incur
liens
transfer
sell
assets
engage
certain
mergers
and
consolidations
and
enter
into
transactions
with
affiliates
The
Note
Purchase
Agreement
also
includes
customary
Table
Contents
representations
and
warranties
and
events
default
the
case
event
default
arising
from
specified
events
bankruptcy
insolvency
all
outstanding
Senior
Notes
will
become
due
and
payable
immediately
without
further
action
notice
the
case
payment
events
defaults
any
holder
Senior
Notes
affected
thereby
may
declare
all
Senior
Notes
held
due
and
payable
immediately
the
case
any
other
event
default
majority
the
holders
the
Senior
Notes
may
declare
all
the
Senior
Notes
due
and
payable
immediately
Pursuant
the
Note
Purchase
Agreement
long
any
Senior
Notes
are
outstanding
the
Company
will
not
permit
its
leverage
ratio
determined
pursuant
the
Note
Purchase
Agreement
the
end
any
fiscal
quarter
exceed
its
interest
coverage
ratio
determined
pursuant
the
Note
Purchase
Agreement
the
end
any
fiscal
quarter
for
any
period
four
consecutive
fiscal
quarters
less
than
iii
priority
debt
any
time
exceed
consolidated
net
worth
determined
pursuant
the
Note
Purchase
Agreement
December
the
Company
was
compliance
with
the
covenants
the
Note
Purchase
Agreement
The
Company
leverage
ratio
defined
the
Note
Purchase
Agreement
was
and
interest
coverage
ratio
defined
the
Note
Purchase
Agreement
was
Annual
maturities
debt
outstanding
less
deferred
financing
cost
amortization
December
are
follows
millions
Thereafter
Total
Interest
expense
for
the
years
ended
December
and
was
million
million
and
million
respectively
April
the
Financial
Accounting
Standards
Board
FASB
issued
Accounting
Standards
Update
ASU
Simplifying the Presentation Debt
Issuance Costs which
amended
the
existing
guidance
require
that
debt
issuance
costs
presented
the
consolidated
balance
sheet
reduction
from
the
carrying
amount
the
related
debt
liability
instead
other
asset
The
Company
adopted
ASU
retrospective
basis
for
the
year
ended
December
December
and
there
were
million
and
million
respectively
debt
issuance
costs
recorded
reduction
the
carrying
value
the
related
debt
liability
under
the
Note
Purchase
Agreement
The
million
debt
issuance
costs
December
will
amortized
over
the
remaining
term
the
Note
Purchase
Agreement
The
Company
also
adopted
ASU
Presentation and Subsequent Measurement
Debt Issuance Costs Associated with Line Credit Arrangements and
elected
not
reclassify
the
debt
issuance
costs
related
line credit
arrangements
for
the
Credit
Agreement
Note
Derivative
Instruments
and
Hedging
Activities
Interest
Rate
Risks
The
Company
exposure
interest
rate
risk
relates
primarily
outstanding
variable
rate
debt
and
adverse
movements
the
related
short term
market
rates
The
most
significant
component
the
Company
interest
rate
risk
relates
amounts
outstanding
under
the
Credit
Agreement
which
totaled
million
December
The
Company
currently
has
approximately
equal
levels
fixed
and
floating
rate
debt
which
limits
the
exposure
adverse
movements
interest
rates
Table
Contents
Foreign
Exchange
Rate
Risk
Management
The
Company
generates
substantial
portion
its
revenues
and
expenses
international
markets
principally
Germany
and
other
countries
the
European
Union
and
Switzerland
which
subjects
its
operations
the
exposure
foreign
rate
fluctuations
The
impact
foreign
exchange
rate
movement
can
positive
negative
any
period
The
Company
periodically
enters
into
foreign
currency
contracts
order
minimize
the
volatility
that
fluctuations
currency
translation
have
its
monetary
transactions
Under
these
arrangements
the
Company
typically
agrees
purchase
fixed
amount
foreign
currency
exchange
for
fixed
amount
Dollars
other
currencies
specified
dates
with
maturities
less
than
twelve
months
These
transactions
not
qualify
for
hedge
accounting
and
accordingly
the
instrument
recorded
fair
value
with
the
corresponding
gains
and
losses
recorded
the
consolidated
statements
income
and
comprehensive
income
The
Company
had
the
following
notional
amounts
outstanding
under
foreign
currency
contracts
December
millions
Buy
December
Euro
Swiss
Francs
Singapore
Dollar
Euro
December
Euro
Swiss
Francs
Dollars
Israel
Shekel
Euro
Notional
Amount
Buy
Currency
Sell
Dollars
Dollars
Dollars
Polish
Zloty
Dollars
Dollars
Israel
Shekel
Dollars
Polish
Zloty
Maturity
January
January
January
January
January
January
January
January
January
Notional
Amount
Dollars
Fair
Value
Assets
Fair
Value
Liabilities
addition
the
Company
periodically
enters
into
purchase
and
sales
contracts
denominated
currencies
other
than
the
functional
currency
the
parties
the
transaction
The
Company
accounts
for
these
transactions
separately
valuing
the
embedded
derivative
component
these
contracts
The
contracts
denominated
currencies
other
than
the
functional
currency
the
transacting
parties
amounted
million
for
the
delivery
products
and
million
for
the
purchase
products
December
and
million
for
the
delivery
products
and
million
for
the
purchase
products
December
The
changes
the
fair
value
these
embedded
derivatives
are
recorded
interest
and
other
income
expense
net
the
consolidated
statements
income
and
comprehensive
income
Commodity
Price
Risk
Management
The
Company
has
arrangement
with
customer
under
which
has
firm
commitment
deliver
copper
based
superconductors
fixed
price
order
minimize
the
volatility
that
fluctuations
the
price
copper
have
the
Company
sales
these
commodities
the
Company
enters
into
commodity
hedge
contracts
December
and
the
Company
has
fixed
price
commodity
contracts
with
notional
amounts
aggregating
million
and
million
respectively
The
changes
the
fair
value
these
commodity
contracts
are
recorded
interest
and
other
income
expense
net
the
consolidated
statements
income
and
comprehensive
income
Table
Contents
The
fair
value
the
derivative
instruments
described
above
were
recorded
the
consolidated
balance
sheets
for
the
years
ended
December
and
follows
millions
Derivative
assets
Foreign
exchange
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Fixed
price
commodity
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Other
current
assets
Other
current
assets
Other
current
assets
Other
long term
assets
Derivative
liabilities
Foreign
exchange
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Other
current
liabilities
Other
current
liabilities
Other
long term
liabilities
Balance
Sheet
Location
The
impact
net
income
unrealized
gains
and
losses
resulting
from
changes
the
fair
value
derivative
instruments
for
the
years
ending
December
are
follows
millions
and
are
recorded
within
interest
and
other
income
expense
net
the
consolidated
statements
income
and
comprehensive
income
Foreign
exchange
contracts
Embedded
derivatives
purchase
and
delivery
contracts
Fixed
price
commodity
contracts
Income
expense
net
Note
Income
Taxes
December
Enactment
Date
the
President
the
United
States
signed
tax
reform
legislation
Tax
Act
which
enacted
wide
range
changes
the
corporate
income
tax
system
many
which
differ
significantly
from
the
provisions
the
previous
tax
law
The
Tax
Act
contains
several
key
provisions
including
among
other
things
one time
tax
the
mandatory
deemed
repatriation
post
untaxed
foreign
earnings
and
profits
referred
the
toll
charge
reduction
the
corporate
tax
rate
from
for
the
tax
years
beginning
after
December
The
introduction
new
tax
certain
off shore
earnings
referred
the
Global
Intangible
Low Taxed
Income
GILTI
effective
tax
rate
for
tax
years
beginning
after
December
increasing
for
tax
years
beginning
after
December
with
partial
offset
foreign
tax
credits
and
The
introduction
territorial
tax
system
beginning
providing
dividends
received
deduction
certain
qualified
dividends
from
foreign
subsidiaries
Also
December
the
Securities
and
Exchange
Commission
SEC
issued
Staff
Accounting
Bulletin
SAB
which
provides
companies
with
additional
guidance
how
implement
the
provisions
the
Tax
Act
their
financial
statements
The
guidance
provides
for
measurement
period
one
year
from
the
Enactment
Date
which
provisional
amounts
may
adjusted
when
additional
information
obtained
prepared
analyzed
about
facts
and
circumstances
that
existed
the
Enactment
Date
known
which
would
have
impacted
the
amounts
that
were
initially
recorded
the
Company
Table
Contents
The
Company
has
not
yet
completed
the
assessment
the
tax
effects
associated
with
the
enactment
the
Tax
Act
however
reasonable
estimate
has
been
made
the
effects
the
existing
deferred
tax
balances
and
the
one time
transition
tax
Changes
the
tax
rates
and
laws
are
accounted
for
the
period
enactment
Therefore
during
the
fourth
quarter
the
Company
recorded
incremental
income
tax
provision
million
which
primarily
comprised
the
following
estimated
income
tax
provision
million
for
the
federal
and
state
impacts
the
one time
deemed
repatriation
pre
accordance
with
the
Tax
Act
the
federal
portion
the
toll
charge
liability
may
paid
over
eight
years
Such
liability
can
reduced
certain
credits
Accordingly
have
recorded
million
and
million
long term
income
tax
liabilities
and
accrued
income
taxes
current
respectively
December
estimated
net
income
tax
benefit
million
for
the
remeasurement
our
deferred
tax
assets
and
liabilities
the
newly
enacted
tax
rate
and
result
the
Tax
Act
and
our
expectations
about
distributing
certain
cash
balances
from
its
foreign
subsidiaries
the
United
States
also
recorded
estimated
income
tax
provisions
for
estimated
state
income
taxes
and
foreign
withholding
taxes
million
The
net
charge
million
recorded
was
based
currently
available
information
and
interpretations
applying
the
provisions
the
Tax
Act
the
time
filing
this
Annual
Report
Form
The
Company
expects
finalize
these
provisional
estimates
before
the
end
after
completing
the
review
and
analysis
including
reviews
and
analysis
any
interpretations
issued
during
this
measurement
period
The
Company
still
evaluating
the
GILTI
provisions
the
Tax
Act
and
its
impact
any
the
consolidated
financial
statements
December
Companies
are
allowed
adopt
accounting
policy
either
recognize
deferred
taxes
for
GILTI
treat
such
tax
cost
the
year
incurred
The
Company
has
not
yet
determined
the
accounting
policy
because
determining
the
impact
the
GILTI
provisions
requires
analysis
the
existing
legal
entity
structure
the
reversal
GAAP
and
tax
basis
differences
the
assets
and
liabilities
foreign
subsidiaries
and
the
ability
offset
any
tax
with
foreign
tax
credits
such
the
Company
did
not
record
deferred
income
tax
expense
benefit
related
the
GILTI
provisions
the
Tax
Act
the
consolidated
statement
income
for
the
year
ended
December
This
will
also
finalized
during
the
measurement
period
The
Company
recorded
provisional
amount
for
the
toll
charge
which
represents
its
reasonable
estimate
the
liability
due
for
the
mandatory
deemed
repatriation
its
post
untaxed
foreign
Determining
the
provisional
toll
charge
liability
required
significant
effort
based
number
factors
including
Analyzing
the
accumulated
untaxed
foreign
since
including
historical
practices
and
assertions
made
determining
such
Determining
the
composition
including
intercompany
receivables
and
payables
specified
foreign
corporations
our
post
untaxed
foreign
that
held
cash
liquid
assets
and
other
assets
several
measurement
dates
This
required
because
different
tax
rate
applied
each
when
determining
the
toll
charge
liability
and
Assessing
the
potential
impact
existing
uncertain
tax
positions
determining
our
accumulated
undistributed
Due
the
timing
the
Enactment
Date
the
Company
had
limited
time
understand
the
Tax
Act
and
its
various
interpretations
assess
how
apply
the
new
tax
law
the
specific
facts
and
Table
Contents
circumstances
the
Company
and
determine
the
toll
charge
such
the
amounts
recorded
for
the
toll
charge
are
provisional
The
actual
results
the
implementation
the
Tax
Act
may
materially
differ
from
the
Company
current
estimate
due
among
other
things
further
guidance
that
may
issued
tax
authorities
regulatory
bodies
including
the
SEC
and
the
FASB
interpret
the
Tax
Act
The
Company
will
continue
analyze
the
Tax
Act
and
any
additional
guidance
that
may
issued
and
finalize
the
full
effects
applying
the
new
legislation
the
measurement
period
The
domestic
and
foreign
components
income
before
taxes
are
follows
for
the
years
ended
December
millions
Domestic
Foreign
The
components
the
income
tax
provision
are
follows
for
the
years
ended
December
millions
Current
income
tax
benefit
expense
Federal
State
Foreign
Total
current
income
tax
expense
Deferred
income
tax
benefit
expense
Federal
State
Foreign
Total
deferred
income
tax
benefit
expense
Income
tax
provision
Table
Contents
The
income
tax
provision
differs
from
the
tax
provision
computed
the
federal
statutory
rate
due
the
following
significant
components
for
the
years
ended
December
Statutory
tax
rate
Foreign
tax
rate
differential
Permanent
differences
Mandatory
Repatriation
Tax
contingencies
Change
tax
rates
Withholding
taxes
Permanent
Reinvestment
Assertion
Accrual
State
income
taxes
net
federal
benefits
Purchase
accounting
Tax
credits
Other
Change
valuation
allowance
for
unbenefitted
losses
Effective
tax
rate
The
tax
effect
temporary
items
that
give
rise
significant
portions
the
deferred
tax
assets
and
liabilities
December
and
are
follows
millions
Deferred
tax
assets
Accounts
receivable
Accrued
expenses
Compensation
Deferred
revenue
Net
operating
loss
carryforwards
Fixed
assets
Inventory
Foreign
tax
and
other
tax
credit
carryforwards
Unrealized
currency
gain loss
Gross
deferred
tax
assets
Less
valuation
allowance
Total
deferred
tax
assets
Deferred
tax
liabilities
Fixed
assets
Foreign
statutory
reserves
Intangibles
Accrued
expenses
Accrued
Withholding
Tax
Other
Total
deferred
tax
liabilities
Net
deferred
tax
assets
The
Company
uses
the
liability
method
account
for
income
taxes
Under
this
method
deferred
income
taxes
are
recognized
for
the
future
tax
consequences
differences
between
the
tax
and
financial
accounting
bases
assets
and
liabilities
each
reporting
period
Deferred
income
taxes
are
Table
Contents
based
enacted
tax
laws
and
statutory
tax
rates
applicable
the
period
which
these
differences
are
expected
affect
taxable
income
valuation
allowance
established
when
necessary
reduce
deferred
tax
assets
the
expected
realizable
amounts
The
Company
can
only
recognize
deferred
tax
asset
the
extent
this
more
likely
than
not
that
these
assets
will
realized
Judgments
around
realizability
depend
the
availability
and
weight
both
positive
and
negative
evidence
Changes
the
valuation
allowance
for
deferred
tax
assets
during
the
years
ended
December
and
were
follows
Balance
December
Decreases
recorded
benefit
income
tax
provision
Balance
December
Decreases
recorded
benefit
income
tax
provision
Balance
December
Decreases
recorded
benefit
income
tax
provision
Balance
December
The
decreases
related
primarily
the
realizability
foreign
net
operating
and
capital
losses
based
future
taxable
income
December
the
Company
has
approximately
million
net
operating
loss
carryforwards
available
reduce
state
taxable
income
The
Company
also
has
approximately
million
German
Trade
Tax
and
Corporate
Income
Tax
net
operating
losses
that
are
carried
forward
indefinitely
Additionally
the
Company
has
million
other
foreign
net
operating
losses
that
are
expected
expire
various
times
beginning
The
Company
also
has
state
research
and
development
tax
credits
million
Utilization
these
credits
and
state
net
operating
losses
may
subject
annual
limitations
due
the
ownership
percentage
change
limitations
provided
the
Internal
Revenue
Code
Section
and
similar
state
provisions
the
event
deemed
change
control
under
Internal
Revenue
Code
Section
annual
limitation
the
utilization
net
operating
losses
and
credits
may
result
the
expiration
all
portion
the
net
operating
loss
and
credit
carryforwards
The
Company
reflects
certain
statutory
reserves
its
tabular
reconciliation
unrecognized
tax
benefits
Effective
for
the
year
ended
December
and
thereafter
these
unrecognized
tax
benefits
are
presented
reduction
the
associated
net
deferred
tax
assets
December
and
accordance
with
the
Tax
Act
the
Company
recorded
state
and
foreign
withholding
taxes
the
cash
and
liquid
assets
portion
the
unremitted
earnings
and
profits
foreign
subsidiaries
expected
repatriated
from
its
foreign
subsidiaries
the
United
States
The
Company
continues
indefinitely
reinvested
amounting
million
non cash
that
related
the
Tax
Act
deemed
repatriation
this
ultimately
distributed
the
United
States
the
form
dividends
otherwise
the
Company
would
likely
subject
additional
withholding
tax
The
Company
will
continue
evaluate
its
assertions
the
cumulative
historical
outside
basis
differences
its
foreign
subsidiaries
December
The
Company
expects
finalize
its
analysis
and
accounting
related
the
toll
charge
and
any
remaining
outside
basis
differences
its
foreign
subsidiaries
during
the
measurement
period
The
Company
estimates
the
amount
unrecognized
deferred
withholding
taxes
the
undistributed
approximately
million
December
The
Company
had
gross
unrecognized
tax
benefits
excluding
interest
approximately
million
December
that
recognized
would
reduce
the
Company
effective
tax
rate
the
next
twelve
months
reasonably
possible
that
the
Company
will
reduce
its
unrecognized
Table
Contents
tax
benefits
million
due
the
expiration
statutes
limitations
and
favorable
settlement
with
taxing
authorities
which
would
reduce
the
Company
effective
tax
rate
tabular
reconciliation
the
beginning
and
ending
amount
unrecognized
tax
benefits
follows
millions
Gross
unrecognized
tax
benefits
December
Gross
decreases tax
positions
prior
periods
Gross
increases current
period
tax
positions
Settlements
Lapse
statutes
Gross
unrecognized
tax
benefits
December
Gross
decreases tax
positions
prior
periods
Gross
increases current
period
tax
positions
Settlements
Lapse
statutes
Gross
unrecognized
tax
benefits
December
Lapse
statutes
Gross
unrecognized
tax
benefits
December
The
Company
policy
include
accrued
interest
and
penalties
related
unrecognized
tax
benefits
and
income
tax
liabilities
when
applicable
income
tax
expense
December
and
the
Company
had
approximately
million
and
million
respectively
accrued
interest
and
penalties
related
uncertain
tax
positions
included
other
long term
liabilities
the
consolidated
balance
sheets
The
Company
recorded
benefit
million
and
million
for
penalties
and
interest
related
unrecognized
tax
benefits
the
provision
for
income
taxes
during
the
year
ended
December
and
December
respectively
The
Company
files
tax
returns
the
United
States
which
includes
federal
state
and
local
jurisdictions
and
many
foreign
jurisdictions
with
varying
statutes
limitations
The
Company
considers
Germany
the
United
States
and
Switzerland
its
significant
tax
jurisdictions
The
majority
the
Company
earnings
are
derived
Germany
and
Switzerland
Accounting
for
the
various
federal
and
local
taxing
authorities
the
statutory
rates
for
were
approximately
and
for
Germany
and
Switzerland
respectively
The
mix
earnings
those
two
jurisdictions
resulted
reduction
from
the
statutory
rate
The
Company
has
not
been
party
any
tax
holiday
agreements
The
tax
years
are
open
examination
Germany
and
Switzerland
the
third
quarter
the
Company
settled
tax
audits
Germany
and
Italy
the
Company
settled
tax
audits
Germany
and
Switzerland
The
settlements
were
immaterial
the
consolidated
financial
statements
Tax
years
remain
open
for
examination
the
United
States
Note
Post
Retirement
Benefit
Plans
Defined
Contribution
Plans
The
Company
sponsors
various
defined
contribution
plans
that
cover
certain
domestic
and
international
employees
The
Company
may
make
contributions
these
plans
its
discretion
The
Company
contributed
million
million
and
million
such
plans
the
years
ended
December
and
respectively
Table
Contents
Defined
Benefit
Plans
Substantially
all
the
Company
employees
Switzerland
France
and
Japan
well
certain
employees
Germany
are
covered
Company sponsored
defined
benefit
pension
plans
Retirement
benefits
are
generally
earned
based
years
service
and
compensation
during
active
employment
Eligibility
generally
determined
accordance
with
local
statutory
requirements
however
the
level
benefits
and
terms
vesting
varies
among
plans
The
components
net
periodic
benefit
costs
for
the
years
ended
December
and
were
follows
millions
Components
net
periodic
benefit
costs
Service
cost
Interest
cost
Expected
return
plan
assets
Settlement
loss
recognized
Amortization
net
loss
Net
periodic
benefit
costs
The
net
periodic
benefit
costs
for
the
year
ended
December
includes
one time
non cash
settlement
loss
million
the
Company
outsourced
its
pension
plan
Switzerland
outside
insurance
provider
transferred
certain
plan
assets
and
pension
obligations
for
retirees
and
other
certain
members
the
population
made
certain
plan
design
changes
and
measured
the
liability
The
Company
measures
its
benefit
obligation
and
the
fair
value
plan
assets
December
each
year
The
changes
benefit
obligations
and
plan
assets
under
the
defined
benefit
pension
plans
projected
benefit
obligation
and
funded
status
the
plans
were
follows
December
millions
Change
benefit
obligation
Benefit
obligation
beginning
year
Service
cost
Interest
cost
Plan
participant
contributions
Benefits
paid
Actuarial
loss
gain
Premiums
paid
Impact
foreign
currency
exchange
rates
Benefit
obligation
end
year
Change
plan
assets
Fair
value
plan
assets
beginning
year
Return
plan
assets
Plan
participant
and
employer
contributions
Benefits
paid
Premiums
paid
Impact
foreign
currency
exchange
rates
Fair
value
plan
assets
end
year
Net
under
funded
status
Table
Contents
The
accumulated
benefit
obligation
for
the
defined
benefit
pension
plans
million
and
million
December
and
respectively
All
defined
benefit
pension
plans
have
accumulated
benefit
obligation
and
projected
benefit
obligation
excess
plan
assets
December
and
The
following
amounts
were
recognized
the
accompanying
consolidated
balance
sheets
for
the
Company
defined
benefit
plans
December
millions
Current
liabilities
Non current
liabilities
Net
benefit
obligation
The
following
pre tax
amounts
were
recognized
accumulated
other
comprehensive
income
for
the
Company
defined
benefit
plans
December
millions
Reconciliation
amounts
recognized
the
consolidated
balance
sheets
Prior
service
cost
Net
actuarial
loss
Accumulated
other
comprehensive
loss
Accumulated
contributions
excess
net
periodic
benefit
cost
Net
amount
recognized
The
amount
accumulated
other
comprehensive
income
December
expected
recognized
amortization
net
loss
within
net
periodic
benefit
cost
million
For
the
defined
benefit
pension
plans
the
Company
uses
corridor
approach
amortize
actuarial
gains
and
losses
Under
this
approach
net
actuarial
gains
losses
excess
ten
percent
the
larger
the
projected
benefit
obligation
the
fair
value
plan
assets
are
amortized
over
the
average
remaining
service
active
participants
who
are
expected
receive
benefits
under
the
plans
The
range
assumptions
used
for
defined
benefit
pension
plans
reflects
the
different
economic
environments
within
the
various
countries
The
range
assumptions
used
determine
the
projected
benefit
obligations
for
the
years
ended
December
are
follows
Discount
rates
Expected
return
plan
assets
Expected
rate
compensation
increase
determine
the
expected
long term
rate
return
pension
plan
assets
the
Company
considers
current
asset
allocations
well
historical
and
expected
returns
various
asset
categories
plan
assets
For
the
defined
benefit
pension
plans
the
Company
applies
the
expected
rate
return
market related
value
assets
which
stabilizes
variability
assets
which
the
expected
return
applied
Table
Contents
Asset
Allocations
Asset
Category
The
fair
value
the
Company
pension
plan
assets
December
and
asset
category
and
level
the
fair
value
hierarchy
follows
millions
December
Plan
Assets
Group
BPCE
Life
Swiss
Life
Collective
BVG
Foundation
Total
plan
assets
Total
Quoted
Prices
Active
Markets
Available
Level
Significant
Other
Observable
Inputs
Level
Significant
Unobservable
Inputs
Level
December
Plan
Assets
Group
BPCE
Life
Swiss
Life
Collective
BVG
Foundation
Total
plan
assets
Total
Quoted
Prices
Active
Markets
Available
Level
Significant
Other
Observable
Inputs
Level
Significant
Unobservable
Inputs
Level
The
Company
pension
plan
France
invested
larger
fund
that
invests
variety
instruments
The
assets
are
not
directly
dedicated
the
French
pension
plan
The
Group
BPCE
Life
fund
invests
debt
securities
foreign
corporations
and
governments
equity
securities
foreign
government
funds
and
private
real
estate
funds
The
Company
pension
plan
Switzerland
outsourced
Swiss
Life
outside
insurance
provider
Under
the
insurance
contract
the
plan
assets
are
invested
Swiss
Life
Collective
BVG
Foundation
the
Foundation
which
umbrella
fund
for
which
the
retirement
savings
and
interest
rates
are
guaranteed
minimum
the
mandatory
withdrawal
portion
defined
Swiss
law
and
and
for
the
years
ended
December
and
respectively
the
non mandatory
portion
The
Foundation
utilizes
plan
administrators
and
investment
managers
oversee
the
investment
allocation
process
set
long term
strategic
targets
and
monitor
asset
allocations
The
target
allocations
are
bonds
including
cash
equity
investments
and
real
estate
and
mortgages
Should
the
Foundation
yield
return
greater
than
the
guaranteed
amounts
the
Company
according
Swiss
law
shall
receive
the
additional
return
with
Swiss
Life
retaining
The
withdrawal
benefits
and
interest
allocations
are
secured
all
times
Swiss
Life
Contributions
and
Estimated
Future
Benefit
Payments
During
the
Company
expects
contributions
consistent
with
The
estimated
future
benefit
payments
are
based
the
same
assumptions
used
measure
the
Company
benefit
obligation
Table
Contents
December
The
following
benefit
payments
reflect
future
employee
service
appropriate
millions
Note
Commitments
and
Contingencies
accordance
with
ASC
Topic
Contingencies
the
Company
accrues
anticipated
costs
settlement
damages
other
costs
the
extent
specific
losses
are
probable
and
estimable
Litigation
and
Related
Contingencies
Lawsuits
claims
and
proceedings
nature
considered
normal
its
businesses
may
pending
from
time
time
against
the
Company
Third
parties
might
allege
that
the
Company
its
collaborators
are
infringing
their
patent
rights
that
the
Company
otherwise
violating
their
intellectual
property
rights
Loss
contingency
provisions
are
recorded
the
potential
loss
from
any
claim
asserted
unasserted
legal
proceeding
considered
probable
and
the
amount
can
reasonably
estimated
range
loss
can
determined
These
accruals
represent
management
best
estimate
probable
loss
Disclosure
also
provided
when
reasonably
possible
that
loss
will
incurred
when
reasonably
possible
that
the
amount
loss
will
exceed
the
recorded
provision
The
Company
believes
the
outcome
pending
proceedings
individually
and
the
aggregate
will
not
have
material
impact
the
Company
financial
statements
December
and
material
accruals
have
been
recorded
for
potential
contingencies
Governmental
Investigations
The
Company
subject
from
time
time
investigations
foreign
governmental
agencies
from
which
civil
criminal
administrative
proceedings
could
result
October
the
Company
received
notice
investigation
and
subpoena
produce
documents
from
the
Division
Enforcement
the
SEC
The
subpoena
seeks
information
related
employee
terminated
part
restructuring
and
certain
matters
involving
the
Company
policies
and
accounting
practices
related
revenue
recognition
and
restructuring
activities
well
related
financial
reporting
disclosure
and
compliance
matters
since
January
The
subpoena
also
seeks
information
concerning
among
other
things
the
Company
previously
identified
material
weakness
internal
controls
over
the
accounting
for
income
taxes
related
financial
reporting
matters
and
certain
payments
for
non employee
travel
expenses
The
Company
producing
documents
response
the
subpoena
and
intends
continue
cooperate
fully
with
the
SEC
investigation
this
time
the
Company
unable
predict
the
duration
scope
outcome
this
investigation
The
Korea
Fair
Trade
Commission
KFTC
has
conducted
investigation
into
improper
bidding
Bruker
Korea
Ltd
and
several
other
companies
connection
with
bids
for
sales
ray
systems
and
Three
the
bids
under
investigation
involved
Bruker
Korea
The
Company
cooperated
fully
with
the
KFTC
regarding
this
matter
September
the
KFTC
fined
Bruker
Korea
approximately
and
referred
the
matter
the
Korean
Public
Prosecutor
Office
PPO
for
criminal
prosecution
May
the
PPO
issued
official
notice
its
decision
not
pursue
criminal
proceedings
against
Bruker
Korea
Additionally
since
December
various
Korean
governmental
entities
imposed
suspensions
Bruker
Korea
with
overlapping
Table
Contents
suspension
periods
ranging
from
three
six
months
During
the
periods
these
suspensions
Bruker
Korea
was
prohibited
from
bidding
for
conducting
sales
Korean
governmental
agencies
Sales
these
customers
were
less
than
the
Company
revenue
for
the
year
ended
December
December
all
such
suspension
periods
have
lapsed
The
Company
considers
these
matters
resolved
and
additional
payments
are
owed
accrued
December
connection
with
such
resolutions
Operating
Leases
Certain
buildings
office
equipment
and
vehicles
are
leased
under
agreements
that
are
accounted
for
operating
leases
Total
rental
expense
under
operating
leases
was
million
million
and
million
during
the
years
ended
December
and
respectively
Future
minimum
lease
payments
under
non cancelable
operating
leases
December
for
each
the
next
five
years
and
thereafter
are
follows
millions
Thereafter
Total
Capital
Leases
The
Company
leases
certain
assets
under
agreements
that
are
classified
capital
leases
The
cost
these
assets
under
the
capital
leases
included
the
consolidated
balance
sheets
property
plant
and
equipment
and
was
million
December
Accumulated
amortization
the
leased
buildings
December
was
million
There
were
assets
under
capital
lease
agreements
December
Amortization
expense
related
assets
under
capital
leases
was
included
depreciation
expense
The
obligations
related
capital
leases
was
recorded
component
long term
debt
the
current
portion
long term
debt
the
consolidated
balance
sheets
depending
when
the
lease
payments
are
due
Unconditional
Purchase
Commitments
The
Company
has
entered
into
unconditional
purchase
commitments
the
ordinary
course
business
that
include
agreements
purchase
goods
services
fixed
assets
and
pay
royalties
that
are
enforceable
and
legally
binding
and
that
specify
all
significant
terms
including
fixed
minimum
quantities
purchased
fixed
minimum
variable
price
provisions
and
the
approximate
timing
the
transaction
Purchase
commitments
exclude
agreements
that
are
cancelable
any
time
without
penalty
The
aggregate
amount
the
Company
unconditional
purchase
commitments
totaled
million
December
and
the
majority
these
commitments
are
expected
settled
during
License
Agreements
The
Company
has
entered
into
cross licensing
agreements
for
various
technologies
that
allow
other
companies
utilize
certain
its
patents
and
related
technologies
over
various
periods
into
perpetuity
Income
from
these
agreements
for
the
years
ended
December
and
was
million
million
and
million
respectively
and
classified
other
revenue
the
consolidated
statements
income
and
comprehensive
income
The
unearned
portions
proceeds
from
the
cross licensing
agreements
are
classified
short term
long term
deferred
revenue
depending
when
the
revenue
will
earned
Table
Contents
The
Company
has
also
entered
into
license
agreements
allowing
utilize
certain
patents
these
patents
are
used
connection
with
commercial
product
sale
the
Company
pays
royalties
the
related
product
revenues
Licensing
fees
for
the
years
ended
December
and
were
million
million
and
million
respectively
and
are
recorded
cost
product
revenue
the
consolidated
statements
income
and
comprehensive
income
Letters
Credit
and
Guarantees
December
and
the
Company
had
bank
guarantees
million
and
million
respectively
related
primarily
customer
advances
These
arrangements
guarantee
the
refund
advance
payments
received
from
customers
the
event
that
the
merchandise
not
delivered
warranty
obligations
are
not
fulfilled
compliance
with
the
terms
the
contract
These
guarantees
affect
the
availability
the
Company
lines
credit
Indemnifications
The
Company
enters
into
standard
indemnification
arrangements
the
Company
ordinary
course
business
Pursuant
these
arrangements
the
Company
indemnifies
holds
harmless
and
agrees
reimburse
the
indemnified
parties
for
losses
suffered
incurred
the
indemnified
party
These
parties
are
generally
the
Company
business
partners
customers
connection
with
any
patent
any
copyright
other
intellectual
property
infringement
claim
any
third
party
with
respect
its
products
The
term
these
indemnification
agreements
generally
perpetual
any
time
after
the
execution
the
agreement
The
maximum
potential
amount
future
payments
the
Company
could
required
make
under
these
agreements
unlimited
The
Company
believes
the
estimated
fair
value
these
agreements
minimal
based
historical
experiences
Note
Shareholders
Equity
Share
Repurchase
Program
May
the
Company
Board
Directors
approved
share
repurchase
program
the
Anti Dilutive
Repurchase
Program
under
which
the
Company
was
authorized
repurchase
the
Company
common
stock
amounts
intended
approximately
offset
annual
basis
the
dilutive
effect
shares
that
have
been
may
issued
pursuant
option
restricted
stock
awards
under
the
Company
incentive
compensation
plans
total
shares
were
repurchased
aggregate
cost
million
under
the
Anti Dilutive
Repurchase
Program
November
the
Company
Board
Directors
suspended
the
Anti Dilutive
Repurchase
Program
until
January
and
approved
additional
share
repurchase
program
This
program
authorized
repurchases
common
stock
million
from
time
time
amounts
prices
and
such
times
the
Company
deemed
appropriate
subject
market
conditions
legal
requirements
and
other
considerations
total
shares
were
repurchased
aggregate
cost
million
December
under
that
completed
repurchase
program
May
the
Company
Board
Directors
approved
additional
share
repurchase
program
the
Repurchase
Program
under
which
repurchases
common
stock
million
were
authorized
occur
from
time
time
amounts
prices
and
such
times
the
Company
deems
appropriate
subject
market
conditions
legal
requirements
and
other
considerations
total
shares
were
repurchased
aggregate
cost
million
the
year
ended
December
under
the
Repurchase
Program
Any
future
repurchases
will
funded
from
cash
hand
future
cash
flows
from
operations
and
available
borrowings
under
the
revolving
credit
facility
The
repurchased
shares
are
reflected
within
Treasury
stock
the
accompanying
consolidated
balance
sheet
December
and
Table
Contents
Cash
Dividends
Common
Stock
February
the
Company
announced
the
establishment
dividend
policy
and
the
declaration
its
Board
Directors
initial
quarterly
cash
dividend
the
amount
per
share
the
Company
issued
and
outstanding
common
stock
Under
the
dividend
policy
the
Company
will
target
cash
dividend
the
Company
shareholders
the
amount
per
share
per
annum
payable
equal
quarterly
installments
The
following
summary
the
dividends
paid
the
years
ended
December
and
millions
Dividends
Paid
Shareholders
Record
Aggregate
Cost
March
June
September
December
March
June
September
December
Dividends
Paid
Shareholders
Record
Aggregate
Cost
March
June
September
December
March
June
September
December
Subsequent
dividend
declarations
and
the
establishment
record
and
payment
dates
for
such
future
dividend
payments
any
are
subject
the
Board
Directors
continuing
determination
that
the
dividend
policy
the
best
interests
the
Company
shareholders
The
dividend
policy
may
suspended
cancelled
the
discretion
the
Board
Directors
any
time
Accumulated
Other
Comprehensive
Income
Loss
The
following
summary
the
components
accumulated
other
comprehensive
income
loss
net
tax
December
millions
Balance
December
Other
comprehensive
income
loss
Realized
loss
reclassification
Balance
December
Other
comprehensive
income
loss
Realized
loss
reclassification
Balance
December
Other
comprehensive
income
Realized
loss
reclassification
Balance
December
Foreign
Currency
Translation
Pension
Liability
Adjustment
Accumulated
Other
Comprehensive
Income
Loss
Note
Stock Based
Compensation
February
the
Bruker
BioSciences
Corporation
Amended
and
Restated
Stock
Option
Plan
the
Plan
expired
the
end
its
scheduled
ten year
term
March
the
Company
Board
Directors
unanimously
approved
and
adopted
the
Bruker
Corporation
Incentive
Compensation
Plan
the
Plan
and
May
the
Plan
was
approved
the
Company
stockholders
The
Plan
provided
for
the
issuance
shares
the
Company
common
stock
The
Plan
allowed
committee
the
Board
Directors
the
Table
Contents
Compensation
Committee
grant
incentive
stock
options
non qualified
stock
options
and
restricted
stock
awards
The
Compensation
Committee
had
the
authority
determine
which
employees
would
receive
the
awards
the
amount
the
awards
and
other
terms
and
conditions
any
awards
Awards
granted
under
the
Plan
typically
were
made
subject
vesting
period
three
five
years
May
the
Bruker
Corporation
Incentive
Compensation
Plan
the
Plan
was
approved
the
Company
stockholders
With
the
approval
the
Plan
further
grants
will
made
under
the
Plan
The
Plan
provides
for
the
issuance
shares
the
Company
common
stock
and
permits
the
grant
awards
non qualified
stock
options
incentive
stock
options
stock
appreciation
rights
restricted
stock
unrestricted
stock
restricted
stock
units
performance
shares
and
performance
units
well
cash based
awards
The
Plan
administered
the
Compensation
Committee
The
Compensation
Committee
has
the
authority
determine
which
employees
will
receive
awards
the
amount
any
awards
and
other
terms
and
conditions
such
awards
Stock
option
awards
granted
under
the
Plan
typically
vest
over
period
three
four
years
Stock
option
activity
for
the
year
ended
December
was
follows
Outstanding
December
Granted
Exercised
Forfeited Expired
Outstanding
December
Exercisable
December
Exercisable
and
expected
vest
December
Shares
Subject
Options
Weighted
Average
Option
Price
Weighted
Average
Remaining
Contractual
Term
Yrs
Aggregate
Intrinsic
Value
millions
addition
the
options
that
are
vested
December
the
Company
expects
portion
the
unvested
options
vest
the
future
Options
expected
vest
the
future
are
determined
applying
estimated
forfeiture
rate
the
options
that
are
unvested
December
The
aggregate
intrinsic
value
based
the
positive
difference
between
the
fair
value
the
Company
common
stock
price
December
the
date
exercises
appropriate
and
the
exercise
price
the
underlying
stock
options
The
weighted
average
fair
value
options
granted
was
and
per
share
for
the
years
ended
December
and
respectively
The
total
intrinsic
value
options
exercised
was
million
million
and
million
for
the
years
ended
December
and
respectively
Unrecognized
pre tax
stock based
compensation
expense
million
related
stock
options
awarded
under
the
and
Plans
expected
recognized
over
the
weighted
average
remaining
service
period
years
for
stock
options
outstanding
December
Restricted
shares
the
Company
common
stock
are
periodically
awarded
executive
officers
directors
and
certain
key
employees
the
Company
subject
service
restrictions
which
vest
ratably
over
periods
one
four
years
The
restricted
shares
common
stock
may
not
sold
Table
Contents
transferred
during
the
restriction
period
Stock based
compensation
for
restricted
stock
recorded
based
the
stock
price
the
grant
date
and
charged
expense
ratably
throughout
the
restriction
period
The
following
table
summarizes
information
about
restricted
stock
award
activity
during
the
year
ended
December
Outstanding
December
Vested
Forfeited
Outstanding
December
Shares
Subject
Restriction
Weighted
Average
Grant
Date
Fair
Value
The
total
fair
value
restricted
stock
vested
was
million
million
and
million
for
the
years
ended
December
and
respectively
Unrecognized
pre tax
stock based
compensation
expense
million
related
restricted
stock
awarded
under
the
Plan
expected
recognized
over
the
weighted
average
remaining
service
period
years
for
awards
outstanding
December
Restricted
stock
units
the
Company
common
stock
are
periodically
awarded
executive
officers
directors
and
certain
employees
the
Company
which
vest
ratably
over
service
periods
one
four
years
Stock based
compensation
for
restricted
stock
units
recorded
based
the
stock
price
the
grant
date
and
charged
expense
ratably
throughout
the
vesting
period
The
following
table
summarizes
information
about
restricted
stock
unit
activity
for
year
ended
December
Outstanding
December
Granted
Vested
Forfeited
Outstanding
December
Shares
Subject
Restriction
Weighted
Average
Grant
Date
Fair
Value
The
total
fair
value
restricted
stock
vested
was
million
for
the
year
ended
December
restricted
stock
units
vested
the
years
ended
December
and
Unrecognized
pre tax
stock based
compensation
expense
million
related
restricted
stock
units
awarded
under
the
Plan
expected
recognized
over
the
weighted
average
remaining
service
period
years
for
units
outstanding
December
March
the
FASB
issued
ASU
Stock Compensation Improvements Employee Share Based Payment Accounting
The
new
standard
simplifies
accounting
for
share based
payment
transactions
including
income
tax
consequences
and
the
classification
the
tax
impact
the
statement
cash
flows
The
Company
adopted
this
standard
effective
January
The
ASU
requires
that
the
difference
between
the
actual
tax
benefit
realized
upon
exercise
vesting
applicable
and
the
tax
benefit
recorded
based
the
fair
value
the
stock
award
the
time
grant
the
excess
tax
benefits
reflected
reduction
the
current
period
provision
for
income
taxes
Table
Contents
with
any
shortfall
recorded
increase
the
tax
provision
rather
than
component
changes
additional
paid
capital
The
ASU
also
required
the
excess
tax
benefit
realized
reflected
operating
cash
flow
rather
than
financing
cash
flow
This
standard
was
adopted
the
Company
modified
retrospective
basis
with
respect
the
previously
unrecognized
windfalls
which
resulted
cumulative
adjustment
retained
earnings
million
January
related
the
timing
when
excess
tax
benefits
are
recognized
The
Company
adopted
this
standard
prospective
basis
with
respect
the
statements
income
and
cash
flows
and
recognized
excess
tax
benefit
related
stock
compensation
which
decreased
income
tax
expense
the
amount
million
for
the
year
ended
December
The
excess
tax
benefits
were
previously
recorded
equity
The
Company
continues
utilize
historical
forfeiture
rate
estimate
future
forfeitures
Note
Other
Charges
Net
The
components
other
charges
net
for
the
years
ended
December
and
were
follows
millions
Acquisition related
expenses
income
net
Professional
fees
incurred
connection
with
investigation
matters
Pension
settlement
charge
Information
technology
transformation
costs
Restructuring
charges
Long lived
asset
impairments
Other
charges
net
Restructuring
Initiatives
The
Company
commenced
restructuring
initiative
address
lower
demand
the
Bruker
CALID
and
Bruker
Nano
Groups
result
delays
European
academic
funding
and
ongoing
weakness
several
the
industrial
end
market
segments
that
affect
the
Bruker
Nano
Group
This
initiative
was
intended
improve
the
Bruker
CALID
and
Bruker
Nano
Group
operating
results
response
these
market
conditions
Restructuring
actions
will
result
reduction
approximately
employees
within
the
Bruker
CALID
and
Bruker
Nano
Groups
The
following
summary
the
restructuring
expenses
related
this
initiative
which
are
recorded
the
accompanying
consolidated
statements
income
and
comprehensive
income
for
the
years
ended
December
and
Cost
revenues
Other
charges
net
Severance
and
Exit
Costs
Inventory
Writedown
and
Asset
Impairment
Total
Severance
and
Exit
Costs
Inventory
Writedown
and
Asset
Impairment
Total
Table
Contents
The
Company
commenced
restructuring
initiative
the
second
quarter
within
the
Bruker
BioSpin
Group
which
was
developed
result
revenue
decline
that
occurred
during
the
second
half
and
continued
during
the
first
half
This
initiative
was
intended
improve
Bruker
BioSpin
Group
operating
results
Restructuring
actions
resulted
reduction
employee
headcount
within
the
Bruker
BioSpin
Group
approximately
and
the
closure
and
consolidation
Bruker
BioSpin
Group
manufacturing
facility
The
following
summary
the
restructuring
expenses
related
this
initiative
which
are
recorded
the
accompanying
consolidated
statements
income
and
comprehensive
income
for
years
ended
December
and
Inventory
Writedown
Severance
and
and
Asset
Exit
Costs
Impairment
Cost
revenues
Other
charges
net
Inventory
Writedown
Severance
and
and
Asset
Exit
Costs
Impairment
Total
Inventory
Writedown
Severance
and
and
Asset
Exit
Costs
Total
Impairment
Total
December
expenses
incurred
under
this
restructuring
initiative
were
substantially
complete
Restructuring
charges
for
the
years
ended
December
and
included
charges
for
various
other
programs
which
were
recorded
the
accompanying
consolidated
statements
income
and
comprehensive
income
follows
Cost
revenues
Other
charges
net
Table
Contents
The
following
table
sets
forth
the
changes
the
restructuring
reserves
for
the
years
ended
December
and
millions
Balance
December
Restructuring
charges
Cash
payments
Non cash
adjustments
Foreign
currency
impact
Balance
December
Restructuring
charges
Cash
payments
Non cash
adjustments
Foreign
currency
impact
Balance
December
Restructuring
charges
Cash
payments
Non cash
adjustments
Foreign
currency
impact
Balance
December
Total
Severance
Exit
Costs
Provisions
for
Excess
Inventory
Restructuring
charges
segment
and
for
the
years
ended
December
are
follows
millions
BSI
BEST
Note
Interest
and
Other
Income
Expense
Net
The
components
interest
and
other
income
expense
net
for
the
years
ended
December
and
were
follows
millions
Interest
income
Interest
expense
Exchange
gains
losses
foreign
currency
transactions
Gain
bargain
purchase
Loss
gain
disposal
product
line
Other
Interest
and
other
income
expense
net
Table
Contents
Note
Business
Segment
Information
The
Company
has
two
reportable
segments
BSI
and
BEST
discussed
Note
the
consolidated
financial
statements
Selected
business
segment
information
presented
below
for
the
years
ended
December
millions
Revenue
BSI
BEST
Eliminations
Total
revenue
Operating
Income
BSI
BEST
Corporate
eliminations
and
other
Total
operating
income
Represents
product
and
service
revenue
between
reportable
segments
Represents
corporate
costs
and
eliminations
not
allocated
the
reportable
segments
The
Company
recorded
impairment
charge
million
million
and
million
for
the
years
ended
December
and
respectively
within
the
BSI
and
BEST
Segments
Please
see
Note
Property
Plant
and
Equipment
net
and
Note
Goodwill
and
Other
Intangible
Assets
for
description
impairment
charges
recorded
and
These
impairment
charges
are
included
within
other
charges
net
the
accompanying
consolidated
statements
income
and
comprehensive
income
Total
assets
segment
and
for
the
years
ended
December
are
follows
millions
Assets
BSI
BEST
Eliminations
and
other
Total
assets
Assets
not
allocated
the
reportable
segments
and
eliminations
intercompany
transactions
Table
Contents
Total
capital
expenditures
and
depreciation
and
amortization
segment
are
presented
below
for
the
years
ended
December
millions
Capital
Expenditures
BSI
BEST
Total
capital
expenditures
Depreciation
and
Amortization
BSI
BEST
Total
depreciation
and
amortization
Revenue
and
property
plant
and
equipment
net
geographical
area
and
for
the
year
ended
December
are
follows
millions
Revenue
United
States
Germany
Rest
Europe
Asia
Pacific
Other
Total
revenue
Property
plant
and
equipment
net
United
States
Germany
Rest
Europe
Asia
Pacific
Other
Total
property
plant
and
equipment
net
Note
Related
Parties
The
Company
leases
certain
office
space
from
certain
its
principal
shareholders
including
director
and
executive
officer
and
another
member
the
Company
Board
Directors
and
members
their
immediate
families
which
have
expiration
dates
ranging
from
Total
rent
expense
under
these
leases
was
million
million
and
million
for
each
the
years
ended
December
and
respectively
During
the
years
ended
December
and
the
Company
recorded
revenue
million
million
and
million
respectively
arising
from
commercial
transactions
with
life
sciences
company
which
member
the
Company
Board
Directors
Chairman
and
Chief
Executive
Officer
Table
Contents
During
the
year
ended
December
and
the
Company
recorded
revenue
million
and
million
respectively
from
commercial
transactions
with
thermal
analysis
company
which
one
the
former
members
its
Board
Directors
serves
consultant
Note
Recent
Accounting
Pronouncements
January
the
Financial
Accounting
Standards
Board
FASB
issued
Accounting
Standards
Update
ASU
Intangibles Goodwill and
Other Topic Simplifying the Test for Goodwill Impairment The
new
standard
simplifies
the
subsequent
measurement
goodwill
eliminating
the
second
step
the
goodwill
impairment
test
This
ASU
will
applied
prospectively
and
effective
for
annual
interim
goodwill
impairment
tests
fiscal
years
beginning
after
December
The
adoption
this
standard
not
expected
have
material
impact
the
Company
consolidated
financial
statements
upon
adoption
January
the
FASB
issued
ASU
Business Combinations Topic Clarifying the Definition Business This
new
standard
clarifies
the
definition
business
and
provides
screen
determine
when
integrated
set
assets
and
activities
not
business
The
screen
requires
that
when
substantially
all
the
fair
value
the
gross
assets
acquired
disposed
concentrated
single
identifiable
asset
group
similar
identifiable
assets
the
set
not
business
This
new
standard
was
adopted
the
effective
date
January
The
Company
has
evaluated
the
provisions
this
standard
and
has
determined
that
the
impact
adoption
ASU
was
not
material
the
consolidated
financial
statements
October
the
FASB
issued
ASU
Income Taxes Topic Intra Entity Transfer Assets Other than Inventory
The
new
standard
requires
recognition
current
and
deferred
income
taxes
resulting
from
intra entity
transfer
any
asset
excluding
inventory
when
the
transfer
occurs
This
change
from
existing
GAAP
which
prohibits
recognition
current
and
deferred
income
taxes
until
the
asset
sold
third
party
This
new
standard
was
adopted
the
effective
date
January
The
Company
has
evaluated
the
provisions
this
standard
and
has
determined
that
the
impact
adoption
ASU
was
not
material
the
consolidated
financial
statements
February
the
FASB
issued
ASU
Leases
The
new
standard
provides
guidance
the
recognition
measurement
presentation
and
disclosure
leases
The
new
standard
supersedes
present
GAAP
guidance
leases
and
requires
substantially
all
leases
reported
the
balance
sheet
right use
assets
and
lease
liabilities
well
additional
disclosures
The
new
standard
effective
January
and
early
adoption
permitted
The
Company
evaluating
the
provisions
this
standard
and
has
not
determined
what
impact
the
adoption
ASU
will
have
the
Company
consolidated
financial
statements
May
the
FASB
issued
ASU
Revenue from Contracts with Customers
which
supersedes
the
revenue
recognition
requirements
under
Accounting
Standards
Codification
ASC
Topic
The
new
guidance
was
the
result
joint
project
between
the
FASB
and
the
International
Accounting
Standards
Board
clarify
the
principles
for
recognizing
revenue
and
develop
common
revenue
standards
for
GAAP
and
International
Financial
Reporting
Standards
The
core
principle
the
new
guidance
that
revenue
should
recognized
depict
the
transfer
promised
goods
services
customers
amount
that
reflects
the
consideration
which
the
entity
expects
entitled
exchange
for
those
goods
services
August
the
FASB
elected
defer
the
effective
date
ASU
one
year
annual
periods
beginning
after
December
with
early
application
permitted
the
original
effective
date
The
new
guidance
may
applied
retrospective
basis
for
all
prior
periods
presented
modified
retrospective
basis
with
the
cumulative
effect
the
new
guidance
the
date
initial
application
The
new
guidance
will
Table
Contents
effective
for
the
Company
January
and
the
Company
currently
intends
use
the
modified
retrospective
transition
method
Under
the
new
guidance
there
are
specific
criteria
determine
performance
obligation
should
recognized
over
time
point
time
Accordingly
the
Company
has
identified
certain
project based
orders
the
BEST
Segment
and
CBRNE
detection
orders
the
Bruker
CALID
Group
for
which
the
timing
when
the
Company
recognizes
revenue
may
impacted
Due
the
complexity
these
project based
orders
revenue
recognition
under
the
new
standard
highly
dependent
specific
contract
terms
During
the
fourth
quarter
the
Company
substantially
completed
the
assessment
over
the
impact
that
this
new
standard
will
have
its
consolidated
balance
sheets
The
Company
preliminarily
expects
recognize
adjustment
approximately
million
retained
earnings
January
reflect
the
cumulative
effect
the
accounting
changes
made
upon
the
adoption
the
standard
The
finalization
the
assessment
may
result
significant
changes
the
estimates
that
may
materially
impact
the
preliminary
estimate
the
cumulative
effect
Note
Quarterly
Financial
Data
Unaudited
summary
operating
results
for
the
quarterly
periods
the
years
ended
December
and
set
forth
below
millions
except
per
share
data
Year
ended
December
Net
revenue
Gross
profit
Operating
income
Net
income
loss
attributable
Bruker
Corporation
Net
income
loss
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
Year
ended
December
Net
revenue
Gross
profit
Operating
income
Net
income
attributable
Bruker
Corporation
Net
income
per
common
share
attributable
Bruker
Corporation
shareholders
Basic
Diluted
March
June
Quarter
Ended
September
December
The
first
and
fourth
quarter
includes
impairment
assets
million
and
million
respectively
comprised
other
longlived
assets
The
second
and
fourth
quarter
includes
impairment
assets
million
and
million
respectively
comprised
other
long lived
assets
Table
Contents
The
third
quarter
includes
bargain
purchase
gain
million
related
the
Merlin
Diagnostika
GmbH
acquisition
and
the
fourth
quarter
includes
adjustment
the
bargain
purchase
gain
million
related
the
same
acquisition
The
fourth
quarter
includes
bargain
purchase
gain
million
related
the
Oxford
Instruments
Superconducting
Wire
LLC
acquisition
The
fourth
quarter
includes
million
incremental
income
tax
provision
related
the
Tax
Act
Table
Contents
ITEM
CHANGES
AND
DISAGREEMENTS
WITH
ACCOUNTANTS
AUDITING
AND
FINANCIAL
DISCLOSURE
meeting
held
June
the
audit
committee
the
Company
Board
Directors
approved
the
dismissal
Ernst
Young
LLP
Ernst
Young
the
Company
independent
registered
public
accounting
firm
effective
June
and
the
appointment
PricewaterhouseCoopers
LLP
the
Company
independent
registered
public
accounting
firm
effective
June
perform
independent
audit
services
for
the
fiscal
year
ending
December
The
report
Ernst
Young
the
consolidated
financial
statements
the
Company
for
the
fiscal
year
ended
December
did
not
contain
adverse
opinion
disclaimer
opinion
and
were
not
qualified
modified
uncertainty
audit
scope
accounting
principles
connection
with
the
audit
our
financial
statements
for
the
fiscal
year
ended
December
and
the
subsequent
interim
period
through
June
there
were
disagreements
that
term
defined
Item
Regulation
and
the
related
instructions
with
Ernst
Young
any
matter
accounting
principles
practices
financial
statement
disclosure
auditing
scope
and
procedures
which
not
resolved
the
satisfaction
Ernst
Young
would
have
caused
Ernst
Young
make
reference
the
matter
their
reports
for
such
years
There
were
reportable
events
that
term
described
Item
Regulation
except
for
material
weakness
the
Company
internal
control
over
financial
reporting
December
concerning
the
accounting
for
income
taxes
which
material
weakness
was
identified
subsequent
the
filing
our
Annual
Report
Form
for
the
year
ended
December
result
such
material
weakness
our
management
concluded
November
that
the
Company
internal
control
over
financial
reporting
was
not
effective
December
November
the
Company
filed
Amendment
its
Annual
Report
Form
for
the
fiscal
year
ended
December
well
amendments
each
its
Quarterly
Reports
Form
for
the
periods
ended
March
and
June
reflect
the
conclusion
management
that
there
was
material
weakness
internal
control
over
financial
reporting
the
end
the
periods
covered
those
reports
The
Company
Amendment
its
Annual
Report
Form
for
the
fiscal
year
ended
December
also
included
revised
auditor
reports
from
Ernst
Young
stating
that
the
Company
internal
control
over
financial
reporting
December
was
not
effective
ITEM
CONTROLS
AND
PROCEDURES
Disclosure
Controls
and
Procedures
have
established
disclosure
controls
and
procedures
such
term
defined
Rules
and
under
the
Securities
Exchange
Act
amended
the
Exchange
Act
that
are
designed
ensure
that
information
required
disclosed
the
reports
that
file
submit
under
the
Exchange
Act
recorded
processed
summarized
and
reported
within
the
time
periods
specified
the
rules
and
forms
the
SEC
and
ensure
that
information
required
disclosed
accumulated
and
communicated
management
including
our
Chief
Executive
Officer
principal
executive
officer
and
Chief
Financial
Officer
principal
financial
officer
allow
timely
decisions
regarding
required
disclosures
Under
the
supervision
and
with
the
participation
our
management
including
our
Chief
Executive
Officer
and
Chief
Financial
Officer
conducted
evaluation
the
effectiveness
our
disclosure
controls
and
procedures
December
Based
this
evaluation
our
Chief
Executive
Officer
and
Chief
Financial
Officer
concluded
that
our
disclosure
controls
and
procedures
were
effective
reasonable
assurance
level
December
Table
Contents
Management
Report
Internal
Control
over
Financial
Reporting
Our
management
responsible
for
establishing
and
maintaining
adequate
internal
control
over
financial
reporting
Under
the
supervision
and
with
the
participation
our
management
including
our
Chief
Executive
Officer
and
Chief
Financial
Officer
conducted
evaluation
the
effectiveness
our
internal
control
over
financial
reporting
December
based
the
criteria
set
forth
the
Committee
Sponsoring
Organizations
the
Treadway
Commission
COSO
Internal Control Integrated Framework
Based
this
evaluation
management
concluded
that
our
internal
control
over
financial
reporting
was
effective
December
excluded
Hysitron
Incorporated
Hysitron
from
our
assessment
internal
control
over
financial
reporting
December
because
was
acquired
the
Company
purchase
business
combination
during
The
total
assets
and
total
revenues
Hysitron
represent
and
respectively
the
related
consolidated
financial
statement
amounts
and
for
the
year
ended
December
The
effectiveness
our
internal
control
over
financial
reporting
December
has
been
audited
PricewaterhouseCoopers
LLP
independent
registered
public
accounting
firm
stated
their
report
which
appears
herein
Changes
Internal
Control
over
Financial
Reporting
There
were
changes
our
internal
control
over
financial
reporting
that
occurred
during
the
quarter
ended
December
that
materially
affected
are
reasonably
likely
materially
affect
our
internal
control
over
financial
reporting
Table
Contents
ITEM
OTHER
INFORMATION
None
PART
III
ITEM
DIRECTORS
EXECUTIVE
OFFICERS
AND
CORPORATE
GOVERNANCE
The
full
text
the
Company
code
ethics
which
applies
its
Principal
Executive
Officer
Principal
Financial
Officer
Principal
Accounting
Officer
and
Board
Directors
published
the
Company
Investor
Relations
web
site
bruker
intend
disclose
future
amendments
certain
provisions
our
Code
waivers
such
provisions
granted
executive
officers
and
directors
the
web
site
within
four
business
days
following
the
date
such
amendment
waiver
Information
regarding
our
executive
officers
may
found
under
the
caption
Executive Officers
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
Information
regarding
our
directors
including
committees
our
Board
Directors
and
our
Audit
Committee
Financial
Experts
may
found
under
the
captions
Election Directors Board Meetings Committees and Compensation and
Audit Committee Report
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
Information
regarding
compliance
with
Section
the
Exchange
Act
may
found
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
under
the
caption
Section Beneficial Ownership Reporting Compliance
Information
regarding
the
procedures
which
security
holders
may
recommend
nominees
our
Board
Directors
may
found
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
under
the
caption
Director Nominations
Such
information
incorporated
herein
reference
ITEM
EXECUTIVE
COMPENSATION
Information
regarding
executive
compensation
may
found
under
the
captions
Compensation Directors Compensation Discussion and Analysis
Summary Executive Compensation Compensation Committee Interlocks and Insider Participation and
Compensation Committee Report
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
Such
information
incorporated
herein
reference
ITEM
SECURITY
OWNERSHIP
CERTAIN
BENEFICIAL
OWNERS
AND
MANAGEMENT
AND
RELATED
STOCKHOLDER
MATTERS
The
following
table
summarizes
information
about
our
equity
compensation
plans
December
Plan
Category
Number
Securities
Issued
Upon
Exercise
Outstanding
Options
Warrants
and
Rights
Equity
compensation
plans
approved
security
holders
Equity
compensation
plans
not
approved
security
holders
Weighted Average
Exercise
Price
Outstanding
Options
Warrants
and
Rights
Number
Securities
Remaining
Available
for
Future
Issuance
Under
Equity
Compensation
Plans
excluding
securities
reflected
column
The
Bruker
Corporation
Incentive
Compensation
Plan
the
Plan
was
approved
our
stockholders
May
The
Plan
has
term
ten
years
and
provides
for
the
issuance
Table
Contents
shares
the
Company
common
stock
With
the
approval
the
Plan
additional
grants
can
made
from
the
Company
Incentive
Compensation
Plan
Outstanding
awards
under
the
Incentive
Compensation
Plan
will
continue
accordance
with
their
terms
The
information
contained
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
under
the
caption
Security Ownership Certain
Beneficial Owners and Management
incorporated
herein
reference
ITEM
CERTAIN
RELATIONSHIPS
AND
RELATED
TRANSACTIONS
AND
DIRECTOR
INDEPENDENCE
The
information
contained
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
under
the
captions
Related Persons Transactions
and
Board Meetings Committees and Compensation
incorporated
herein
reference
ITEM
PRINCIPAL
ACCOUNTING
FEES
AND
SERVICES
The
information
contained
our
definitive
proxy
statement
for
our
Annual
Meeting
Stockholders
under
the
captions
Independent Registered Public
Accounting Firm and
Ratification Independent Registered Public Accounting Firm
incorporated
herein
reference
Table
Contents
PART
ITEM
EXHIBITS
FINANCIAL
STATEMENTS
AND
SCHEDULES
Financial
Statements
and
Schedules
Financial
Statements
The
following
consolidated
financial
statements
Bruker
Corporation
are
filed
part
this
report
under
Item
Financial
Statements
and
Supplementary
Data
Report
PricewaterhouseCoopers
LLP
Independent
Registered
Public
Accounting
Firm
Report
Ernst
Young
LLP
Independent
Registered
Public
Accounting
Firm
Consolidated
Balance
Sheets
December
and
Consolidated
Statements
Income
and
Comprehensive
Income
for
the
years
ended
December
and
Consolidated
Statements
Shareholders
Equity
for
the
years
ended
December
and
Consolidated
Statements
Cash
Flows
for
the
years
ended
December
and
Notes
Consolidated
Financial
Statements
Financial
Statement
Schedules
All
schedules
have
been
omitted
because
they
are
not
required
because
the
required
information
provided
the
Consolidated
Financial
Statements
Notes
thereto
set
forth
under
Item
above
Exhibits
List
Exhibits
Exhibit
Filed
Herewith
Description
Amended
Certificate
Incorporation
the
Registrant
Bylaws
the
Registrant
Specimen
stock
certificate
representing
shares
common
stock
the
Registrant
Bruker
Corporation
Incentive
Compensation
Plan
Form
Incentive
Stock
Option
Agreement
Bruker
Corporation
Incentive
Compensation
Plan
Form
NonQualified
Stock
Option
Agreement
Bruker
Corporation
Incentive
Compensation
Plan
Form
Restricted
Stock
Agreement
Bruker
Corporation
Incentive
Compensation
Plan
Incorporated
Reference
Form
Date
December
August
December
June
June
June
June
Table
Contents
Exhibit
Filed
Herewith
Description
Amended
and
Restated
Credit
Agreement
dated
May
among
the
Company
Bruker
AXS
GmbH
Bruker
Daltonik
GmbH
Bruker
Optik
GmbH
Bruker
Physik
GmbH
Bruker
BioSpin
Invest
Bruker
BioSpin
and
Bruker
BioSpin
International
the
other
foreign
subsidiary
borrowers
from
time
time
party
thereto
the
lenders
from
time
time
party
thereto
Deutsche
Bank
Securities
Inc
Commerzbank
New
York
Grand
Cayman
And
Stuttgart
Branches
and
RBS
Citizens
National
Association
Documentation
Agents
Bank
America
Syndication
Agent
and
JPMorgan
Chase
Bank
Administrative
Agent
Incorporated
Reference
Form
Date
May
Note
Purchase
Agreement
dated
January
January
Bruker
Energy
Supercon
Technologies
Inc
Stock
Option
Plan
December
Form
Bruker
Energy
Supercon
Technologies
Inc
Incentive
Stock
Option
Agreement
December
Form
Bruker
Energy
Supercon
Technologies
Inc
Non Qualified
Stock
Option
Agreement
December
Employment
offer
letter
agreement
dated
June
between
Bruker
Corporation
and
Juergen
Srega
March
Credit
Agreement
dated
October
and
among
the
Company
and
certain
its
foreign
subsidiaries
borrowers
Citizens
Bank
Deutsche
Bank
Securities
Inc
and
Bank
Documentation
Agents
Bank
America
and
Wells
Fargo
Bank
National
Association
Syndication
Agents
JPMorgan
Chase
Bank
Administrative
Agent
for
itself
and
the
other
lenders
party
thereto
and
the
several
banks
other
financial
institutions
entities
from
time
time
party
thereto
lenders
incorporated
reference
Exhibit
the
Company
Current
Report
the
Form
filed
October
File
October
Employment
agreement
with
effective
date
November
between
Bruker
Corporation
and
Ren
Lenggenhager
November
Table
Contents
Exhibit
Filed
Herewith
Description
Incorporated
Reference
Form
Date
Bruker
Corporation
Incentive
Compensation
Plan
Form
Incentive
Stock
Option
Award
Agreement
August
Bruker
Corporation
Incentive
Compensation
Plan
Form
NonQualified
Stock
Option
Award
Agreement
August
Bruker
Corporation
Incentive
Compensation
Plan
Form
Restricted
Stock
Unit
Award
Agreement
August
Bruker
Corporation
Incentive
Compensation
Plan
Form
Director
Restricted
Stock
Unit
Award
Agreement
March
Project
Completion
Agreement
dated
March
May
Subsidiaries
the
Registrant
Consent
PricewaterhouseCoopers
LLP
Independent
Registered
Public
Accounting
Firm
Consent
Ernst
Young
LLP
Independent
Registered
Public
Accounting
Firm
Power
attorney
included
signature
page
hereto
Certification
Principal
Executive
Officer
pursuant
Section
the
Sarbanes Oxley
Act
Certification
Principal
Financial
Officer
pursuant
Section
the
Sarbanes Oxley
Act
Certification
Chief
Executive
Officer
and
Chief
Financial
Officer
pursuant
Section
adopted
pursuant
Section
the
Sarbanes Oxley
Act
Table
Contents
Exhibit
Filed
Herewith
Description
The
following
materials
from
the
Bruker
Corporation
Annual
Report
Form
for
the
fiscal
year
ended
December
formatted
Extensible
Business
Reporting
Language
XBRL
the
Consolidated
Balance
Sheets
Consolidated
Statements
Income
and
Comprehensive
Income
iii
Consolidated
Statements
Shareholders
Equity
and
Comprehensive
Income
Loss
Consolidated
Statements
Cash
Flows
and
Notes
the
Consolidated
Financial
Statements
Incorporated
Reference
Form
Date
Certain
portions
have
been
omitted
pursuant
order
granting
confidential
treatment
and
have
been
filed
separately
with
the
Securities
and
Exchange
Commission
Designates
management
contract
compensatory
plan
arrangement
accordance
with
Rule
under
the
Exchange
Act
reference
made
the
documents
previously
filed
with
the
Securities
and
Exchange
Commission
which
documents
are
hereby
incorporated
reference
The
dates
listed
for
Forms
are
dates
the
respective
forms
were
filed
the
dates
listed
for
Forms
Forms
and
Forms
are
for
the
quarterly
annual
period
ended
dates
and
the
dates
listed
for
Forms
Forms
and
Forms
are
dates
which
the
Securities
and
Exchange
Commission
declared
them
effective
ITEM
FORM
SUMMARY
Not
Applicable
Table
Contents
SIGNATURES
Pursuant
the
requirements
Section
the
Securities
Exchange
Act
the
registrant
has
duly
caused
this
report
signed
its
behalf
the
undersigned
thereunto
duly
authorized
BRUKER
CORPORATION
Date
March
FRANK
LAUKIEN
Name
Frank
Laukien
Title
President Chief Executive Officer and Chairman
the
undersigned
officers
and
directors
Bruker
Corporation
hereby
severally
constitute
and
appoint
Frank
Laukien
sign
for
and
our
names
the
capacities
indicated
below
the
report
Form
filed
herewith
and
any
and
all
amendments
such
report
and
file
the
same
with
all
exhibits
thereto
and
other
documents
connection
therewith
each
case
with
the
Securities
and
Exchange
Commission
and
generally
all
such
things
our
names
and
our
behalf
our
capacities
consistent
with
the
provisions
the
Securities
Exchange
Act
amended
and
all
requirements
the
Securities
and
Exchange
Commission
Pursuant
the
requirements
the
Securities
Exchange
Act
this
report
has
been
signed
below
the
following
persons
behalf
the
registrant
and
the
capacities
and
the
dates
indicated
Name
FRANK
LAUKIEN
Gerald
Herman
CYNTHIA
FRIEND
Date
President
Chief
Executive
Officer
and
Chairman
Principal
Executive
Officer
March
Chief
Financial
Officer
and
Senior
Vice
President
Principal
Financial
Officer
March
Vice
President
and
Corporate
Controller
Principal
Accounting
Officer
March
Director
March
Director
March
Director
March
Anthony
Mattacchione
GERALD
HERMAN
Frank
Laukien
ANTHONY
MATTACCHIONE
Title
Cynthia
Friend
MARC
KASTNER
Marc
Kastner
RICHARD
KNISS
Richard
Kniss
Table
Contents
Name
JOERG
LAUKIEN
Title
Date
Director
March
Director
March
Director
March
Director
March
Director
March
Director
March
Director
March
Director
March
Joerg
Laukien
WILLIAM
LINTON
William
Linton
GILLES
MARTIN
Gilles
Martin
JOHN
ORNELL
John
Ornell
RICHARD
PACKER
Richard
Packer
ADELENE
PERKINS
Adelene
Perkins
HERMANN
REQUARDT
Hermann
Requardt
ROBERT
ROSENTHAL
Robert
Rosenthal
QuickLinks
Click
here
rapidly
navigate
through
this
document
EXHIBIT
SUBSIDIARIES
BRUKER
CORPORATION
Name
Subsidiary
Bruker
Energy
Supercon
Technologies
Inc
Bruker
HTS
GmbH
Bruker
Advanced
Supercon
GmbH
Bruker
EAS
GmbH
Hydrostatic
Extrusions
Ltd
Research
Instruments
GmbH
Bruker
AXS
Inc
Bruker
AXS
GmbH
Bruker
Austria
GmbH
Bruker
Brasil
Ltda
Bruker
Nano
GmbH
Bruker
Mexicana
Bruker
Polska
Bruker
South
Africa
Pty
Ltd
InCoaTec
GmbH
Bruker
AXS
Handheld
Inc
Bruker
AXS
Bruker
Nano
Inc
Vutara
LLC
Bruker
BioSciences
Securities
Corporation
Bruker
BioSpin
Corporation
Bruker
Invest
Bruker
BioSpin
Bruker
Espanola
Bruker
Malaysia
SDN
BHD
Bruker
Singapore
Pte
Ltd
Bruker
Beijing
Scientific
Technology
Ltd
Bruker
Ltd
Bruker
India
Scientific
PVT
Ltd
Bruker
BioSpin
Bruker
Korea
Ltd
Bruker
BioSpin
MRI
GmbH
Bruker
BioSpin
MRI
Inc
Bruker
Nederland
Bruker
Ltd
Bruker
Ltd
Bruker
AXS
Ltd
Oxford
Research
Systems
Ltd
Bruker
PTY
Ltd
Bruker
France
Bruker
Belgium
Bruker
Italia
XGLabs
Bruker
Portugal
Unipessoal
LDA
Bruker
Scientific
Instruments
Hong
Kong
Ltd
Bruker
MicroCT
Bruker
Turkey
Teknolojik
Sistemler
Ticaret
Ltd
Sirketi
Luxendo
GmbH
Bruker
Scientific
Israel
Ltd
Jurisdiction
Incorporation
Delaware
Germany
Germany
Germany
United
Kingdom
Germany
Delaware
Germany
Austria
Brazil
Germany
Mexico
Poland
South
Africa
Germany
Delaware
Japan
Arizona
Delaware
Massachusetts
Massachusetts
Switzerland
Switzerland
Spain
Malaysia
Singapore
China
Russia
India
Japan
Korea
Germany
Massachusetts
Netherlands
Canada
United
Kingdom
United
Kingdom
United
Kingdom
Australia
France
Belgium
Italy
Italy
Portugal
Hong
Kong
Belgium
Turkey
Germany
Israel
Name
Subsidiary
Bruker
Israel
Ltd
Bruker
Ltd
Bruker
Physik
GmbH
Bruker
BioSpin
GmbH
Bruker
Daltonics
Inc
Bruker
Daltonik
GmbH
Bruker
InVivo
Biotech
Svs
GmbH
Merlin
Diagnostika
GmbH
Bruker
Taiwan
Ltd
Bruker
Daltonics
Bruker
Daltonics
Pty
Ltd
Bruker
Nordic
Bruker
Chemical
Analysis
Bruker
Daltonics
GmbH
Bruker
Daltonics
Ltd
Bruker
Daltonics
Bruker
Detection
Corporation
Bruker
Optics
Inc
Bruker
Optics
Bruker
Optics
GmbH
Bruker
Optik
GmbH
Bruker
Optics
Ukraine
Bruker
Finance
Bruker
Business
Support
Center
Bruker
OST
LLC
Jurisdiction
Incorporation
Israel
United
Kingdom
Germany
Germany
Delaware
Germany
Czech
Republic
Germany
Germany
Taiwan
Japan
South
Africa
Sweden
Netherlands
Switzerland
United
Kingdom
Italy
Massachusetts
Delaware
Japan
Switzerland
Germany
Ukraine
Netherlands
Poland
United
States
These
entities
are
wholly owned
subsidiaries
Bruker
Energy
Supercon
Technologies
Inc
These
entities
are
wholly owned
subsidiaries
Bruker
HTS
GmbH
Research
Instruments
GmbH
indirect
subsidiary
Bruker
Energy
Supercon
Technologies
Inc
Research
Instruments
GmbH
owned
Bruker
Energy
Supercon
Technologies
Inc
Bruker
AXS
GmbH
owned
Bruker
AXS
Inc
and
owned
Bruker
Corporation
These
entities
are
wholly owned
subsidiaries
Bruker
AXS
GmbH
Bruker
Mexicana
owned
Bruker
AXS
GmbH
and
owned
Bruker
AXS
Inc
InCoaTec
GmbH
indirect
subsidiary
Bruker
AXS
GmbH
InCoaTec
GmbH
owned
Bruker
AXS
GmbH
These
entities
are
wholly owned
subsidiaries
Bruker
AXS
Inc
Vutara
LLC
wholly owned
subsidiary
Bruker
Nano
Inc
Bruker
Invest
owned
Bruker
BioSpin
Corporation
and
owned
Bruker
Corporation
These
entities
are
wholly owned
subsidiaries
Bruker
Invest
Bruker
Beijing
Scientific
Technology
Ltd
wholly owned
subsidiary
Bruker
Singapore
Pte
Ltd
Bruker
India
Suppliers
PVT
Ltd
wholly owned
subsidiary
Bruker
India
Scientific
PVT
Ltd
Bruker
AXS
Ltd
owned
Bruker
Invest
and
owned
Bruker
Ltd
Oxford
Research
Systems
Ltd
owned
Bruker
Invest
and
owned
Bruker
Ltd
Bruker
Israel
Ltd
wholly owned
subsidiary
Bruker
Scientific
Israel
Ltd
Bruker
Ltd
wholly owned
subsidiary
Bruker
Israel
Ltd
Bruker
Physik
GmbH
owned
Bruker
BioSpin
Corporation
owned
Bruker
Daltonik
GmbH
and
owned
Bruker
Optik
GmbH
Bruker
BioSpin
GmbH
wholly owned
subsidiary
Bruker
Physik
GmbH
Bruker
Daltonik
GmbH
owned
Bruker
Daltonics
Inc
and
owned
Bruker
Corporation
These
entities
are
wholly owned
subsidiaries
Bruker
Daltonik
GmbH
These
entities
are
wholly owned
subsidiaries
Bruker
Daltonics
Inc
These
entities
are
wholly owned
subsidiaries
Bruker
Optics
Inc
These
entities
are
wholly owned
subsidiaries
Bruker
Optik
GmbH
These
entities
are
wholly owned
subsidiaries
Bruker
BioSpin
Bruker
India
Scientific
PVT
Ltd
owned
Bruker
Invest
owned
Bruker
Daltonik
GmbH
and
owned
Bruker
AXS
GmbH
XGLabs
wholly owned
subsidiary
Bruker
Italia
Bruker
Business
Support
Center
wholly owned
subsidiary
Bruker
Finance
QuickLinks
EXHIBIT
SUBSIDIARIES
BRUKER
CORPORATION
QuickLinks
Click
here
rapidly
navigate
through
this
document
EXHIBIT
CONSENT
INDEPENDENT
REGISTERED
PUBLIC
ACCOUNTING
FIRM
hereby
consent
the
incorporation
reference
the
Registration
Statement
Form
and
Forms
Nos
and
Bruker
Corporation
our
report
dated
March
relating
the
financial
statements
and
the
effectiveness
internal
control
over
financial
reporting
which
appears
this
Form
PricewaterhouseCoopers
LLP
Boston
Massachusetts
March
QuickLinks
EXHIBIT
CONSENT
INDEPENDENT
REGISTERED
PUBLIC
ACCOUNTING
FIRM
QuickLinks
Click
here
rapidly
navigate
through
this
document
EXHIBIT
CONSENT
INDEPENDENT
REGISTERED
PUBLIC
ACCOUNTING
FIRM
consent
the
incorporation
reference
the
following
Registration
Statements
Registration
Statement
Form
pertaining
the
Bruker
Corporation
Incentive
Compensation
Plan
Registration
Statement
Form
pertaining
the
Bruker
Corporation
Incentive
Compensation
Plan
Registration
Statement
Form
and
related
Prospectus
Bruker
Corporation
for
the
registration
shares
its
common
stock
and
Registration
Statements
Form
Nos
and
pertaining
the
Bruker
BioSciences
Corporation
Amended
and
Restated
Stock
Option
Plan
our
report
dated
February
except
for
Note
Summary
Significant
Accounting
Policies Restricted
Cash
which
the
date
March
with
respect
the
consolidated
financial
statements
Bruker
Corporation
included
this
Annual
Report
Form
Bruker
Corporation
for
the
year
ended
December
Boston
Massachusetts
March
Ernst
Young
LLP
QuickLinks
EXHIBIT
CONSENT
INDEPENDENT
REGISTERED
PUBLIC
ACCOUNTING
FIRM
QuickLinks
Click
here
rapidly
navigate
through
this
document
EXHIBIT
CERTIFICATION
Frank
Laukien
certify
that
have
reviewed
this
annual
report
Form
Bruker
Corporation
Based
knowledge
this
report
does
not
contain
any
untrue
statement
material
fact
omit
state
material
fact
necessary
make
the
statements
made
light
the
circumstances
under
which
such
statements
were
made
not
misleading
with
respect
the
period
covered
this
report
Based
knowledge
the
financial
statements
and
other
financial
information
included
this
report
fairly
present
all
material
respects
the
financial
condition
results
operations
and
cash
flows
the
registrant
and
for
the
periods
presented
this
report
The
registrant
other
certifying
officer
and
are
responsible
for
establishing
and
maintaining
disclosure
controls
and
procedures
defined
Exchange
Act
Rules
and
and
internal
control
over
financial
reporting
defined
Exchange
Act
Rules
and
for
the
registrant
and
have
designed
such
disclosure
controls
and
procedures
caused
such
disclosure
controls
and
procedures
designed
under
our
supervision
ensure
that
material
information
relating
the
registrant
including
its
consolidated
subsidiaries
made
known
others
within
those
entities
particularly
during
the
period
which
this
report
being
prepared
designed
such
internal
control
over
financial
reporting
caused
such
internal
control
over
financial
reporting
designed
under
our
supervision
provide
reasonable
assurance
regarding
the
reliability
financial
reporting
and
the
preparation
financial
statements
for
external
purposes
accordance
with
generally
accepted
accounting
principles
evaluated
the
effectiveness
the
registrant
disclosure
controls
and
procedures
and
presented
this
report
our
conclusions
about
the
effectiveness
the
disclosure
controls
and
procedures
the
end
the
period
covered
this
report
based
such
evaluation
and
disclosed
this
report
any
change
the
registrant
internal
control
over
financial
reporting
that
occurred
during
the
registrant
most
recent
fiscal
quarter
the
registrant
fourth
fiscal
quarter
the
case
annual
report
that
has
materially
affected
reasonably
likely
materially
affect
the
registrant
internal
control
over
financial
reporting
and
The
registrant
other
certifying
officer
and
have
disclosed
based
our
most
recent
evaluation
internal
control
over
financial
reporting
the
registrant
auditors
and
the
audit
committee
registrant
board
directors
persons
performing
the
equivalent
functions
all
significant
deficiencies
and
material
weaknesses
the
design
operation
internal
control
over
financial
reporting
which
are
reasonably
likely
adversely
affect
the
registrant
ability
record
process
summarize
and
report
financial
information
and
any
fraud
whether
not
material
that
involves
management
other
employees
who
have
significant
role
the
registrant
internal
control
over
financial
reporting
Date
March
FRANK
LAUKIEN
Frank
Laukien
President Chief Executive Officer and Chairman
Principal Executive Officer
QuickLinks
EXHIBIT
CERTIFICATION
QuickLinks
Click
here
rapidly
navigate
through
this
document
EXHIBIT
CERTIFICATION
Anthony
Mattacchione
certify
that
have
reviewed
this
annual
report
Form
Bruker
Corporation
Based
knowledge
this
report
does
not
contain
any
untrue
statement
material
fact
omit
state
material
fact
necessary
make
the
statements
made
light
the
circumstances
under
which
such
statements
were
made
not
misleading
with
respect
the
period
covered
this
report
Based
knowledge
the
financial
statements
and
other
financial
information
included
this
report
fairly
present
all
material
respects
the
financial
condition
results
operations
and
cash
flows
the
registrant
and
for
the
periods
presented
this
report
The
registrant
other
certifying
officer
and
are
responsible
for
establishing
and
maintaining
disclosure
controls
and
procedures
defined
Exchange
Act
Rules
and
and
internal
control
over
financial
reporting
defined
Exchange
Act
Rules
and
for
the
registrant
and
have
designed
such
disclosure
controls
and
procedures
caused
such
disclosure
controls
and
procedures
designed
under
our
supervision
ensure
that
material
information
relating
the
registrant
including
its
consolidated
subsidiaries
made
known
others
within
those
entities
particularly
during
the
period
which
this
report
being
prepared
designed
such
internal
control
over
financial
reporting
caused
such
internal
control
over
financial
reporting
designed
under
our
supervision
provide
reasonable
assurance
regarding
the
reliability
financial
reporting
and
the
preparation
financial
statements
for
external
purposes
accordance
with
generally
accepted
accounting
principles
evaluated
the
effectiveness
the
registrant
disclosure
controls
and
procedures
and
presented
this
report
our
conclusions
about
the
effectiveness
the
disclosure
controls
and
procedures
the
end
the
period
covered
this
report
based
such
evaluation
and
disclosed
this
report
any
change
the
registrant
internal
control
over
financial
reporting
that
occurred
during
the
registrant
most
recent
fiscal
quarter
the
registrant
fourth
fiscal
quarter
the
case
annual
report
that
has
materially
affected
reasonably
likely
materially
affect
the
registrant
internal
control
over
financial
reporting
and
The
registrant
other
certifying
officer
and
have
disclosed
based
our
most
recent
evaluation
internal
control
over
financial
reporting
the
registrant
auditors
and
the
audit
committee
registrant
board
directors
persons
performing
the
equivalent
functions
all
significant
deficiencies
and
material
weaknesses
the
design
operation
internal
control
over
financial
reporting
which
are
reasonably
likely
adversely
affect
the
registrant
ability
record
process
summarize
and
report
financial
information
and
any
fraud
whether
not
material
that
involves
management
other
employees
who
have
significant
role
the
registrant
internal
control
over
financial
reporting
Date
March
ANTHONY
MATTACCHIONE
Anthony
Mattacchione
Chief Financial Officer and Senior Vice President
Principal Financial Officer
QuickLinks
EXHIBIT
CERTIFICATION
QuickLinks
Click
here
rapidly
navigate
through
this
document
EXHIBIT
CERTIFICATION
PURSUANT
SECTION
ADOPTED
PURSUANT
SECTION
THE
SARBANES OXLEY
ACT
connection
with
the
Annual
Report
Bruker
Corporation
the
Company
Form
for
the
year
ended
December
filed
with
the
Securities
and
Exchange
Commission
the
date
hereof
the
Report
each
the
undersigned
Frank
Laukien
President
Chief
Executive
Officer
and
Chairman
the
Board
Directors
the
Company
and
Anthony
Mattacchione
Chief
Financial
Officer
and
Senior
Vice
President
the
Company
certifies
pursuant
section
adopted
pursuant
Section
the
Sarbanes Oxley
Act
that
the
best
his
knowledge
The
Report
fully
complies
with
the
requirements
section
the
Securities
Exchange
Act
and
The
information
contained
the
Report
fairly
presents
all
material
respects
the
financial
condition
and
results
operations
the
Company
Date
March
FRANK
LAUKIEN
Frank
Laukien
President Chief Executive Officer and Chairman
Principal Executive Officer
Date
March
ANTHONY
MATTACCHIONE
Anthony
Mattacchione
Chief Financial Officer and Senior Vice President
Principal Financial Officer
QuickLinks
EXHIBIT
CERTIFICATION
PURSUANT
SECTION
ADOPTED
PURSUANT
SECTION
THE
SARBANES OXLEY
ACT
